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 1 
Summary 
Melioidosis is an important cause of community-acquired sepsis, endemic 
to Southeast Asia and Northern Australia. Melioidosis is caused by the soil 
saprophyte, Burkholderia pseudomallei, a motile Gram-negative bacillus, and is 
associated with a mortality rate that approaches 50% in Northeast Thailand. 
The most important risk factor for melioidosis is diabetes mellitus, and two-
thirds of all adult patients with melioidosis have diabetes as a risk factor. It has 
been noted previously, however, that patients with diabetes have lower 
mortality than patients without diabetes. In this dissertation, we look at a 
cohort of 1160 consecutive adult melioidosis patients presenting to 
Sappasithiprasong Hospital in Ubon Ratchathani, Thailand, 410 (35%) of whom 
were diagnosed with diabetes prior to admission. We confirmed previous 
findings that diabetes protected from mortality in melioidosis, but also found 
that this protective effect was confined to a smaller subset of patients (208 
patients) who were treated with glibenclamide prior to admission. Patients with 
hyperglycaemia (but no diagnosis of diabetes prior to admission) had the same 
mortality rate as patients without diabetes. In vitro experiments found no 
inhibitory effect of glibenclamide on bacterial growth, and we therefore looked 
for evidence of an effect of glibenclamide on the host. We conducted a gene 
expression study of circulating blood leukocytes in melioidosis patients and 
compared them to uninfected controls. In this study, we found that 
glibenclamide was associated with an anti-inflammatory effect on the host 
response to melioidosis. To further elucidate a mechanism for the action of 
glibenclamide, we studied the effect of glibenclamide therapy in a mouse model 
of melioidosis and found that the effect of glibenclamide was specific to 
interleukin-1β secretion. This reduction in interleukin-1β secretion was 
associated with reduced cellular influx into the lungs as well as lower bacterial 
loads in blood, liver and spleen. 
 
 2 
1. Introduction 
Melioidosis is infection caused by the Gram-negative bacillus, 
Burkholderia pseudomallei,5 and was first reported in 1912 in a post mortem 
series of 38 patients seen by Whitmore and Krishnaswami at the Rangoon 
General Hospital, Burma, the majority of whom were morphine addicts.6–8 
Whitmore recognised that the causative agent of melioidosis was a novel 
organism, which he named Bacillus pseudomallei.8 The clinical disease only 
acquired its name in 1921, being coined from the Greek melis (distemper of 
asses) and eidos (resemblance), and refers to its resemblance to glanders, an 
infection of equids caused by the related organism, B. mallei.9 
The history of melioidosis research is punctuated by waves of activity that 
coincide with the military interests of the Western powers. British interest in the 
disease coincided with British imperial interests (specifically Burma for 
petroleum, Malaya for petroleum and rubber),10,11 and waned as the empire 
waned. France reported approximately 100 cases among the 400,000 troops of 
the French Expeditionary Forces in Indochina between 1948 and 1954.12 
America’s interest in (and therefore, research funding for) melioidosis increased 
and declined proportionate to its involvement in the Vietnam war.13–18 
Following the events of September 11, 2001, funding for melioidosis research in 
the last ten years has again increased with the realisation that B. pseudomallei 
is easily obtained (it is an environmental organism) and when aerosolised, 
might see utility as a bioterror agent with a high mortality rate. 
1.1 Burkholderia pseudomallei 
1.1.1 Taxonomy 
B. pseudomallei was for a long time placed in the genus Pseudomonas on 
the basis of its Gram-stain appearance and biochemistry19 (it is a non-lactose 
fermenting oxidase-positive Gram-negative bacillus20), but the organism was 
moved to a new genus, Burkholderia, in 1992 on the basis of 16S ribosomal 
RNA (rRNA) sequence.21  
The causative organism of melioidosis and its characteristics were 
described very shortly after the disease was first described.8 Initially named 
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Bacillus pseudomallei by its discoverer,6 it was later named Bacterium 
whitmori (Stanton & Fletcher 1921) for its discoverer, by which appellation it is 
still known to French researchers (bacille de Whitmore or Whitmore’s 
bacillus).22 
In common with many other non-fermenting Gram-negative bacteria, the 
organism has struggled to find a taxonomic home. The 5th edition of Bergey’s 
Manual placed it in the genus Malleomyces23 due to the many characteristics it 
shares with the causative agent of glanders (B. mallei was type species for the 
now-defunct genus Malleomyces).24,25 It was, for a time, called Pfeifferella 
whitmori.26 It was suggested also that the bacterium be housed in the genus 
Loefflerella.27 The organism was transferred to the genus Pseudomonas in the 
6th edition of Bergey’s Manual,19 a decision supported by the best 
morphological, phenotypic and biochemical evidence available at the time.28 
The organism was finally transferred to the genus Burkholderia in 1992 (as 
Burkholderia pseudomallei comb. nov.) on evidence from its 16S ribosomal 
subunit sequence:21 B. pseudomallei and P. aeruginosa are now no longer even 
in the same class, let alone the same genus, family or order. B. mallei was also 
moved to the same genus using the same criteria,21 and has been shown to have 
evolved from B. pseudomallei by specialisation to an equine host and a process 
of genome reduction.29 Indeed, B. mallei may be considered a subspecies of 
B. pseudomallei by multilocus sequence typing.30 Although B. mallei can 
survive in tap water for up to four weeks (and horses can become infected from 
contaminated drinking water),20 B. mallei has lost the ability to persist 
indefinitely in the environment. 
In environmental isolates, the main differential for B. pseudomallei is 
B. thailandensis. One puzzle of the early 1990’s was that environmental surveys 
of B. pseudomallei seemed to show a much larger endemic area than was 
clinically evident.31,32 Many of those environmental isolates were later shown to 
be due to a separate species, B. thailandensis, which is distinguished from 
B. pseudomallei on the basis of its ability to assimilate arabinose and its 
avirulence in mice and hamsters.32–37 In 1998, B. thailandensis was given status 
as a separate species on the basis of evidence from its 16S ribosomal subunit 
sequence.38 
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Phylogenetic studies combined with geographical data support an 
Australian origin for B. pseudomallei with a single introduction event into 
Southeast Asia hypothesised to have occurred during a recent glacial period. 
B. pseudomallei isolates may be resolved into two distinct populations divided 
by Wallace’s Line39 (a deep-water channel that forms a physical boundary 
separating Australian flora and fauna from those of Asia). Wallace’s Line has 
separated Australia and Asia for a period in excess of 50 million years, even 
during glacial advances (when sea levels dropped by up to 120 metres from 
current levels).  It runs along the Lombok Straits, separating Bali (to the west) 
and Lombok (to the east). Further north, Wallace’s Line runs between Borneo 
(west) and Sulawesi (east). 
 
Figure 1. Wallace’s Line. 
Wallace’s Line marks the end of the Sunda Shelf, an area of shallow ocean linking the 
islands of Sumatra, Java, Bali and Borneo to the continent of Asia. Lydekker’s Line marks 
the limit of the Sahul Shelf, which links Australia and New Guinea. Weber’s line marks 
the transitional area between the two. Image ©2007 Maximilian Dörrbecker. 
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1.1.2 Laboratory identification of B. pseudomallei 
The clinical features of melioidosis are non-specific, and the diagnosis of 
melioidosis therefore depends on finding B. pseudomallei in a clinical 
specimen.40,41 It is recommended that B. pseudomallei be handled in biosafety 
level 3 facilities42 and this recommendation is motivated by the fact that it may 
be acquired by inhalation and mortality following infection is high. It has been 
argued that level 2 facilities offer adequate protection as long as samples are 
centrifuged in sealed cups and opened only in a biosafety cabinet.43,44 
 
Figure 2. Microscopic appearance of B. pseudomallei. 
Drawing of B. pseudomallei in a pus from an abscess in a guinea pig. The figure is taken 
from Stanton & Fletcher’s 1932 monograph and emphasises the safety-pin appearance of 
the bacterium. 
 
 
B. pseudomallei is a motile, non-lactose fermenting, oxidase-positive, 
Gram-negative bacillus.19 Although initially believed to be a strict aerobe,20 
B. pseudomallei will grow anaerobically if nitrate is present as a terminal 
electron acceptor.45,46 The optimum temperature for B. pseudomallei is 24–
32°C, but it will grow at temperatures up to 42°C.13,47 Clinical samples are 
usually incubated at 37°C in 5% carbon dioxide. 
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B. pseudomallei is not fastidious and grows readily on a wide variety of 
media, including blood agar, tryptic soy broth, LB, CLED and MacConkey. It 
will even survive for extended periods in nutrient deficient media. Stanton & 
Fletcher (1932) reported that B. pseudomallei would survive for 44 days in tap 
water, Miller et al. (1948) reported 8 weeks.20 Wuthiekanun has found that 
B. pseudomallei can survive in distilled water for 16 years and possibly 
longer.48–50 
In culture, the B. pseudomallei has a characteristic bipolar (‘safety pin’) 
appearance when stained for light microscopy (Figure 2), which was first noted 
by Whitmore,8 and has been ascribed to the presence of large lipid vacuoles in 
the centre of the cell that do not stain.20 Although characteristic,17 this safety pin 
appearance is not sufficiently specific as to be diagnostic51 and does not occur 
frequently in clinical specimens.52 B. pseudomallei does not form spores.8 
Cultured bacteria are ~0·8 × 1·5 µm, but bacteria found in clinical samples may 
also form long tangled filaments (Figure 3).41,52 
Recognition of B. pseudomallei is seldom a problem for the microbiologist 
when the specimen has been taken from an otherwise sterile site such as blood, 
or pus from a deep collection. The main technical problem is that the doubling 
time for B. pseudomallei is roughly two hours, which is longer than many other 
bacteria. In specimens taken from non-sterile sites (e.g., catheter urine, sputum 
and throat swabs) colonies of B. pseudomallei are easily overgrown.53 For this 
reason, selective media should be used to isolate B. pseudomallei from these 
specimens.53 
Ashdown agar is made from a base of trypticase soy agar (TSA): it contains 
crystal violet to inhibit the growth of Gram-positive bacteria and gentamicin to 
inhibit the growth of other Gram-negatives.53 B. pseudomallei colonies absorb 
neutral red, which acts as an indicator and helps to distinguish B. pseudomallei 
from other bacteria. The addition of glycerol causes the colonies to wrinkle 
(colonies are smooth on TSA) and the appearance of B. pseudomallei colonies 
on Ashdown agar has been likened to the appearance of cornflowers (Figure 3). 
Colonial morphology is extremely variable, with seven morphotypes described, 
and it is common for pure cultures of a single strain to exhibit multiple 
morphologies.54 
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Figure 3. Appearance of B. pseudomallei in clinical specimens. 
Note.—Both microscope specimens are from the urine of a 71-year-old woman with 
B. pseudomallei septic arthritis of the right knee. She had no urinary symptoms and she 
had previously had melioidosis two years previous to this presentation. Long filamentous 
bacteria were seen on Gram stain of urine (A, magnification ×1000) and 
immunofluorescence staining showed these to be B. pseudomallei (B, magnification 
×1000). The cells visible in the background are a combination of leukocytes and 
epithelial cells. Culture of this sample confirmed B. pseudomallei (C, Ashdown agar). The 
lavender colonies take on their characteristic wrinkled appearance after four-days’ 
incubation and are said to resemble cornflowers (D). Images A, B, C © 2008 Gavin Koh. 
Image D © 2007 J Stegman. 
 
 
Ashdown agar is cheap and easily prepared using readily available 
ingredients. However, many laboratories in the West have moved away from 
preparing their own media to using commercially prepared media, and 
Ashdown agar is not commercially available. For these laboratories, 
B 
D 
 8 
commercially prepared Burkholderia cepacia agar or Pseudomonas cepacia 
agar are suitable alternatives.55,56 
Diagnosis may be achieved with biochemical methods. Using the API 20E 
system (bioMérieux, Marcy l’Etoile, France), most B. pseudomallei isolates have 
one of the following seven digit profiles: 2006727, 2206706, 2206707 and 
2206727.36 Profiles on API 20NE are 1156576, 1156577, 1556576 and 1556577.57 
Of the automated systems available commercially, VITEK 1 (bioMérieux) 
correctly identifies 99% of isolates.58 Performance on VITEK 2 (bioMérieux) has 
been uniformly poor by contrast. In an initial assessment performed in 2002, 
VITEK 2 correctly identified only 19% of isolates.58 In 2006, using a new 
colorimetric GN card, this had improved to only 63–81%.59 Common 
misidentifications include Burkholderia cepacia, Pseudomonas aeruginosa, 
Chromobacterium violaceum and other non-lactose fermenting Gram-negative 
bacilli. 
Variation in the API profile occurs primarily in citrate utilisation, and in 
sucrose and amygdalin assimilation. The antibiotic susceptibility pattern for 
B. pseudomallei is also helpful in allowing it to be differentiated from 
P. aeruginosa, because B. pseudomallei is invariably resistant to gentamicin 
and colistin, but is usually susceptible to co-amoxiclav,36,40,60 a resistance 
pattern that does not occur in P. aeruginosa. 
The ability of patient sera to agglutinate suspensions of B. pseudomallei 
was first reported in 1932, first by the English physicians, Stanton and Fletcher, 
and by the Dutch physicians, de Moor and van der Walle. Both these groups 
evaluated this technique as a means of diagnosing melioidosis serologically. It 
was Miller in 1947,20 who first had the insight that the ability of serum from 
infected rabbits to agglutinate unknown bacteria obtained from cultures might 
be used as a means to identify B. pseudomallei. Unfortunately, Miller’s slide 
agglutination test never entered routine clinical use. 
The sensitivity of slide agglutination test may be increased by conjugating 
the antibody to latex beads, so that even bacteria from a single colony may form 
a visible precipitate. A non-commercial latex agglutination test based on a 
monoclonal antibody to the exopolysaccharide of B. pseudomallei has been 
clinically evaluated and has a sensitivity of 99·5%. The test has been available in 
Thailand since 2002 (Chulaborn Research Institute, Bangkok, Thailand).57,61 As 
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with previous tests based on serological methods (including Miller’s test20), the 
test cannot distinguish B. mallei from B. pseudomallei. 
Immunofluorescence microscopy is useful in samples with a high bacterial 
load62 (≥104 cfu/ml; e.g., sputum, urine or pus from a normally sterile site) and 
is capable of giving same-day results with >99% specificity.63,64 Bacterial loads 
in blood are too low for immunofluorescence microscopy,65,62 which means that 
immunofluorescence is not useful in patients who are bacteraemic but with no 
identifiable focus. The sensitivity is reported to be 66–73% in an idealised 
research setting,63,64 but is probably lower in routine clinical practice. 
Molecular techniques have been attempted, but are not routinely available 
in clinical practice. Targets for polymerase chain reaction (PCR) have included 
the 16S ribosomal subunit,66,67 the gltB and narK genes68 (which are also part of 
the MLST scheme); orf11, orf13 and BpSCU2 (components of the type 3 
secretion system),69 fliC (which codes for flagellin),67 and repetitive elements of 
non-protein-coding DNA.70 Few of these have been validated in the clinical 
setting, and the need for equipment capable of PCR make the majority of these 
methods impractical in the field. On top of this, mere amplification of genes 
may not be sufficient and additional tests such as gene sequencing may be 
required.71 
Loop-mediated isothermal amplification (LAMP) appears to have a 
number of characteristics that make it preferable to PCR for nucleic acid 
amplification in resource-poor settings. The method employs a DNA polymerase 
and a set of four specially designed primers that recognise a total of six distinct 
sequences on the target DNA. The reaction is simple to set up and requires 
much less training than PCR, and the initial capital outlay is minimal (the only 
equipment required is a water bath or heat block capable of maintaining a 
constant temperature of 60–65°C). A LAMP assay was developed targeting the 
BPSS 1406 hypothetical protein, situated within the TTS1 gene cluster of 
B. pseudomallei.72 The lower limit of detection was 38 genomic copies per 
reaction, which is still too high to reliably detect B. pseudomallei in blood.62,65 
Performance was better in other sample types including sputum, urine and pus 
(sensitivity 45·8–75%, specificity ≥97·9%). No direct comparison was made 
against immunofluorescence, but these results seem comparable to that 
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technique,63,64 which means LAMP is unlikely to supplant immunofluorescence 
as a method for rapid antigen detection. 
Techniques for rapid diagnosis are urgently needed, because culture-based 
methods entail a minimum turnaround time of 48 hours or more. 
Immunofluorescence microscopy currently fulfils that function, but is 
insufficiently sensitive. 
B. thailandensis has a biochemical phenotype very similar to 
B. pseudomallei, but B. thailandensis almost never causes disease in humans. 
There are only two reported cases of human B. thailandensis infection in the 
literature73,74 and the need for a clinical laboratory to distinguish between the 
two species therefore almost never arises. If necessary, B. thailandensis can be 
differentiated from B. pseudomallei by its ability to assimilate arabinose, which 
B. pseudomallei cannot do.34,38 A definitive distinction between the two species 
may be made using MLST.30 
B. mallei (the causative agent of glanders) is morphologically and 
biochemically indistinguishable from B. pseudomallei, except that the 
bacterium is immotile. Like B. pseudomallei, automated laboratory methods 
may misidentify it as other non-lactose fermenting Gram-negative bacilli.75 For 
a clinical laboratory on the ‘front lines’, the first indication that the isolate is 
B. mallei and not B. pseudomallei is the susceptibility profile: ~80% of B. mallei 
isolates are susceptible to gentamicin and may also be susceptible to some 
macrolides.76,77 Some isolates may also be susceptible to ampicillin, which 
B. pseudomallei never is.76 A definitive diagnosis may require 16S RNA 
sequencing or MLST, but this issue is unlikely to arise, except in a biothreat 
setting, since glanders has been largely eradicated and the last naturally 
occurring infection reported in the English-language literature was in 1949.75 
Outbreaks continue to occur in susceptible equids, the most recent of which was 
an outbreak in dromedaries in Bahrain.78 
1.1.3 A brief survey of virulence factors 
B. pseudomallei is a facultative intracellular pathogen79–81 and much of the 
literature on host-pathogen interactions centres on, or needs to be interpreted 
in light of, this fact. 
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Virulence factor Function References 
BimA Actin polymerization, 
intracytoplasmic movement and cell-
to-cell spread 
 
Kespichayawattana 2000,82 
Breitbach 2003,83 Stevens 2005,84 
French 201181  
BPSS1823 Intracellular survival, swarming 
motility, resistance to low pH, 
protease production 
 
Norville 201185  
Capsular polysaccharide Resistance to serum lysis; complement 
resistance 
 
 
 
 
Reckseidler 2001,86 Atkins 2002,87 
Reckseidler-Zenteno 2005,88 
Warawa 2009,89 
Wikraiphat 2009,90 
Reckseidler-Zenteno 201091  
Flagellin Motility; cell invasion 
 
 
 
Brett 1994,92 DeShazer 1997,93 
Chua 2003,94 Inglis 2003,95 
Chuaygud 200896 
Lipopolysaccharide Complement resistance;  
endotoxin 
 
 
Matsuura 1996,97Luc[1 
DeShazer 1998,98 
Wikraiphat 2009,90 Novem 200999  
Quorum sensing Downstream virulence factors as yet 
unidentified 
 
 
Ulrich 2004,100 Juhas 2004,101 
Valade 2004,102 Song 2005,103 
Diggle 2006,104 
Lumjiaktase 2006105 
 
Superoxide dismutase Resistance to killing by superoxide Vanaporn 2011106 
 
Type IV pilin Adhesion to respiratory epithelium 
 
Essex-Lopresti 2005107 
Type III secretion 
systems 
Injecting effector proteins into the host 
cell; escape from endocytic vacuoles 
 
Stevens 2002,108 Stevens 2004,109 
Warawa 2005,110 Pilatz 2006,111 
Burtnick 2008,112 Sun 2010,113 
French 201181 
 
Type VI secretion 
systems 
Injecting effector proteins into the host 
cell 
Schell 2007,114 Shalom 2007,115 
Burtnick 2011,116 French 201181 
Table 1. Summary of B. pseudomallei virulence factors. 
 
In 1990, Pruksachartvuthi et al. showed by electron microscopy that 
B. pseudomallei was able to persist within both neutrophils and monocytes 
collected from healthy human volunteers.79 That the intracellular bacteria were 
viable and capable of replication was confirmed by culture.79 B. pseudomallei is 
also capable of parasitizing a number of phagocytic and non-phagocytic cell 
lines, including A549 (human adenocarcinomic basal epithelial lung cells),80,85 
CHO (Cricetulus griseus ovary cells), HeLa (human cervical epithelial cells),80 
J774.1A1 (Mus musculus BALB/c peritoneal macrophage),117 Vero 
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(Cercopithecus aethiops kidney epithelial cells),80 and U937 cells (human 
monocyte line).80 It will also invade rat alveolar macrophages80 and 
Acanthamoeba species.118 
After entry into the cell, B. pseudomallei is able to evade intracellular 
killing,85,119 lyse the endosome membrane and enter the cytoplasm.81 In the 
cytoplasm, it is able to mobilise by polymerising actin at one pole of the 
bacterial cell to form membrane protrusions, which allow it to invade adjacent 
cells.82–84 Virulence factors of B. pseudomallei are summarised in Table 1. 
1.2 Epidemiology 
1.2.1 Geographical distribution of melioidosis 
Descriptions of the epidemiology of melioidosis are hampered by the lack 
of clinical awareness and laboratory facilities in areas where it is likely to be 
endemic.120,121 Without the ready availability of microbiological diagnosis, 
melioidosis may go completely unrecognised even in areas where it is highly 
endemic.120 The geographical distribution of B. pseudomallei should therefore 
be regarded as poorly defined. 
The first evidence for melioidosis in Thailand was from a 1930 case report 
of a Russian man, normally resident in Bangkok, who presented in a delirious 
state to police in Phnom Penh, Kampuchea (now Cambodia). Diagnosis was 
made post mortem.122 The first case of melioidosis reported in Thailand itself 
was in 1947, in a Dutch soldier who had been held a prisoner-of-war by the 
Japanese.123 The first reported case in a native Thai had to wait until 1955.124 It 
was not until the expansion of microbiological services that occurred in the 
1970’s and 80’s that it became clear melioidosis was highly endemic in Thailand 
and probably always had been.125,126 
The opposite has occurred in Burma. In 1917, Krishnaswami reported over 
a hundred cases of melioidosis in Rangoon just five years after first describing 
the disease.127 Yet, no case of indigenous melioidosis was reported in Burma 
between 194540 and 2000128 despite the fact that Burma continued to export 
cases of melioidosis throughout that period129,130 and despite a high 
seroprevalence in the native population.131 
The global distribution of melioidosis has been described in detail by 
Currie, Dance and Cheng,132,133 and their map is reproduced in Figure 4. 
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Figure 4. Map of the global distribution of melioidosis. 
Note.—Pink asterisks show the location of three outbreaks that occurred in temperate 
regions: one in France, and two in Australia. Figure taken from Cheng and Currie Clin 
Microbiol Rev 2005;18:383–416. 
 
 
 
Melioidosis is a disease of the tropics and appears to be confined to a band 
roughly 20° north of the equator and 20° south. The endemic area is focused 
around southeast Asia and northern Australia; its northernmost extent is 
southern China, Hong Kong and Taiwan; its southernmost extent is northern 
Australia. Melioidosis is almost certainly endemic to India134–136 and probably 
always has been. There are sporadic cases from Africa and Central 
America,132,133,137,138 but the lack of microbiological facilities in much of these 
areas means the true extent of melioidosis is unknown. 
1.2.2 Melioidosis as a zoonosis 
A zoonosis is a disease where infection occurs by transmission from a 
vertebrate animal to human (World Health Organization, Geneva, Switzerland). 
In 1925, Stanton and Fletcher described melioidosis as a zoonosis based on 
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observations that rodents succumb to the disease.10 However, in that same 
paper, Stanton and Fletcher also noted that melioidosis is fatal to rodents, 
which makes it very unlikely that rodents could be an efficient reservoir or 
vector. In their 1932 monograph, they revised this assertion, stating, ‘The way in 
which man contracts melioidosis is a problem as yet unsolved,’ but continued to 
assert that they ‘believe that infection usually occurs…through the consumption 
of food which has been contaminated by the excreta of infected rodents.’  
In 1948, Harries et al. noted that they were unable to find melioidosis in 
any of >500 rats examined in Rangoon,129 and in 1969 Strauss et al. performed 
a similar survey of 422 wild rats (Rattus tionamicus jalorensis, 
R. argentiventor, R. exulans and R. rattus) in a survey of Carey Island, 
Selangor, Malaysia,140 and expressed doubt that rats are a reservoir for the 
disease. In the 1955, Chambon et al. showed that B. pseudomallei is primarily 
environmental,141 and transmission from animals to humans has not been 
shown to be an important cause of infection.132 
The disease is dealt with by the Bacterial Zoonoses Branch of the US 
Centers for Disease Control and melioidosis continues to be listed with the 
zoonoses by textbooks.142 Some books published as recently as 2002 continue to 
assert erroneously that animals are a reservoir for disease.143 
Melioidosis infects a large numbers of animals and birds.144 Sheep and 
goats are particularly susceptible, resulting in the absolute requirement for 
pasteurisation of tropical commercial goat’s milk.144 Gorillas are also extremely 
susceptible, so much so that extraordinary measures are needed to isolate them 
from the environment in a melioidosis-endemic area.145 Four male animals 
imported to the Singapore Zoological Gardens died within months of arriving 
from Rotterdam, and the one surviving animal was returned to Rotterdam for 
treatment. On outbreak at the Paris zoo in the 1970’s («L’affaire du jardin des 
plantes») was attributed to an imported panda.146 Horses were initially reported 
to be immune, as demonstrated by attempts at experimental inoculation,10 but 
cases of naturally occurring infection have subsequently been reported.146–149 
There appears to be no basis for the oft-repeated150 claim that water buffalos are 
immune. 
Rats, mice and hamsters are all susceptible and are important small 
animal models of melioidosis.151–153 Of the three, Syrian golden hamsters are the 
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most susceptible.154,155 In fact, such is the susceptibility of hamsters to 
B. pseudomallei, that Miller et al. developed a method of purifying 
B. pseudomallei from mixed cultures by infecting hamsters with the 
contaminated sample and recovering the pure organism from the hearts blood 
of the animals after they succumbed to the disease.20 
Strauss’ environmental surveys of the 1960’s used hundreds of hamsters to 
purify samples. Filtered samples of soil or surface water were rendered isotonic 
with saline then injected intraperitoneally into hamsters to yield pure cultures 
of B. pseudomallei when they died five days later of melioidosis.140 Hamsters 
are not susceptible to B. thailandensis,37 and it is interesting to speculate 
whether B. thailandensis would have been discovered had hamsters continued 
to be used in environmental surveys. 
1.2.3 Melioidosis is an environmental organism 
In 1955, Chambon demonstrated that B. pseudomallei could be isolated 
from soil and water in South Vietnam (including rice fields), that the isolated 
organism was virulent, and that it produced the characteristic histological 
features of melioidosis in guinea pigs, rabbits and mice.141 These findings were 
confirmed and extended by a series of detailed epidemiological studies 
published in 1969 by Strauss.140,156,157 Strauss was able to culture 
B. pseudomallei from 14·6% of the samples taken from rice paddy fields, 
whereas samples taken from land used for all other purposes had isolation rates 
<10%.156 In two seroprevalence surveys of army recruits from states where the 
principal crop was rice, the proportion with haemagglutinating antibody titres 
≥1:40 was 22·9%. By contrast, on Pulau Carey, where agricultural activity was 
confined to rubber, oil palm, coconut palm, and tea cultivation, only 3·4% of 
army recruits had haemagglutinating antibody.157,140 Strauss also surveyed 422 
wild rats and found no evidence of carriage.140 Based on this evidence, Strauss 
concluded that B. pseudomallei is a normal inhabitant of the soil and of water 
(particularly rice paddy fields), and that there was no evidence that rodents or 
animals of any kind were required for maintenance of the organism. Subsequent 
surveys have confirmed the association of B. pseudomallei with soil in 
Thailand33,158 and ground water in Australia.159 Environmental concentrations 
correlate with the incidence of clinical melioidosis.158,160,Table 2 
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The distribution of B. pseudomallei in soil is extremely irregular, and a site 
with no detectable bacteria may lie as little as five metres from a site with 
>10,000 cfu/g soil.161 The reasons for this are unknown, but competition with 
other Burkholderia species has been suggested as a reason.162 Kaestli found that 
in sites undisturbed by human activity, B. pseudomallei was more commonly 
found in areas rich in grasses. In environmentally disturbed sites, 
B. pseudomallei was associated with the presence of livestock animals and lower 
soil pH.163 It has been suggested that water-logged, clay soils may be better at 
harbouring the bacterium than sandy, well-drained soils.47,164 In common with 
other Burkholderia species,165 B. pseudomallei is able to survive and replicate 
intracellularly within Acanthamoeba species in vitro.118,166 
 
Region of Thailand No. of positive sites Infection rate per 
100,000 inpatients 
Central 24·5% 13·4 
North 13·8% 18 
Northeast 50·1% 137·9 
South 18·4% 14·4 
Table 2. Isolation rate of B. pseudomallei from soil compared to 
incidence of melioidosis by region of Thailand. 
Adapted from Vuddhakul et al. Am J Trop Med Hyg 1999;60:458–61. 
 
 
1.2.4 Melioidosis and rainfall 
The association between melioidosis and rainfall was first noted by Strauss 
in 1969, who found that he was unable to isolate B. pseudomallei from his 
environmental samples when the weather was dry, but that samples became 
positive after each rainfall.140 Studies of human melioidosis cases in Australia, 
Thailand and Singapore show a clear association with heavy rainfall in the 7 
days preceding onset of the illness or the 14 days preceding admission to 
hospital, and there is a positive correlation year-by-year between the amount of 
rain and the number of cases of melioidosis.167–171 There is certainly a 
correlation with extreme weather events such as hurricanes.172,173  
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Figure 5. The relationship between rainfall and melioidosis cases in 
Ubon Ratchathani, Thailand. 
Note.—This graph shows the quarterly incidence of melioidosis (solid line) over five 
years (1987 to 1991), with the rainfall (interrupted line) in each quarter superimposed. 
Figure from Suputtamongkol et al. Int J Epidemiol 1994;23:1082–90. 
 
 
1.2.5 Human factors 
B. pseudomallei is an organism of soil and surface water and a history of 
contact with soil or surface water is therefore common, and a history of 
residence in or travel to an endemic area is almost invariable.169,174–177 In 
Northeast Thailand, rice farming is an important part of the local economy. Rice 
fields are flooded for much of the growing season and farmers spend much time 
bare foot in paddy fields. Rice farming is therefore an important risk factor for 
melioidosis.169 
Patients with melioidosis are more likely to be male. The ratio of males to 
females is 1·41:1 in Thailand,170 2·21:1 in Australia,176 and 2·8–7·2:1 in 
Singapore.168 The statistics in Singapore are skewed by the fact that only males 
are called up for military service, which involves high levels of exposure to 
contaminated soil, and adjusting for this fact reduces the sex ratio to 1·3:1.174 
Harries et al. reported five cases of melioidosis in West African troops 
(numbering approximately 30,000 in total) stationed in Burma,129 and 
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marvelled that no cases were reported among Indian and Burmese troops 
stationed at the same place. In Australia, aboriginals are overrepresented (24% 
of the population, but 50% of melioidosis cases).177 In Singapore, Indians and 
Malays are at greater risk of melioidosis than the Chinese,174,178 possibly related 
to higher rates of diabetes in those two races.179 
 
 
Figure 6. Farming barefoot in northeast Thailand. 
Note.—Farmers in Northeast Thailand walk through flooded paddy fields barefoot for 
practical reasons. Images courtesy of Andrew Taylor © 2008 (left) and Vanaporn 
Wuthiekanun © 2006 (right). 
 
 
Diabetes mellitus is the most frequently identified risk factor in patients 
with melioidosis: 39% of patients in Australia,176 60% of patients in Thailand175 
and 76% in India have diabetes.135 In Northeast Thailand, patients with diabetes 
have 21·4-times greater risk of having melioidosis compared to people without 
diabetes.170 Heavy alcohol use is a risk factor in 12–39%, renal disease (chronic 
renal failure or kidney stones) in 12–20·1%. Glucocorticoids are present in many 
herbal preparations (called variously ya tom, yam mor or ya chut) which 
patients use to self-medicate, and use of herbal medicines is an important cause 
of immunosuppression in northeast Thailand. Other important risk factors 
include thalassaemia and malignancy.135,170,175,176 Patients with cystic fibrosis 
may be particularly susceptibility; fortuitously, the endemic ranges for the two 
diseases do not overlap, except in northern Australia.52,137 HIV does not appear 
to be a risk factor.180 
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1.2.6 Routes of acquisition 
The route of entry into the body is unknown. In Thailand, rice farmers 
wade knee-deep in the muddy water of rice paddy fields, and rice farming is an 
important risk factor for melioidosis.175 By contrast, melioidosis is not a large 
problem in rice-farming areas of Malaysia, where the process of farming has 
been largely mechanised, and the direct exposure of farmers to soil and surface 
water is limited. It has been suggested that the organism may gain entry via 
scratches and small skin-breaks in the feet and legs, and there is one reported 
case of inoculation following a snake bite.40,125 In this hypothetical scenario, 
pneumonia is explained by haematogenous spread. Against this hypothesis is 
the fact that the majority of cases in Singapore (whose population is entirely 
urban) have no history of contact with soil or surface water, despite a clear 
association with rainfall.168 
The evidence supporting an inhalational route for melioidosis is largely 
circumstantial. There is a clear relationship between rainfall and melioidosis 
pneumonia,167,169,170 and during the Vietnam War, an epidemiological link was 
found between the helicopter crewmen and melioidosis infection,13 of whom 
many developed melioidosis pneumonia. This led to the conjecture that the 
infection may have been due to inhalation of dust generated by the helicopter 
rotors and that inhalation of aerosolized bacteria may be an important mode of 
infection.17,181 Data from animal models also appear to support this: the size of 
inoculum needed to produce an equivalent effect in mice is four orders of 
magnitude smaller than that needed to infect the same inbred strains 
subcutaneously.182 There is one case of laboratory-acquired melioidosis 
reported in the literature due to inhalation of aerosolized bacteria,183 so human 
infection by this route is possible and viable bacteria have been found to be 
aerosolized by severe weather events such as typhoons.184 
A third possible route of infection is via ingestion. Melioidosis has been 
transmitted from mother to child via infected breast milk185 and it is possible to 
infect mice by oral gavage, but the doses required are of the order of 108 cfu,186 
which is an order of magnitude higher than that required for subcutaneous 
infection, and at least six orders of magnitude higher than that required for 
inhalation. Much of the population in Northeast Thailand draw their water from 
wells or other untreated water-sources that may become contaminated with soil 
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during the rainy season. Two outbreaks in Northern Australia were associated 
with contamination of drinking water,187–189 but this does not necessarily mean 
that the main mode of transmission in those outbreaks was ingestion, as potable 
water was also used for washing and bathing. 
The tsunami of Boxing Day, 2004, was associated with a spike in the 
incidence of melioidosis in affected areas.190–196 Cases of human-to-human 
transmission have been described, but are exceptionally rare.52,185,197,198 Vertical 
transmission has been described but is extremely rare.199 
1.3 Clinical features of melioidosis 
A definitive diagnosis of melioidosis may only be made on the basis of 
microbiology (please refer to section 0 below),40,41 and the main limitation to 
diagnosis is the availability of adequate laboratory facilities.  
Melioidosis has two main presentations: acute and chronic. Paediatric 
disease is discussed in a separate section below. 
1.3.1 Acute melioidosis 
Acute melioidosis has no specific clinical features and should be suspected 
in any septic patient with a history of residence in or travel to an endemic area. 
The presence of a recognised risk factor (particularly diabetes) is helpful, but 
the absence of risk factors does not exclude melioidosis. Where an inoculating 
event has been noted, the mean incubation period is 9 days.177 
In Northeast Thailand, the median duration of symptoms prior to 
presentation is 10 days.200 Acute melioidosis is often disseminated, with 
multiple sites being involved: 59–62% have bacteraemia and 49–56% have 
pneumonia200,201 (appearances on the chest radiograph range from lobar 
pneumonia to widespread cotton wool patches); 28–52% have abscesses of the 
spleen and/or liver200–202 and 23–27% have skin and/or soft tissue infections 
(principally wound infections and skin abscesses; cellulitis and erysipelas are 
rare).200,201 Other infections include those of the urinary tract (ranging from 
pyelonephritis to prostatitis to asymptomatic bacteriuria), osteomyelitis,203 
septic arthritis,203 myositis,203 keratitis,204 endophthalmitis,205,206 orchitis,207,208 
and mycotic aneurysms.209 Mortality is 42·6%.170 
Melioidosis in Australia presents in a similar manner to Thailand, with 
some notable exceptions. Mortality is much lower (14%), which may be related 
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to differences in supportive care.176 In Australia, 20% of male patients have 
prostatic abscesses,176 whereas this presentation is rare in Thailand. It is not 
certain whether this is a true difference or whether it represents differences in 
the availability of imaging (computed tomography of the pelvis is not routinely 
performed in northeast Thailand). 
There exists in Australia a syndrome of encephalomyelitis (2·6% of cases), 
which manifests as a constellation of cerebellar signs, brainstem features and 
cranial nerve palsies.176 Few abnormalities are visible on CT, but dramatic 
changes are visible on MRI.210 By contrast, neurological melioidosis in 
Southeast Asia (1·6% of cases in Northeast Thailand211) presents with cerebral 
abscesses (which may be multiple). These usually present with seizures and/or 
focal neurological deficits and are clearly evident on CT.212,211,213 In Singapore, 
four of five cases of cerebral melioidosis were linked to sinusitis.213 Primary 
meningitis is extremely rare and there appears to be only one case reported in 
the literature,214 although meningitis has been reported to occur secondary to 
rupture of a cerebral abscess.40 
1.3.2 Chronic melioidosis 
Chronic melioidosis (defined as disease with onset ≥2 months prior to 
presentation215) comprises 12% of all adult melioidosis cases.215 It usually 
presents as localised disease, the majority of which are chronic non-healing 
localised skin or soft tissue lesions, osteomyelitis, or pulmonary abscesses. It 
often resembles tuberculosis clinically and is well described in the 
literature.26,216–220 Survival is the norm: of 30 cases of chronic melioidosis 
reported in Northern Australia, all survived.221 
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Figure 7. Clinical manifestations of melioidosis. 
Note.—Pulmonary melioidosis has a wide range of presentations: A. Multiple bilateral 
cotton wool patches. B. Left hilar lung abscess. C. Lobar pneumonia of the right upper 
lobe. D. Large liver abscess in a 32-year-old female. E. Right renal abscess in a 63-year-
old female. F. Cutaneous abscess on the right arm of a 47-year-old male. 
All images ©2007–2008 Gavin Koh.  
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The majority of early cases reported were acute and fulminant, but it was 
recognised early on that in a small number of patients, the presentation could 
have an indolent onset and chronic course. The first two cases of chronic 
melioidosis were reported by Stanton & Fletcher in 1932, both with 
osteomyelitis. Both patients survived to discharge, although one patient 
continued to have discharging sinuses in his feet two years later. Grant and 
Barwell describe a case of melioidosis in a 27-year-old soldier who present 
initially in 1938 with septic arthritis of the right hip and ankle (initially 
diagnosed as gonorrhoea), who went on to develop chronic pneumonia and 
osteomyelitis of the frontal bone over the next five years. Mayer and Finlayson 
describe the case of a 33-year-old soldier who developed bilateral lumbosacral 
abscesses while stationed in Singapore in 1940. A year later, he developed a 
chronic right lower lobe pneumonia and the lumbosacral abscesses were 
recognised to have arisen from osteomyelitis of the lower thoracic spine. He was 
initially diagnosed with tuberculosis, but the diagnosis was revised two years 
after presentation in the light of B. pseudomallei being cultured from the pus. 
The patient had been unwell for 4 years at the time the report was published.216 
1.3.3 Paediatric melioidosis 
In Thailand, there are two age peaks: one in early childhood (≤10 years, 
mean age 6·8 years) and one in middle age (≥45 years).169,170,222 Paediatric 
melioidosis in Thailand is largely a benign condition. Two-thirds of cases 
present with localised disease222 (38–40% of paediatric cases present with a 
unilateral parotid abscess) and have a good prognosis.223,224 A third present with 
pneumonia or bacteraemia and have a presentation and prognosis similar to 
adult disease.222 Preliminary reports from Cambodia suggest that the spectrum 
of paediatric disease there appears similar to that found in Thailand.225 
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Figure 8. A 2-year-old child with unilateral parotitis at 
Sappasithiprasong Hospital in Ubon Ratchathani, Thailand. 
This 2-year-old male child developed swelling of his left cheek one week after playing in 
a freshwater lake. The abscess was drained surgically and the child was discharged on 
oral co-amoxiclav. Image © 2008 Gavin Koh. Signed consent obtained from parents. 
 
 
In contrast to Thailand, Australia and Malaysia report no paediatric peak, 
and when melioidosis does occur in children, the presentation and prognosis is 
similar to when it occurs in adults.215,226–228,227 Paediatric melioidosis in 
Malaysia is associated with immunocompromise (particularly haematological 
malignancy),226 while paediatric melioidosis in Australia is associated with 
cystic fibrosis.227,229 Cultural differences may play a role: children in Northeast 
Thailand are accustomed to playing in flooded paddy fields (splashing around 
and catching the fish and crabs that grow there: both an important part of the 
diet of Northeast Thailand). Their exposure to contaminated water is therefore 
much greater than in elsewhere, and the syndrome of unilateral parotitis in 
paediatric patients appears confined to Thailand.215,226 
1.3.4 Incubation period and latent melioidosis 
The only systematic attempt to measure the incubation period in 
melioidosis was made by Currie et al. in 2000: of 52 patients who reported an 
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inoculating event, the mean time to onset of symptoms was 9 days (range 1 to 
21 days).177 
However, the incubation period for melioidosis may be much longer. 
There were fewer than 300 cases of melioidosis among American soldiers 
during the Vietnam war, but additional cases continued to present many years 
after the war’s end,230–232 earning it the name, ‘Vietnamese time bomb’.233 
Incubation periods of 18 years234 and 28 years235 have been reported in a 
Vietnam veteran and a World War II veteran respectively. The longest reported 
incubation period is 62 years, in an American man who had been taken prisoner 
by the Japanese in 1942, who had worked building railroads in Singapore, 
Malaysia, Burma and Thailand. After the war, he returned to Texas and did not 
subsequently travel to a melioidosis endemic area. He presented in 2004 with a 
non-healing ulcer on his right hand following a dog bite and wound culture grew 
B. pseudomallei. 
Latent melioidosis describes persistent clinically silent infection that may 
activate many years after initial exposure or infection, and is named by analogy 
to latent tuberculosis. We do not know how to diagnose latent melioidosis, 
except retrospectively after reactivation. There is no information as to whether 
serology for B. pseudomallei can identify latent melioidosis, or even whether 
negative serology for B. pseudomallei excludes latent melioidosis. 
Latent melioidosis seems to be uncommon and Currie et al. estimate that 
latent disease accounts for no more than 4% of all cases.177 There has not been 
an explosion of melioidosis cases in America despite the fact that an estimated 
225,000 soldiers returning from Vietnam were seropositive.236 The 
overwhelming majority of melioidosis cases are reported in endemic areas, are 
of seasonal onset, and occur during the rainy season, all of which suggest that 
recent acquisition and short incubation periods are the norm.169,177 The available 
evidence supports the conclusion that unlike latent tuberculosis, the majority of 
patients with evidence of exposure to B. pseudomallei do not go on to develop 
clinical melioidosis, even if they do have silent infection. The only appropriate 
recommendation therefore is clinical vigilance. 
Asymptomatic carriage of B. pseudomallei is rare. Currie et al. describe a 
single case who was persistently sputum culture-positive for 12 months after 
stopping antimicrobial chemotherapy.221 A single case of asymptomatic throat 
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carriage in 58-year-old Vietnamese female rice farmer was reported by Phung et 
al.,221,237,238 but Wuthiekanun found no instances of throat carriage on screening 
3,524 Thai subjects.239 Patients with cystic fibrosis may harbour 
B. pseudomallei in their sputum even after appropriate treatment.240,241  
For all practical purposes, asymptomatic carriage of B. pseudomallei is 
very rare. B. pseudomallei cannot be considered part of the normal human 
flora, and the presence of even a single colony should be considered diagnostic 
of melioidosis.  
1.3.5 Seroprevalence 
Melioidosis seroprevalence is defined as the prevalence in the general 
population of people with a serum titre for anti-B. pseudomallei antibodies 
within the diagnostic range for melioidosis. 
As early as 1932, Dutch and English workers both dismissed serodiagnosis 
as useless in the diagnosis of melioidosis, because titres in healthy controls were 
so high.11,242 Post World War II, Brygoo working in Vietnam (1953) and Nigg 
working in Thailand (1963), both rediscovered the fact that healthy persons may 
carry specific antibodies to B. pseudomallei in high titre. While evaluating 
serology as a method for diagnosing melioidosis, Brygoo noted that 9·4% (24 of 
255) Vietnamese controls had titres ≥1:40.243 Nigg (apparently unaware of 
Brygoo’s work) made her observations as part of a trial of a killed 
B. pseudomallei vaccine conducted by the US military in Thailand. She found 
that a proportion of the healthy Thai volunteers for her study had elevated titres 
of antibody (as high as 1:5,120) even prior to immunisation. 
B. pseudomallei is ubiquitously present in the soil in endemic areas, but 
seroprevalence varies greatly and survey results are hard to compare because of 
differences in study population (hospitalised patients versus community-based 
studies) and in the cut-off titre selected (Table 3). The highest seroprevalence 
recorded is in Northeast Thailand (Figure 9),244 but seroprevalence throughout 
Southeast Asia is high (Table 3). Positive serology is therefore extremely 
common in otherwise healthy people in endemic areas such as Northeast 
Thailand and this severely limits the utility of serological tests during the 
investigation of suspected melioidosis. 
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Seroprevalence (cut-off) Study population Location Reference 
7·3% (1:40) 1,592 adults Malaysia Strauss 1969157 
47·1% (1:40) 227 blood donors Thailand Khupulsup 1986244 
0·73% (1:16) 683 soldiers Singapore Yap 1991245 
83% (1:10), 22% (1:80) 295 children Thailand Charoenwong 1992246 
21% (1:40) 406 adults Vietnam Phung 1993237 
26·5% (1:40) 200 blood donors Malaysia Norazah 1996247 
8·7% (1:40) 160 adults Australia O’Brien 2004248 
38% (1:40), 7% (1:160) 968 adults Burma Wuthiekanun 2006131 
8·2% (1:40) 747 children Papua New Guinea Warner 2007249 
2·5% (1:40) 1,500 blood donors Australia Lazzaroni 2008250 
16·4% (any reaction), 
6·5% (1:160) 
968 children Cambodia Wuthiekanun 2008251 
Table 3. Summary of seroprevalence studies conducted using IHA. 
 
 
Figure 9. Seroprevalence rises with age in Northeast Thailand. 
The graph shows the distribution of IHA titres by age in 2,214 children from Northeast 
Thailand. The proportion of children with any detectable titre rises rapidly in the first four 
years of life then plateaus at 60–71%. By contrast, there is a gradual rise in the proportion 
of children with a titre of ≥1:160, and by age 13, a fifth of children have an antibody titre 
over 1:160. Figure taken from Wuthiekanun Am J Trop Med Hyg 2006;74:1074–5. 
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There is conflicting evidence whether the high seroprevalence seen in 
endemic areas is due only to exposure to B. pseudomallei, or whether there is 
cross-reactivity with B. thailandensis. Tiyawisutsri et al. examined 117 Thai 
adult patients with culture-proven melioidosis and found that their sera did not 
cross-react with B. thailandensis.252 Gilmore et al. performed a similar study of 
25 Australian patients with culture-proven melioidosis and found that their sera 
did cross-react with B. thailandensis.253 The methods used were similar except 
that different strains were used in each study, but it is not clear whether this is 
sufficient to explain the difference in results obtained. 
1.4 Diagnosis 
1.4.1 Microbiology 
 
‘…there are, indeed, no cardinal symptoms upon which a trustworthy 
diagnosis can be based, and the true nature of the disease can be determined 
only by the cultivation of the causative organism…’  
— A. T. Stanton & W. Fletcher, 1932 
 
An early complaint (first made in 1932) was that melioidosis has no 
cardinal symptoms or signs on which to base a diagnosis.11 Indeed, the clinical 
manifestations of melioidosis are protean and melioidosis most frequently 
presents as undifferentiated sepsis. Infection has been described in almost every 
organ in the human body, except that melioidosis seldom, if ever, causes 
primary meningitis or endocarditis.40 
A definitive diagnosis of melioidosis is made by isolating B. pseudomallei 
from any clinical specimen, because B. pseudomallei is not part of the normal 
human flora.40,41 Stanton & Fletcher’s 1932 monograph advised that a medical 
officer suspecting melioidosis in a patient, but who had no access to a 
laboratory, should inoculate guinea pigs with blood or pus, then send the 
infected animals to the nearest laboratory for diagnosis.11  
The identification of even a single colony may clinch the diagnosis. Every 
patient with suspected melioidosis should have a set of blood cultures, urine 
specimen and a throat swab taken. Sputum, swabs from skin lesions, pus/fluid 
from collections, etc. should be collected as indicated clinically.41,239 Bone 
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marrow aspirates offer no benefits over blood culture.254 Throat swabs may be 
culture-positive regardless of the presence or absence of respiratory 
symptoms.239 Urine may be culture-positive even when there are no urinary 
symptoms. Throat swabs and urine should therefore always be collected 
regardless of symptoms or signs. 
1.4.2 Serological diagnosis 
Serological diagnosis is the identification of antibodies directed against 
B. pseudomallei in the serum of blood from patients with melioidosis. Antibody 
reactions to B. pseudomallei are common following environmental exposure, 
are not protective,250 and high titres may be found in patients with melioidosis. 
Serological tests have therefore been the focus of the development of rapid 
diagnostic tests for melioidosis. 
The earliest reports measured the ability of patient serum to agglutinate 
suspensions of whole bacteria. In 1932, De Moor et al., reporting from Batavia, 
Dutch East Indies (modern day Jakarta, Indonesia), considered the use of 
serology to diagnose melioidosis, but dismissed it as having little value,242 
because sera from normal controls agglutinated B. pseudomallei at titres 
≥1:400. They therefore suggested that in the absence of positive cultures, only 
titres ≥1:1000 could be considered diagnostic. Harries et al. (1948) suggested 
that a titre of 1:80 be reported as ‘significant’ and that a titre of 1:160 was 
‘diagnostic’, based on the observation that the majority of 56 control sera taken 
from patients with other infections (principally syphilis) had no detectable titre 
and none had titres >1:20.129 The difference between de Moor’s and Harries’ 
results appears to be accounted for by the fact that the controls used by de Moor 
were drawn from the native population (who would be expected to have a high 
background exposure to B. pseudomallei), whereas the controls Harries used 
were mainly British soldiers (who came from a non-endemic area and would 
therefore not have had any exposure). Serological diagnosis based on 
agglutinating whole bacteria continued to be reported sporadically until 1958.25 
Complement fixation tests have also been used.255,256 
The only validated serological test for melioidosis is the indirect 
haemagglutination test (IHA).257 IHA in its current form was described by 
Strauss et al. in 1968256 (although he was not the first to use IHA in melioidosis: 
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Nigg had described a version using human blood cells 5 years earlier258). Sheep 
erythrocytes are ‘sensitised’ with B. pseudomallei antigen derived from broth 
cultures (called ‘melioidin’ by analogy to tuberculin) and the result reported is 
the maximum dilution of patient serum that causes the sensitised erythrocytes 
to agglutinate. The use of crude antigen in IHA means that the strain (or mix of 
strains) used may result in differences in performance, and results from studies 
performed using different strains may not be comparable. 
Strauss collected sera from 1,592 healthy persons resident in Malaysia and 
compared them to sera collected from 200 healthy persons resident in the US. 
He set a 1:40 cut-off because none of the subjects in the US cohort had titres 
greater than 1:20. He then showed that 7·3% of subjects in the Malaysian cohort 
had titres ≥1:40. Alexander et al. validated the 1:40 cut-off for IHA on 169 
melioidosis patients, using as controls, 201 US soldiers serving in Vietnam and 
Thailand and 200 control sera collected in the US,256 and concluded that the 
1:40 cut-off was reliably specific for melioidosis. 
A limitation of IHA clearly evident in Alexander’s study was the high 
number of false negatives encountered in the first week of disease onset: only 
38–45% were positive at the 1:40 cut-off during the first seven days. This is a 
problem, because around half of all the patients who die of acute melioidosis die 
within the first 48 hours of presentation.199,200,259 In the study performed by 
Alexander et al., the number of sera with reactions above the cut-off increased 
to 88% in the second week, then plateaued at 89–100% in the third week. 
Alexander was not the first to make this observation: de Moor reported this in 
1932, and one of his arguments against the use of serodiagnosis was that 
antibodies took too long to appear and serology was therefore useless in the 
majority of patients.242 
This low sensitivity of IHA in acute melioidosis has been confirmed by 
subsequent studies, with studies in Thailand tending to report slightly higher 
sensitivities than elsewhere. Teparrugkul, in Ubon Ratchathani, reported a 
sensitivity of 86% when using the 1:40 cut-off and 70% when the cut-off was 
1:160.260 In Australia, only 56% of patients with culture-confirmed melioidosis 
had positive IHA results at admission (cut-off 1:40),261 but most patients with 
negative titres at admission subsequently seroconverted. An application for IHA 
may therefore be in the diagnosis of patients with subacute or chronic disease 
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who are culture-negative, but in whom seroconversion or a rising titre can be 
demonstrated. 
The specificity of a test for melioidosis is defined as the percentage of 
healthy people without melioidosis who test negative for melioidosis. The 
specificity of IHA is therefore a function of the local seroprevalence for 
melioidosis (speaking imprecisely, it is 100%–seroprevalence). Specificity of 
IHA is therefore low in areas of high seroprevalence, because the number of 
false positives is high. 
Increasing the cut-off used increases the specificity of IHA at the expense 
of decreasing the sensitivity.262 In 1990, Appassakij et al. suggested a cut-off of 
1:160 and evaluated this in 373 healthy blood donors, 65 cord blood samples 
and 30 melioidosis patients.263 He found that at this cut-off, sensitivity of the 
test was 77% and specificity was 92%. Consistent with earlier studies, the test 
was less likely to be positive in acute, fulminant melioidosis. 
Not all studies from Thailand have been able to achieve such high 
specificities. In the cohort reported by Teparrugkul (325 patients and 177 
controls), a 1:40 cut-off gave a sensitivity of 86% and specificity of 38%; raising 
the cut-off to 1:160 decreased sensitivity to 70%, but raised the specificity to 
only 67%,260 with similar results obtained from a later cohort at the same 
centre.264 In the cohort reported by Puapermpoonsiri (47 cases, 318 controls), a 
1:40 cut-off gave a sensitivity of 83% and specificity of 90%, but increasing the 
cut-off to 1:160 dropped the sensitivity to only 49% (specificity 97%).265 
The performance of IHA has been even poorer outside of Thailand. In 
Malaysia, a cut-off of 1:40 for IHA resulted in a sensitivity of 36.0% and 
specificity of 73·5%.247 Raising the cut-off to 1:80 dropped the sensitivity to 
29·0%, but increased the specificity to 80·5%. In Australia, Cheng et al. reported 
a sensitivity of only 56% in 275 patients with culture-confirmed melioidosis.261 
An important exception is the island of Singapore, where melioidosis is 
endemic but the background seroprevalence is low: only 0·73% of 683 men in 
national service had IHA titres ≥1:16, sera from 50 healthy blood donors and 50 
sewerage workers were all unreactive.245 This means that cut-offs as low as 1:16 
may be used without sacrificing specificity. The low seroprevalence seen in 
Singapore may be explained by the fact that the population of Singapore is 
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100% urbanised.266 Although the organism is present in the environment, the 
majority of the population have little or no contact with soil or surface water. 
The clinical significance of a positive IHA test in someone who is otherwise 
well is not certain, but has been regarded as a marker for previous exposure to 
B. pseudomallei. Its relationship to latent melioidosis is unknown. The 
specificity of IHA for B. pseudomallei exposure has been disputed and there is 
conflicting evidence whether exposure to the non-virulent bacterium, 
B. thailandensis, might also be responsible for high IHA titres.253,267,252 
A number of other serological tests have been evaluated including an 
indirect fluorescent antibody test for IgM specific antibody,244 enzyme-linked 
immunosorbant assays (ELISA) for B. pseudomallei lipopolysaccharide (LPS)269 
and for B. pseudomallei glycolipid,270 as well as a commercial 
immunochromogenic cassette (PanBio, Queensland, Australia).264,248,270–272,262 
None have so far supplanted IHA.257 
The role of serological methods has been revised in a recent study 
comparing culture against four serological tests. Using Bayesian latent class 
models, which allow for the fact that culture results are an imperfect gold 
standard, the sensitivity of culture for diagnosing melioidosis has been 
estimated to be only 60·2%.274 By contrast, LPS-based ELISAs have reasonable 
sensitivity (80·2%) and specificity (95·0%), and may be good candidates to take 
forward for further development.262  
1.5 Therapy 
1.5.1 Historical perspective 
The majority of reports of melioidosis in the pre-antibiotic era were post 
mortem. The mainstay of treatment was largely supportive, with drainage of 
clinically evident collections and debridement of infected tissue. Non-
chemotherapeutic therapies tried include autogenous vaccination (isolating the 
organism, culturing it in a guinea pig, and then repeatedly inoculating the 
patient with the cultured bacterium).275 
The first reported attempt using modern antimicrobial chemotherapy to 
treat melioidosis was in 1943, when Grant and Barwell attempted to treat 
melioidosis osteomyelitis in a soldier with sulphadiazine. Although a good 
response was achieved, the patient relapsed each time the treatment was 
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stopped.26 Harries et al. noted that sulphonamide monotherapy was ineffective 
in disseminated disease.129 
It was discovered early on that penicillin was ineffective against 
B. pseudomallei in vitro,275–277 as was the other wonder drug, streptomycin.278 
However, chloramphenicol279–281 and the tetracyclines281,282 were active. In 
1952, Dunlop reported the successful treatment of a woman with melioidosis of 
the ovary with surgical drainage and chlortetracycline.283 However, any initial 
enthusiasm for the tetracyclines was tempered by the realisation that resistance 
develops quickly both in vitro and in vivo.284 
B. pseudomallei is intrinsically resistant to a wide variety of antimicrobial 
agents, including all penicillins (except the anti-pseudomonal penicillins),280,285 
all macrolides,286 all first and second-generation cephalosporins280 and 
polymyxins.287 It is intrinsically resistant to all aminoglycosides, except that 
some strains are sensitive to kanamycin in vitro.288,77,280 However, the 
aminoglycosides, as a class, have no intracellular penetration286 and are 
therefore ineffective clinically. There is one reported case of a woman who was 
successfully treated with kanamycin,183 but this was in combination with 
tetracycline, to which the organism was susceptible. 
Until 1989, in Thailand, the conventional treatment for melioidosis was 
combination therapy with co-trimoxazole, doxycycline and chloramphenicol.259 
1.5.2 Current recommendations 
In its most serious manifestation, melioidosis causes severe sepsis 
associated with hypotension and multiple organ failure, requiring intensive 
supportive therapy (fluid management, invasive monitoring and artificial 
ventilation). These measures likely play as great a role in the treatment of 
melioidosis as do antibiotics.289 Human-to-human transmission is very rare and 
patients may be safely accommodated on the open ward.102-105 
Antimicrobial therapy for melioidosis is divided into two phases: an 
intensive phase (parenteral inpatient therapy) and an eradication phase (oral 
outpatient therapy).41 Current treatment recommendations are summarised in 
Table 4. 
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1.5.3 Intensive phase 
Antibiotic therapy should be initiated as soon as possible, as there is 
evidence from other causes of sepsis that delay in initiating appropriate 
antimicrobial therapy increases mortality.290,291 Without access to antimicrobial 
therapy, mortality from the bacteraemic form of melioidosis approaches 100% 
and in the pre-antibiotic era, almost all case series reported in the literature 
were post mortem.127,9 
Ceftazidime treatment was introduced in 1989, after it was shown that it 
halved mortality compared to conventional therapy (co-trimoxazole, 
doxycycline and chloramphenicol).259 The first-line treatment for melioidosis is 
high-dose intravenous ceftazidime41,259 for ≥10 days, continued until there are 
clear signs of clinical improvement (principally defervescence). The median 
fever clearance time is 10 days despite adequate antimicrobial chemotherapy.200 
Failure to defervesce is not therefore itself an indication to change treatment 
and it is not uncommon for patients to require over a month of intravenous 
therapy. 
Carbapenems (principally, meropenem and imipenem) are routinely used 
in Australia.132 Carbapenems may be preferred to ceftazidime because the 
minimum inhibitory concentrations (MIC) for imipenem and meropenem 
against B. pseudomallei are lower than those for ceftazidime,288,292,77 and 
carbapenem therapy is associated with lower levels of antibiotic-induced 
endotoxin release.293 However, a head-to-head comparison of imipenem versus 
ceftazidime found no difference between the regimens, but the trial was stopped 
early owing to withdrawal of drug company support.200 A multi-centre double-
blind randomized-controlled trial comparing meropenem against ceftazidime 
started recruiting in 2007 (ClinicalTrials.gov NCT00579956). 
The addition of co-trimoxazole to standard ceftazidime therapy provides 
no benefit,294,295 despite evidence from animal models to support the practice.296 
However, co-trimoxazole has excellent tissue penetration into brain and 
prostate, so there is a theoretical benefit to adjunctive co-trimoxazole when 
treating these infections.41 Co-amoxiclav is an alternative to ceftazidime if none 
of the first-line drugs are available:297 mortality is the same, but the risk of 
treatment failure is higher. Co-amoxiclav may be useful in resource-poor 
settings where first-line drugs are not immediately available. 
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High intensive parenterala Typical doseb Duration 
ceftazidime 40 mg/kg (max. 2 g) tds,c or 
meropenem 25 mg/kg (max. 1 g) tds, or 
imipenem 20 mg/kg (max. 1 g) tds 
2 g every 8 hc 
1 g every 8 h 
1 g every 8 h 
≥10 days, or until clear clinical 
improvement, which ever is longerd 
Alternatively,   
co-amoxiclav 20/4 mg/kg (max. 1000/200 mg) qqhe 1000/200 mg every 4 h  
Eradication oral phase (Thailand)   
co-trimoxazole (<40kg: 160/800mg bd; 40–60kg: 
240/1200mg bd; >60kg: 320/1600mg bd) + 
doxycycline 2 mg/kg (max. 100 mg) bd 
320/1600 mg every 12 h 
100 mg every 12 h 
12–20 weeks 
Alternatively,   
co-amoxiclav 60/15 mg/kg (max. 1500/375) tdsf 1500/375 mg every 8 h  
Eradication oral phase (Australia)   
co-trimoxazole (<40kg: 160/800mg bd; 40–60kg: 
240/1200mg bd; >60kg: 320/1600mg bd) 
320/1600 mg every 12 h 3–6 months 
Table 4. Summary of antimicrobial chemotherapy of melioidosis. 
Note.— bd = bis die; h = hours; max. = maximum; qds = quater die sumendus; qqh = quaque quarta hora; tds = ter die sumendus. The regimen 
quoted for Thailand is that used at Sappasithiprasong Hospital, Ubon Ratchathani. The regimen quoted for Australia is that used at the Royal 
Darwin Hospital, Northern Territory. All doses require adjustment for renal function. 
a In Australia, oral co-trimoxazole is routinely added to parenteral therapy for infection of the central nervous system and for prostatitis, because of 
the excellent penetration of co-trimoxazole to these sites. 
b Typical dose for a 70 kg adult with normal renal function. 
c The Royal Darwin Hospital uses 50 mg/kg (maximum 2 g) qds. A typical dose is therefore 2 g every 6 hours. 
d Brain abscesses are routinely treated with ≥4 weeks of parenteral antibiotics. Other deep seated abscess that are not amenable to drainage may 
also require prolonged parenteral therapy. 
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e There is no parenteral preparation of co-amoxiclav available in Australia. Ampicillin-sulbactam is available in a parenteral formulation, but there 
is no clinical experience of the use of this drug in melioidosis. 
f If co-amoxiclav preparations are only available in a 2:1 ratio, then additional amoxicillin should be prescribed to achieve the correct ratio of 
amoxicillin to clavulanate. Co-amoxiclav is routinely used in children and pregnant women in Thailand, because doxycycline is relatively contra-
indicated.
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Primary resistant to first-line agents is unusual (Table 5) and there is no 
evidence that these rates are changing. B. pseudomallei is an environmental 
organism, with no human-to-human transmission, and is largely unaffected 
therefore by antibiotic pressure in healthcare settings. Rarely, resistance can arise 
during the course of treatment,298,299 and patients who remain febrile on treatment 
should have cultures repeated regularly to look for this.299 
Cefoperazone-sulbactam has been shown to be equivalent to ceftazidime in a 
randomised controlled trial.201 There are no obvious circumstances under which 
cefoperazone-sulbactam would be preferred to ceftazidime or a carbapenem, and 
the drug has not found a home in current guidelines. There is in vitro evidence for 
biapenem,292 doripenem,300 piperacillin-tazobactam184,301 and tigecycline,302–304 
but no clinical experience to support their use.  
 
CAZ IPM MEM AMC Region Reference 
99.5% 100% – 100% Thailand Dance 1989 
99% 100% 100% 100% Thailand Smith 1996292 
100% 100% 100% 99.4% Australia Jenney 2001 
100% 100% 100% 100% Hong Kong Ho 2002184 
98%a 100%a – 98%a Multiple Thibault 200477 
– – – 100% Singapore Sivalingam 2006305 
– 100% 100% – Malaysia Karunakaran 2007306 
99·4% 99·4% – 97·9% Singapore Tan 2008285 
Table 5. Susceptibility of B. pseudomallei to first-line parenteral 
agents. 
Note.—CAZ = ceftazidime; IPM = imipenem; MEM = meropenem; AMC = co-amoxiclav. 
These results are for primary isolates and do not include data from resistance acquired 
during the course of treatment. A dash indicates that that agent was not tested. The 
breakpoints used are those defined by the Clinical Laboratory Standards Institute in the US 
(CAZ ≤8 mg/l; IMP ≤4; MEM ≤4; AMC ≤8/2). 
aBreakpoints defined by Comité de l’Antibiogramme de la Société Française de 
Microbiologie, France (CAZ ≤32 mg/l; IMP ≤8; AMC ≤16/2). 
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1.5.4 Eradication phase 
Thirteen per cent of patients who survive a first episode of melioidosis go on 
to experience a recurrence of their disease:221,307 75% of these are due to relapse 
with the same strain and 25% are due to re-infection.307 The aim of eradication 
therapy is to reduce the risk of relapse. 
Eradication therapy is based on oral medication and is usually conducted on 
an outpatient basis. Patients are not started on oral eradication therapy until they 
are clinically well and ready for discharge home. The occasional patient with a 
solitary abscess that is easily drained, who is afebrile, and who has no systemic 
signs or symptoms, may avoid the intensive phase and go straight onto oral 
eradication therapy. 
Relapse is more likely in patients who have multifocal disease or bacteraemia 
at their first presentation.307 Regimens containing co-trimoxazole have the lowest 
relapse rate. Ciprofloxacin monotherapy, ciprofloxacin/azithromycin combination 
therapy and doxycycline monotherapy are associated with higher relapse rates and 
cannot be recommended.307–310 
Unfortunately, none of the first-line treatments (ceftazidime, meropenem, 
imipenem) may be administered orally as they are not absorbed. 
Standard therapy in Thailand is combination therapy with trimethoprim-
sulphamethoxazole and doxycycline for 12–20 weeks;311 standard therapy in 
Australia is co-trimoxazole alone.132 It is not clear that one therapy is superior to 
the other, and a double-blind randomised placebo-controlled trial to compare the 
two regimens, MERTH (Melioidosis Eradication THerapy/THailand) has just been 
completed. The study finished recruitment in 2009 and completed follow-up in 
2010 (trial registration ISRCTN86140460). A report is expected at the end of 
2011.312 
One potential benefit of co-trimoxazole monotherapy is that co-trimoxazole 
and doxycycline are antagonistic in vitro.313 It is also anticipated that a simplified 
regimen would be better tolerated, because those effects due to doxycycline would 
be eliminated (specifically, oesophageal ulceration and photosensitivity, but also 
non-specific gastrointestinal effects such as nausea and vomiting) and because of 
the smaller pill burden. The dose of co-trimoxazole used in Thailand was revised 
upwards in 2008 on the basis of evidence from pharmacokinetic modelling to be in 
line with that used in Australia.314 
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1.5.5 Vaccination 
There are currently no licensed vaccines for melioidosis. Currently, the best 
vaccine candidates are live attenuated vaccines, but none of these provide 
sterilising immunity and there are no vaccines currently in clinical trials.315,316 
1.5.6 Post-exposure prophylaxis 
Most cases of accidental exposure are likely to occur in a clinical laboratory 
processing a specimen not known or suspected to have B. pseudomallei. Given the 
lack of other evidence, recommendations for post-exposure prophylaxis are based 
on current treatment recommendations. Following a thorough risk assessment, 
post exposure prophylaxis with three weeks’ co-trimoxazole may be offered.317 
Workers intolerant of co-trimoxazole may be offered co-amoxiclav instead. 
Workers who seroconvert may be offered an extended course of therapy (12 weeks) 
and careful monitoring for the development of clinical disease. 
There are not currently any published recommendations for travellers with 
risk factors such as diabetes or cystic fibrosis who travel to endemic areas. 
1.5.7 Antisepsis 
B. pseudomallei is susceptible to 70% ethanol, 1% hypochlorite, 7% tincture 
of iodine, 0·05% benzalkonium chloride and 1% potassium permanganate.20,318 The 
commercial agents, Perasafe™ (DuPont, active ingredient peracetic acid) and 
Virkon® (DuPont, active ingredient commercial confidential, but known to 
include peracetic acid) are also bactericidal for B. pseudomallei.318 
Five per cent phenol does not reliably disinfect B. pseudomallei.20 Outbreaks 
of melioidosis have been associated with contaminated hand wash.319,320 
Chlorination effectively treats drinking water: free chlorine concentrations 
normally used by water purification plants in the West are ~1 mg/l, which is 
sufficient for the majority of strains of B. pseudomallei, but some Australian 
strains require ≥30 mg/l.166,321–323 
1.6 Adjunctive therapies 
1.6.1 Granulocyte-colony stimulating factor 
The only adjunctive treatment ever studied in the specific context of 
melioidosis was granulocyte colony stimulating factor (GCSF).324 GCSF is a 20 kDa 
glycoprotein growth factor produced principally by endothelium and macrophages, 
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that stimulates the proliferation and differentiation of granulocyte precursors in 
the bone marrow.325 Its principal medical application is to reduce the duration of 
neutropenia that occurs in cancer chemotherapy and HIV. As a drug, its generic 
name is filgrastim, and is sold in the UK under the trade names Neupogen®, 
Ratiograstim® and Zarzio®. 
The neutrophil response is critically important in the pathogenesis of 
melioidosis,326 and the introduction of adjunctive therapy with GCSF coincided 
with a reduction in melioidosis mortality from 95% to 10% at one Australian 
centre.327 Unfortunately, a single-centre randomised-controlled trial found no 
evidence of benefit.324 
1.6.2 Intensive glucose management 
On the basis that plasma glucose levels are often high in sepsis and that high 
levels correlate with mortality, it has been proposed that intensive insulin therapy 
to tightly control glucose levels in the intensive care setting should decrease 
mortality in critically ill patients (not just patients with sepsis).328 In a study of 
1,548 surgical intensive care patients in Belgium, intensive insulin therapy (target 
range 4·4–6·1 mM) reduced mortality from 8·0% to 4·6%.221 This is potentially 
relevant, because 57% of patients with melioidosis have diabetes or present with 
hyperglycaemia,329 and, insulin/ glucose monitoring are routinely available at 
provincial hospitals in Thailand. 
The van den Berghe study221 was criticised on a number of counts: 
principally, that this was a single centre study, most of the patients were admitted 
post-surgery, the study was open label, and the feeding regimen was unusual (all 
patients received a 200–300 g bolus of glucose at recruitment and total parenteral 
nutrition or enteral feeding was started within 24 hour of admission).330 A repeat 
study by the same investigators in the medical intensive care was unable to 
replicate this finding.331 Studies of intensive glucose control in the context of 
myocardial infarction332 and trauma333 have also found no benefit. Conversely, a 
multi-centre trial of 6104 patients by other investigators found that intensive 
insulin therapy (target 4·5–6·0 mM) in critically ill patients increased mortality.334 
A meta-analysis of 26 trials (13,567 patients, including the data from NICE-
SUGAR)335 found that intensive insulin therapy increases the risk of 
hypoglycaemia without conferring any over mortality benefit to critically ill 
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patients, and the only subgroup of patients found to benefit were surgical patients 
(pooled relative risk 0·63, 95%CI 0·44–0·91).335 
1.6.3 Immunosuppressants 
A recurring theme in the sepsis literature is that the inflammatory response is 
essential, yet high levels of inflammation correlate with mortality in observational 
studies of human sepsis.336 The prevailing theory has been that mortality from 
sepsis is due to an uncontrolled inflammatory response:336 the ‘cytokine storm’.337 
This view has been supported by data from animal models of sepsis,338–344 and that 
has in turn driven the clinical development of anti-inflammatory drugs as 
adjunctive therapies in sepsis. 
Multiple trials looking for a benefit from high-dose corticosteroids in severe 
sepsis and septic shock have not found any benefit, with some studies finding a 
detrimental effect.345–348 Evidence for the use of low-dose corticosteroids in sepsis 
is mixed: a single multi-centre, placebo-controlled, randomised, double-blind trial 
of 300 intensive care patients with septic shock and relative adrenal insufficiency 
(as measured by a cortocotrophin test) found a mortality benefit from low-dose 
corticosteroid and fludrocortisone,349 but this result has not been possible to 
replicate: one trial found that low-dose corticosteroid reduced time on 
vasopressors but not mortality,350 another multi-centre randomised placebo-
controlled trial of 248 patients performed by the same investigators found no 
difference in mortality351 and a further trial in patients with liver cirrhosis found 
that the patients in the hydrocortisone arm had an increased incidence in relapse 
of shock.352 
The results for anti-tumour necrosis factor-alpha (TNFα) therapy have been 
disappointing. Despite evidence from primate models that anti-TNFα has a 
dramatic effect on survival from Escherichia coli353,354,338 and Staphylococcus 
aureus bacteraemia,339 the result from multiple clinical trials is that anti-TNFα 
therapy provides no benefit in sepsis.355–359 In any case, results from mouse 
models of melioidosis would predict TNFα blockade to be detrimental.360 Trials of 
interleukin-1β beta blockade have been similarly disappointing,361–363 despite 
promising results from animal models.340–344 
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1.6.4 Activated protein C 
Activated protein C (APC) is a serine protease that is known primarily as an 
anticoagulant. Inactive protein C circulates in the plasma and is cleaved to its 
active form by activated thrombin. As a drug, its generic name is drotrecogin alfa 
(activated), and its trade name is Xigris®. 
APC is the first (and currently, the only) US Food and Drug Administration 
(FDA)-approved adjunctive treatment for severe sepsis.364,365 Its approval was 
based on the results of a Phase III multi-centre double-blind placebo-controlled 
trial involving 1,690 sepsis patients in 164 centres in 11 countries (the PROWESS 
trial).366 The trial results were published in 2001 and reported a 6% reduction in 
the absolute risk of death, accompanied by a 1·5% increase in the risk of serious 
bleeding events. 
Levels of protein C are low in melioidosis,367,368 and we may speculate that 
melioidosis patients with severe sepsis may benefit from APC therapy. No trials of 
activated protein C therapy are currently planned in melioidosis. 
1.6.5 Gamma interferon 
Gamma interferon (IFNγ) is necessary for the normal host defence against 
B. pseudomallei infection and IFNγ levels are indeed elevated in acute 
melioidosis.369 Small doses of IFNγ greatly potentiate the effect of ceftazidime in 
vitro and mouse models.370 IFNγ supplementation is already used in the 
management of multi-drug resistant tuberculosis, and it seems reasonable to 
hypothesise that patients with other infections caused by intracellular bacteria may 
benefit.371 Using a mouse model of melioidosis, Propst et al. found that IFNγ 
supplementation reduced 20-day mortality in ceftazidime-treated animals from 
100% to 30% (p<0·001);370 however, the dose of ceftazidime given in that study 
was sub-therapeutic, which complicates interpretation.372 
The role of IFNγ in the host response to melioidosis is described in greater 
detail below. 
1.7 The host response to melioidosis 
Much of what we know about the host response to melioidosis comes from a 
limited number of human studies and a larger number of animal studies, primarily 
in mice (both outbred373 and inbred360), rats,80 and hamsters.116 Findings made in 
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a model organism do not necessarily translate to the clinical situation, and findings 
made in one model may not necessarily correlate with findings made in another 
model. Interpretation of the literature is therefore an exercise akin to joining dots 
to form a picture, except that the dots are unnumbered, some are optional, and 
many are not even printed on the same page. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Histological features of human melioidosis. 
Note.—A Lung section taken post mortem from an 18-year-old female. Tangles of 
extracellular bacteria are indicated by large arrow heads. Tangles of intracellular bacteria 
within macrophages and giant cells are indicated by thin arrows (magnification ×1000). B A 
splenic granuloma with central necrosis (magnification ×100) surrounded by foamy 
macrophages and multinucleate giant cells (inset, magnification ×400). Figures adapted from 
Wong Histopathology 1995;26:51. 
 
1.7.1 Histology 
There are few histological descriptions of human melioidosis from 
Thailand because of strong cultural barriers to the collection of tissue 
specimens. The most recent descriptions come from a series of five post mortem 
cases and 14 biopsy specimens from Malaysia,52 although older descriptions 
exist from the Vietnam War17,374,375 and from before World War II.11 
A B 
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In the Malaysian series, Wong et al. describe areas of necrotising 
inflammation containing mixtures of neutrophils, lymphocytes, macrophages and 
multinucleate giant cells. Numerous bacteria are seen within these lesions and may 
occur both intra- and extracellularly (Figure 10). When they occur intracellularly in 
macrophages, the bacteria may be so numerous as to form globi. The lesions may 
sometimes form granulomas with central necrosis and surrounding foamy 
macrophages, which cause them to resemble tuberculosis or cat-scratch fever. 
1.7.2 The gamma interferon response in melioidosis 
B. pseudomallei is a facultative intracellular pathogen,79–81 and the host 
cytokine response to melioidosis may be appropriately summarised as an IFNγ 
response to an intracellular pathogen.369,376,377 While IFNγ elevation is not a 
general feature of other causes of sepsis,378,379 it is a feature of infection caused by 
other intracellular organisms, such as Brucella species,380 Mycobaterium 
tuberculosis,381,382 Neisseria meningitidis,383–385 and Salmonella Typhi.386 This is 
to be expected, given that a primary function of IFNγ is to stimulate the killing of 
intracellular pathogens.387–389 
The interferons were initially discovered in 1947 by Henle and Henle as a 
substance produced in the allantois of chick embryos infected with influenza that 
‘interfered’ with viral replication.390 This substance was given the name interferon 
by Isaacs and Lindeman in 1957,391 but in the mid-1970’s, it was realised that 
interferon was not one protein but a mixture of proteins.392,393 In 1979, Grob and 
Chadha separated human ‘interferon’ into three fractions, later designated alpha, 
beta and gamma.394 Macrophage activating factor was first isolated in 1973 from 
guinea pig lymphocytes and found to activate the intracellular killing effects of 
macrophages,395 but it was cloning of the IFNγ gene (IFNG) in 1982396,397 that 
brought the realisation that IFNγ and MAF are the same molecule.398–402 
In 1991, Brown et al. studied 65 melioidosis patients and found that serum 
concentrations of IFNγ at admission were elevated in melioidosis, and that the 
higher the serum concentration of IFNγ, the more likely the patient was to die.369 
There are two possible interpretations for this finding: the first is that mortality is 
due to an inappropriate and excessive inflammatory response.403 The second is 
that the inflammatory response is appropriately high, that it correlates with higher 
bacterial loads, disease severity, and hence, mortality.376 The distinction is an 
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important one: if the first is true, then suppressing IFNγ would be expected to 
decrease mortality; if the second is true, then suppressing IFNγ would be expected 
to increase mortality. Similar arguments may be made for other cytokines. 
Evidence for the first hypothesis comes from murine models of endotoxic 
shock (a model of septic shock induced with intravenous LPS).404,405 Blocking 
antibodies directed against IFNγ prevented mortality from endotoxic shock404 and 
IFNγ receptor knockout mice were also able to tolerate 100 to 1000-times more 
LPS than wild type mice.405 However, the clinical relevance of data obtained from 
endotoxic shock models has been questioned repeatedly.406–409 
Evidence in favour of the second hypothesis was obtained by Lauw et al. in 
her survey of 62 consecutive melioidosis patients.376,377 Although she did not 
quantify bacterial loads, she found that bacteraemic patients had higher levels of 
IFNγ.376 In murine models of melioidosis, blocking IFNγ increased susceptibility in 
Taylor outbred mice, lowering the intraperitoneal LD50 from 5 × 105 cfu to 
2 cfu,373 whereas exogenous IFNγ supplementation improved survival.370 Taken 
together, the experimental and clinical evidence support the conclusion that IFNγ 
levels are appropriately elevated in melioidosis in response to the intracellular 
nature of the pathogen and the severity of the disease. 
In mice, the primary source of the IFNγ are natural killer (NK) cells and 
memory CD8+ T-lymphocytes,360,410 and this IFNγ response appears to be 
secondary to the synergistic action of IL12 and IL18.360,410 Ablating either IL12 or 
IL18 ablates the IFNγ response and worsens mortality.360,411,412 This is supported 
by the clinical data, which shows elevations of IL18 in plasma376 as well as 
elevations of IL18 mRNA in blood mononuclear cells412 in melioidosis patients. 
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Cytokine Primary source(s) Summary of functions References 
CXCL9 macrophage, 
various 
Secreted in response to 
IFNγ stimulation. 
Chemoattractant for T cells 
and NK cells. 
Lauw 2000377 
CXCL10 macrophage, 
various 
Secreted in response to 
IFNγ stimulation. 
Chemoattractant for T cells 
and NK cells. 
Lauw 2000377 
IFNγ NK, CD8, 
(macrophage) 
Secreted in response to IL12 
and IL18, Stimulate 
macrophages and killing of 
intracellular bacteria. 
Santinarand 1999,373 
Lauw 1999376  
IL6 macrophage Downstream of TLR 
activation. Stimulates 
monocyte differentiation to 
macrophage. Inhibits IL1β 
and TNFα. 
Friedland 1992413 
IL8 macrophages, 
endothelium 
Downstream of TLR 
activation. Recruits 
neutrophils. 
Friedland 1992413 
IL12 monocytes, 
macropha
ges414,415 
Downstream of TLR 
activation. Stimulate IFNγ 
production.416 
Lertmemongkolchai 
2001,360 Koo 2006410 
IL15 monocytes, 
macrophages 
Stimulates proliferation of 
NK cells.416 
Lauw 1999376 
IL18 monocytes, 
macrophages 
Produced by inflammasome 
activation. Stimulate IFNγ 
production.360,411 
Lertmemongkolchai 
2001,360 Koo 2006410 
TNFα macrophages Downstream of TLR 
pathways. Amplifies IFNγ 
production. 
Santinarand 1999,373 
West 2008417 
Table 6. Cytokines and chemokines involved in clinical melioidosis. 
Note.—CD = cluster of differentiation; CD8 = CD8-positive T-lymphocytes; IFN = interferon; 
IL = interleukin; NK = natural killer cells; TLR = Toll-like receptor; TNF = tumour necrosis 
factor. This table is restricted to those cytokines and chemokines that have been measured in 
clinical melioidosis. This table is not intended to be a comprehensive list of cytokines 
known to play a role in the host response to melioidosis. 
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TNFα levels were measured in a clinical study of 55 melioidosis patients, 
and the presence of detectable plasma TNFα at admission correlated with 
mortality.418 In mice, ablating TNFα reduces the magnitude of the IFNγ 
response by up to 30%, but does not ablate it.360 The relationship of TNFα to 
IFNγ is circular, with TNFα being both upstream373 as well as downstream of 
IFNγ secretion.419,420 One interpretation consistent with these data is that the 
role of TNFα in melioidosis is to amplify the IFNγ response, but not to initiate it. 
Downstream of IFNγ, CXCL9 (formerly called MIG) and CXCL10 (formerly 
IP-10) are secreted by a large variety of cell types in response to IFNγ 
stimulation. Plasma concentrations of both CXCL9 and CXCL10 are elevated in 
patients with melioidosis and levels were higher in patients with bacteraemia.377 
CXCL9 and CXCL10 are T-cell and NK cell chemoattractants421 and probably 
work to amplify the IFNγ response. 
In clinical studies of melioidosis, plasma concentrations of IL6, IL8 and 
IL10 have also been found to be elevated and to correlate with mortality (Table 
6).413,422 
1.7.3 Pattern recognition receptors 
Pattern recognition receptors (PPRs) are a set of evolutionarily-conserved 
receptors present on leukocytes to identify pathogen-associated molecular 
patterns (PAMPs), e.g., the lipopolysaccharide of Gram-negative bacteria, 
lipoteichoic acid of Gram-positive bacteria and viral RNA. In evolutionary 
terms, these receptors predate the development of adaptive immunity and allow 
the innate host response to identify antigens that are not ‘self’. 
The best studied of the pattern recognition receptors are the Toll-like 
receptors (TLRs) and the Nod-like receptors (NLRs). 
1.7.4 Toll-like receptors and nuclear factor kappa B 
There are 13 human and mouse Toll-like receptors (TLR) described to 
date.423–425 The TLRs are membrane-bound glycoprotein receptors and are 
members of the interleukin-1 receptor superfamily.424 The TLRs are one of the 
more evolutionarily conserved parts of the innate immune system and may have 
originated in the common ancestor of all bilaterian animals.426,427 TLRs 
signalling (with the exception of TLR3) proceeds via the adaptor molecule, 
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MyD88,424 and the importance of the TLRs in the host response to 
B. pseudomallei infection has been demonstrated by the fact that Myd88 
knockout mice are extremely susceptible to B. pseudomallei infection.428 Mouse 
gene expression studies have also found upregulation of Tlr2, Tlr4 and Tlr7 in 
experimental melioidosis.429 
A major downstream effect of TLR signalling is nuclear factor kappa B 
(NF-κB) activation. NF-κB is a family of constitutively expressed protein 
complexes that function as DNA transcription factors. These complexes are 
homo- or heterodimers of a family of five proteins, RELA (also called p65), 
RELB, c-REL, NF-κB1 (also called p50 and p105) and NF-κB2 (also called p52 
and p100). 
NF-κB is activated by a wide range of stimuli, including cytokines (notably 
TNFα and IL1430), growth factors, mitogens, oxidative stress, chemical stress, 
bacterial and viral antigens. Activation of NF-κB causes it to move from the 
cytoplasm to the nucleus, where it regulates the expression of several hundred 
genes, including several cytokines and chemokines (e.g., IL2, IL8, IL12, GM-
CSF and CD40 ligand).431,432 IL8 secretion is often used as a marker for TLR 
activation, because it is produced in very large quantities.152 NF-κB is a rapidly 
acting transcription factor, due to the fact that it is constitutively expressed in 
the cytoplasm of cells and does not require new protein synthesis for its 
activation. 
Aside from cytokine secretion, NF-κB activation also promotes cell 
survival and proliferation.433,434 Although TLR activation was initially believed 
to result in a non-specific NF-κB response, it is now known that specific 
responses do occur: for example, TLR4 and 9 activation produces a Th1-type 
response, but TLR2 activation results in T regulatory cell activation.435 The 
picture is also complicated by the fact that there also exists extensive crosstalk 
both within the TLR family and between TLRs and other PRRs.436,437 
The best described TLRs are members 1 to 9. Of these, TLRs 1, 2, 4, 5 and 
6 are located on the cell membrane where they form dimers. TLR2/TLR1 and 
TLR2/TLR6 form heterodimers that recognises triacyl lipopeptide and diacyl 
lipopeptide respectively, and both will recognise lipoteichoic acid.427,438 TLR4 
and TLR5 form heterodimers that classically recognise lipopolysaccharide and 
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flagellin respectively.427 TLRs 3, 7, 8 and 9 are found intracellularly on the 
endosomal membrane, where they recognise single and double stranded RNA, 
and unmethylated CpG oligodeoxynucleotides.427 
In clinical melioidosis, Wiersinga et al. found increased expression of 
TLR1, TLR2, TLR4, TLR5, and TLR8 in circulating blood leukocytes,152 while 
levels of TLR3 and TLR7 were no different from controls. The lack of differential 
expression of TLR3 is unsurprising, as this TLR is restricted to dendritic cells, 
which do not circulate; this is reflected in the low absolute expression values 
reported.439 TLR7 is constitutively expressed by human plasmacytoid dendritic 
cells (PDC) and B lymphocytes: upon stimulation, expression of TLR7 increases 
in PDCs but decreases in B lymphocytes.440 Wiersinga’s study did not 
distinguish between types of mononuclear cells and was therefore not designed 
to detect this type of differential expression. 
The increased expression of TLR4 accords with the fact that 
B. pseudomallei is a Gram-negative organism and, as such, expresses the 
classical TLR4 ligand, LPS.99,441,442 Other proteins in the endotoxin receptor 
complex, CD14 and LY96 (=MD2), were also upregulated in melioidosis 
patients443 and it has also been reported that TLR4 polymorphisms are 
associated with an increased susceptibility to melioidosis,444 however, the 
evidence for a role of TLR4 in melioidosis is contradictory. TLR4 appears to 
have no role in the innate host response to B. pseudomallei as evidenced by the 
fact that Tlr4-knockout mice had no phenotype when compared to wild-type 
mice on a C57Bl/6 background.152 Supporting evidence was provided by two 
studies using the closely-related organism, B. thailandensis, in Tlr4-knockout 
mice as well as the Tlr4-deficient C3H/HeJ mouse strain, both of which showed 
that TLR4 is not a major player in sepsis caused by B. pseudomallei.445,446 A 
possible explanation for the lack of a TLR4 response may be due to structural 
differences in the lipid A moiety of B. pseudomallei, which make it less 
immunoreactive.447,99 
Although the ability of TLR2 to recognise lipoteichoic acid has led to it 
being described as a receptor for the recognition of Gram-positive organisms,438 
TLR2 will also recognise E. coli LPS when associated with lymphocyte 
antigen 96 (LY96).448 Wiersinga reported that TLR2 appears also to recognise 
B. pseudomallei LPS in transfected HEK293 cells,152 but West et al. were unable 
 50 
to replicated this finding using a similar system.417 There are no clear reasons to 
explain the conflicting results, but possibilities include strain differences in LPS 
structure442 and the way in which NF-κB activation was assessed (IL8 
production152 versus a dual-luciferase reporter system417). 
Nevertheless, if TLR2 is able to recognise B. pseudomallei LPS, that 
interaction is not beneficial to the host, because TLR2 knockout mice have 
reduced end-organ damage and improved survival,152,446 which is contrary to 
what would be expected given the results of other mouse models of Gram-
negative infection.449–452 The reason why Tlr2-knockouts are protected remains 
an open question. 
1.7.5 Nod-like receptors 
The Nod-like receptors (NLR) are cytosolic receptors named for the 
nucleotide-binding oligomerization domain (or Nod) that they all possess. 
Unlike the TLRs, the NLRs are not membrane-bound: instead, they recognise 
antigens present in the cytosol. 
The NLRs are divided into two major subfamilies, the NLRCs (NLRC1 to 5) 
which possess a caspase recruitment domain and the NLRPs (NLRP1 to 14) 
which possess a pyrin domain.453 A further three genes do not fall into either of 
the two major families (NLRA, NLRB1, NLRX1).453 Like the TLRs, the NLRs are 
evolutionarily conserved and are present in species as distantly related as sea 
urchins454 and zebra fish,455 although they are not present in insects or 
worms.455 
The use of animal models to study NLRs is complicated by the fact that 
there is not a one-to-one correspondence between human and mouse NLRs: 
instead, there are 22 named human NLRs but 34 named mouse Nlrs.453 For 
example, the NLRB family has only one human member (NLRB1) but seven 
mouse members (Nlrb1a to f). Similar discrepancies occur in all the families: so, 
although there is a human NLRP11, there does not exist a corresponding mouse 
Nlrp11. Many of the NLRs remain to be characterised, but are believed to 
function as pattern-recognition receptors. 
NOD1 and NOD2 (also called NLRC1 and NLRC2) were the first NLRs to 
be described456 and will activate NF-κB directly.457 Stimulation of RAW264.7 
cells (transformed mouse monocytes) with B. pseudomallei causes upregulation 
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of both Nod1 and Nod2.458 However, no clinical or animal studies of NOD1 or 
NOD2 have been reported to date, so their role in melioidosis is as yet 
undescribed. 
1.7.6 NLRs, caspases, and the inflammasome 
The inflammasome is a large macromolecular multiprotein complex first 
described in 2002 by Martinon et al. in THP-1 cell lysates (a human monocytic 
leukaemia line).459 The inflammasome was named by analogy to the 
apoptosome, the multiprotein complex that drives caspase-9 activation.460 The 
structure of the inflammasome has been confirmed by purifying and assembling 
the individual components in vitro.461 
The inflammasome is a complex of three proteins: an NLR receptor, an 
adaptor protein, ASC, and caspase-1. Three NLRs are known to initiate 
inflammasome assembly: NLRP1, NLRP3 and NLRC4,460 and all three NLRs 
associate with caspase-1 via ASC.459,462–467 
NLRP1 (also known as NALP1 and CARD7) was the first caspase-1 
activating receptor identified. NLRP1 recognises muramyl dipeptide (MDP), 
which causes a conformational change in NLRP1 that allows it to bind 
nucleotides and form oligomers, thus initiating inflammasome assembly.460 
However, the mechanism by which it does so is unknown, because NLRP1 does 
not bind MDP.460 NLRP3 (also known as cryopyrin and NALP3) is stimulated by 
LPS, MDP, and bacterial RNA, but assembly of the NALP3 inflammasome 
requires a second signal, such as extracellular ATP acting on the P2X7 
potassium channel460 (other second signals include bacterial pore-forming 
toxins, silica and asbestos460). NLRP3 will also recognise silica, asbestos and 
urate.460 Neither NLRP1 nor NLRP3 have been studied in the context of 
melioidosis. 
NLRC4 (also called IPAF and CARD12) will recognise flagellin as well as 
the basal body rod component of the B. pseudomallei type 3 secretion system.468 
Salmonella enterica serovar Typhimurium, Legionella pneumophila and 
Pseudomonas aeruginosa appear to induce assembly of the NLRC4 
inflammasome via the cytosolic delivery of flagellin, which may explain why a 
functioning type III or type IV secretion system is necessary for NLRC4 
activation.466,467,469–471 
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Nlrc4-knockout mice have an increased susceptibility to B. pseudomallei 
(F. Re, unpublished data472). Unlike NLRP1 and NLRP3 activation, NLRC4 
activation is associated with a special type of cell death called pyroptosis, and 
pyroptosis is a feature of B. pseudomallei infection of macrophages.473,474 Taken 
together, these data suggest that the NLRC4 inflammasome may be more 
important than the NLRP1 or NLRP3 inflammasomes in melioidosis, but this 
hypothesis has not yet been addressed experimentally. Pyroptosis is discussed 
in more detail below. 
Caspase-1 was identified in the late 1980’s and early 1990’s as a cysteine 
protease expressed only in monocytes and macrophages,475–480 and was initially 
given the name interleukin 1 converting enzyme or ICE. When the enzyme was 
cloned and sequenced in 1992,480 it was found to be unrelated to any other 
known protein, but by 1996, a further nine human and mouse homologues had 
been found.481 In 1996, ICE was renamed caspase-1482 in recognition of the fact 
that it was the first member of this new family to be discovered. There are 
currently 12 caspases recognised in humans and mice,483 but caspase-12 is 
inactive in 64% of humans.484 
The caspases were first studied in relation to their role in apoptosis,481 but 
three caspases (human caspase-1, -4, and -5; mouse caspase-1, -11 and -12)485 
have roles in the processing and secretion of pro-inflammatory molecules. The 
only caspase for which we have detailed information in melioidosis is 
caspase-1.473,474 
Caspase-1 is constitutively present in the cytosol as inactive 
pro-caspase-1.479,480 Activated caspase-1 is responsible for converting 
pro-IL1β480 and pro-IL18486–489 to their active forms, and will also cleave 
pro-caspase-7.490 It is also responsible for a type of programmed cell death 
called pyroptosis, which occurs only in the context of inflammation.491,492 
Breitbach et al. studied experimental B. pseudomallei infection (100 cfu of 
intranasal B. pseudomallei) in Casp1-knockout mice on a C57Bl/6 
background.474 In this model, all Casp1-knockouts died ≤72 h after inoculation, 
whereas wild-type mice survived ≥6 days. Bacterial loads in lung, liver and 
spleen were also higher at 48 h in Casp1-knockouts compared to wild-type 
controls. This was confirmed by in vitro experiments, which showed that 
intracellular burdens of B. pseudomallei were 10-times higher in Casp1-
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knockout macrophages. Serum concentrations of IL18 and IFNγ were both 
reduced in Casp1-knockout mice. 
It has recently been discovered that the most commonly used strain of 
Casp1-knockout mouse is also caspase-11 deficient,492 implying that work done 
to date with this mouse may require re-evaluation. 
Caspase-3 is the only other caspase that has been studied in melioidosis. 
Breitbach reported that caspase-3 was activated only when Casp1 was knocked 
out.474 This is consistent with what we already know: i.e., B. pseudomallei-
infected macrophages die by pyroptosis and not by apoptosis, and the function 
of caspase-3 is primarily the induction of apoptosis.494–496 Nothing further is 
known of the role of caspase-3 in melioidosis. Other caspases (caspase-2, -4, 
and -8) have also been reported to be upregulated in a BALB/c murine model of 
melioidosis,429 but have not otherwise been studied. 
1.7.7 Caspase-1 substrates: IL1β, IL18 and caspase-7 
Interleukin 1 was first identified by Gery in 1972 as a soluble factor 
produced by mouse peritoneal exudate cells that was capable of stimulating T 
lymphocyte proliferation.497–499 Based on this property, Gery proposed the 
name lymphocyte-activating factor or LAF. Dinarello rediscovered the same 
cytokine in 1977 and called it leukocytic pyrogen. LAF and leukocytic pyrogen 
were shown to be the same in 1979, and renamed interleukin 1.500 Interleukin 1 
was successfully cloned in 1985, which led to the realisation that the IL1 
consisted of two distinct but closely related proteins, IL1α and IL1β.501 
IL1β is secreted primarily by monocytes and macrophages and has myriad 
functions.502 Its systemic effects are fever, headache, nausea, myalgia and 
fatigue. It has endocrine effects (up-regulation of cortisol and ACTH secretion, 
but depression of insulin secretion) and inflammatory effects, including the up-
regulation of chemokines and cytokines (TNFα, IL6, IL8, G-CSF and GM-CSF), 
adhesion molecules (e.g., ICAM-1) and the activation of CD4+ T lymphocytes, B 
lymphocytes and NK cells.502 
Secretion of IL1β is a two-step process.460 Pro-IL1β is not present in the 
cell in significant quantities, so pro-IL1β must first be transcribed and 
translated. Pro-IL1β induction is mediated by NF- κB, and therefore requires 
either TLR or NOD2 activation.465 The second step is inflammasome assembly 
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and cleavage of pro-caspase-1 to its active form, which in turn leads to the 
conversion of pro-IL1β to mature IL1β. 
In contrast to IL1β, preformed pro-IL18 is present in the cell in significant 
quantities, so secretion of IL18 is essentially a one-step process: viz., the 
cleavage of pro-IL18 to mature IL18 by caspase-1.503 This means that the IL18 
response always precedes the IL1β responses. Although pro-IL18 is expressed by 
a wide variety of cell types, the caspase-1 inflammasome is only assembled in 
monocytes or macrophages,477,486,487 which are therefore the only source of 
mature IL18. 
Caspase-7 has been called an executioner or effector caspase,494 because it 
cleaves a large set of substrates that ultimately result in the hallmarks of 
apopotosis, which are DNA fragmentation and mitochondrial damage.495,496 
Caspase-7 is upregulated in murine melioidosis,429 but there is currently no 
published clinical data on caspase-7 in melioidosis. It seems unlikely that the 
primary role of caspase-7 in melioidosis should be apoptosis-related since Sun 
et al. have already shown that in the context of B. pseudomallei infection, the 
predominant mode of cell death is pyroptosis. In Legionella pneumophila 
infection,504 caspase-7 has been shown to have a role in delivering endocytosed 
bacteria to the lysosome. Future studies on caspase-7 using B. pseudomallei 
may prove equally illuminating. 
1.7.8 Caspase-1, pyroptosis, and cytokine-independent killing 
Caspase-1 is responsible for inflammation-related programmed cell death 
called pyroptosis,491,492 which is distinct from apoptosis. Apoptosis is an energy-
dependent process involving the orderly dismantling of a cell by DNA 
fragmentation and blebbing, with minimal inflammation. By contrast, 
pyroptosis is not energy-dependent: instead, it involves perforation of the cell 
membrane, osmotic cell lysis and an accompanying burst of pro-inflammatory 
cytokines.491 Pyroptosis is mediated by a macromolecular complex called the 
pyroptosome, which is similar to, but distinct from, the inflammasome. The 
pyroptosome is an oligomer, composed of multiple ASC dimers that rapidly 
recruit and activate caspase-1.492,505 A cell only ever assembles a single 
pyroptosome. 
 55 
Pyroptosis was originally described in S. Typhimurium infections of mouse 
macrophages.491,492 Miao et al. found that although pyroptosis destroys the 
macrophage, this causes the intracellular organisms to spill out into the 
extracellular milieu where they are killed. Although Miao’s primary 
observations were of S. Typhimurium, he also studied B. thailandensis (which is 
closely related to B. pseudomallei) and found that IL1β/IL18 double knockouts 
were still capable of controlling infection, but that caspase-1 knockouts were 
not. This lead him to conclude that caspase-1 is able to kill intracellular 
pathogens by a cytokine-independent mechanism, most likely pyroptosis.506 
Sun et al. showed that B. pseudomallei induces caspase-1-dependent 
macrophage death, which is then accompanied by the release of IL1β and 
IL18.473 Although the study predates the first description of the pyroptosome by 
two years, Sun found that the process was dependent on the presence of a 
functional type 3 secretion system and membrane pore formation, before 
proceeding to cell swelling and lysis.473 These are all characteristic of pyroptosis, 
even though Sun was not able to apply that term to his observations. It should 
be noted that the precise mechanism by which pyroptosis destroys intracellular 
bacteria is unclear: Miao presented data suggesting that the bacteria are 
subsequently destroyed by neutrophils, but Breitbach’s in vitro system still 
demonstrated an effect despite containing no neutrophils. 
The data from cytokine and pattern recognition studies may be 
summarised thus: the story begins with B. pseudomallei infecting an immature 
monocyte. The infected monocyte is not able to kill the intracellular bacteria 
using reactive oxygen species (ROS) or reactive nitrogen species (RNS) because 
it has not been stimulated by IFNγ. The monocyte is, however, able to assemble 
inflammasomes (and a pyroptosome) under NLRC4 stimulation. The infected 
monocyte sends out a cytokine distress signal (TLR-mediated IL12 and NLR-
mediated IL18) before destroying itself and the bacteria by pyroptosis. The 
distress signal is picked up by NK and CD8+ cells, which generate and amplify 
the critical IFNγ signal. The IFNγ signal then activates intracellular killing 
mechanisms in other cells. 
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1.7.9 Monocytes and macrophages 
Circulating monocytes may be stimulated to differentiate into any one of 
three cells types: dendritic cells, Langerhans cells, or macrophages.507 Monocyte 
differentiation is directed by exposure to different environmental factors 
encountered as the monocyte progresses from the peripheral circulation to the 
tissues. Exposure to IL4 and granulocyte-macrophage colony stimulating factor 
(GM-CSF) causes monocytes to become dendritic cells;508–510 exposure to IL15 
plus GM-CSF causes monocytes to become Langerhans cells;511 while exposure 
to IL6,512,513 IL10514 and macrophage colony stimulating factor (M-CSF)513 
causes them to mature into macrophages. Concentrations of M-CSF have never 
been measured in acute melioidosis, but plasma levels of IL6 and IL10 are 
high,413,422 which supports a role for macrophages in melioidosis. IFNγ levels are 
also high in acute melioidosis,369,376 and IFNγ is able to direct monocytes to 
differentiate into macrophages by stimulating autocrine IL6 and M-CSF 
production.507 
In melioidosis, macrophages are the principal orchestrators of the host 
cytokine response. They are the generals and neutrophils are the foot soldiers. 
Although capable of killing B. pseudomallei, their primary function is not to kill, 
but to initiate the host cytokine response (by secreting IL12, IL18 and 
TNFα),360,373,411 in inflammasome activation,474 and in recruiting neutrophils to 
the site of inflammation (by secreting IL1β515,516* and chemoattractants such as 
IL8). 
B. pseudomallei is a facultative intracellular pathogen, and monocytes are 
an important target.52,79,80 Macrophages are susceptible to being parasitized by 
B. pseudomallei and may be subverted to become incubators for bacterial 
replication in human tissues.52 The effective host response therefore depends on 
IFNγ stimulation. Macrophages stimulated by IFNγ are thought to kill 
intracellular pathogens by producing a burst of reactive nitrogen intermediates 
(RNI) (principally the production of nitric oxide from L-arginine, but also 
nitrogen dioxide and nitrous acid) and reactive oxygen species (ROI) (e.g., 
superoxide anion, peroxide, hydroxyl radical and singlet oxygen).517–520 RNIs 
                                                   
* IL1β is not chemoattractant per se, but it induces the secretion of chemoattractants and the 
expression of cell adhesion molecules on the endothelium. 
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and ROIs both appear to have a role in killing B. pseudomallei,521,522 with the 
role of RNIs possible more important than that of ROIs,521 but they are not the 
only mechanism by which stimulated macrophages are able to kill 
B. pseudomallei519,523 and lysosomal killing is probably important.524 
1.7.10 Lymphocytes 
Host defences to melioidosis are dependent on macrophage-lymphocyte 
interactions,525 but, unusually, T cell help does not predominate in this 
relationship. 
In mouse models of melioidosis, the primary source of IFNγ is natural 
killer (NK) cells and CD8+ T lymphocytes (at least in the earliest stages of the 
host response).360,373,411 This stands in marked contrast to other pathogens such 
as Leishmania major526,527 and Mycobacterium tuberculosis,528,529 where IFNγ 
is produced primarily by CD4+ T lymphocytes. The lack of a role for helper T 
cells in the initial host response to melioidosis means that it lies outside the 
Th1/Th2 paradigm within which host responses are usually defined.530 This may 
also explain why clinical epidemiological studies have not found HIV infection 
to be a risk factor for melioidosis180 (unlike other intracellular infections like 
leishmaniasis531,532 and tuberculosis533,534), because HIV depletes CD4+ cells 
without depleting NK or CD8+ cells.535 
A role has been found for CD4+ cells in later stages of melioidosis in mouse 
models,411 which leads one to speculate that melioidosis patients co-infected 
with HIV may have an increased risk of recurrence, but the small number of 
patients co-infected with HIV and melioidosis makes it difficult to collect 
enough epidemiological data to examine this question adequately.180,307,536 
1.7.11 Neutrophils 
The neutrophil chemoattractant, IL8 (also called CXCL8), is present in 
elevated concentrations in clinical melioidosis.413 Mice do not have IL8, but do 
express the related chemokines, CXCL1, CXCL2, and CXCL5, all of which are 
elevated in experimental melioidosis.242 Unsurprisingly, leukocytosis is a 
feature of acute clinical melioidosis and this leucocytosis is predominantly a 
neutrophilia.242 
The role of neutrophils in experimental B. pseudomallei infection has been 
demonstrated convincingly in two mouse studies.326,537 Bacteria were detectable 
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by flow cytometry ≥24 hours after infection, and the only cell type with which 
bacteria were measurably associated were neutrophils, not monocytes or 
macrophages. The bacteria were confirmed to be intracellular by confocal 
microscopy, but the viability of these bacteria was not confirmed.537 The ability 
of B. pseudomallei to invade and replicate within neutrophils has been 
confirmed by multiple independent teams,79,80,538,539 but the question of 
whether neutrophils are a site for B. pseudomallei survival and replication in 
vivo remains to be answered. 
Neutrophils are an important part of the host defence against melioidosis, 
and animals in whom neutrophil function is compromised do worse at 
controlling the infection. Easton et al. ablated neutrophils using a monoclonal 
antibody against Ly6g (formerly called Gr1) and found that bacterial loads were 
much higher after four days than in untreated mice.326 Secreted 
phosphoprotein 1 (SPP1, formerly called osteopontin) is a 33 kDa extracellular 
matrix protein that is cleaved by thrombin during inflammation to reveal a 
cryptic sequence that is recognised by integrin receptors present on 
neutrophils.540 SPP1 therefore plays a role in the neutrophil recruitment during 
melioidosis. In agreement with Easton’s results, van der Windt et al. found that 
Spp1-knockout mice had fewer neutrophils at the site of infection, had higher 
bacterial loads and worse survival.242 Plasminogen activator, urokinase receptor 
(Plaur, formerly called uPAR or CD87) is expressed by neutrophils and has also 
been shown to be necessary for neutrophil recruitment, probably via an effect 
on integrin expression.242 Again, Plaur-knockout mice had a reduced ability to 
recruit neutrophils to an area of infection and had a reduced ability to clear 
B. pseudomallei, although this time, survival was marginally better in Plaur 
knockout mice.541 This apparent contradiction might be explained by the fact 
that Plaur also promotes phagocytosis541 and B. pseudomallei is capable of 
subverting leukocyte endocytosis to further its own survival. 
Part of the difficulty with studying neutrophils has been that freshly 
isolated neutrophils die within hours of stimulation with live bacteria. It now 
appears that this self-destruction is due to a newly described form of 
neutrophil-mediated killing, in which neutrophils expel their own chromatin to 
form extracellular traps (NET).542 The role of NETs in the host response to 
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B. pseudomallei remains to be explored, but seem likely to be an important part 
of the host response to melioidosis. 
1.8 Diabetes and infection 
Diabetes mellitus is a heterogenous group of disorders characterized by 
chronic elevation of serum glucose levels. The majority of diabetes cases are 
primary and idiopathic, but a minority of cases occur secondary to other 
conditions. Primary diabetes is divided into types 1 and 2, with type 1 diabetes 
being primarily a disease of insulin-deficiency with onset in childhood, resulting 
from the loss of insulin-producing beta-islet cells of the pancreas. Type 2 
diabetes is associated with obesity,543,544 increasing age544–546 and family 
history.547 The primary lesion is not insulin deficiency, but insulin resistance, 
with the tissues requiring ever higher concentrations of insulin to achieve the 
same effect. Diabetes may also occur secondary to pregnancy,548 corticosteroid 
use,549–552 Cushing’s disease,553 pancreatitis,554 pancreatic resection,554 cystic 
fibrosis,555 haemochromatosis (both primary556 and secondary557) and 
acromegaly.558,559 
The majority of cases that occur worldwide are due to type 2 diabetes and 
there is a problem of under diagnosis, even in developed countries,560 because 
patients often feel well in the early stages of type 2 diabetes and because 
screening programmes are not often in place. In 2010, there were an estimated 
347 million adults worldwide with diabetes and that number is projected to 
increase.546 Although age standardised rates of diabetes are not increasing in 
Southeast Asia, the number of patients with diabetes is increasing due to 
population growth and aging.546 However, the epidemiology of diabetes in 
Thailand is complicated by the fact that diabetes in Thailand is associated with 
relative insulin deficiency, not just insulin resistance.775 The reasons for this are 
not known. 
1.8.1 Diabetes and infection 
Patients with diabetes mellitus have an increased risk of developing 
infections and sepsis,561,562 and constitute 20·1–22·7% of all sepsis 
patients.334,563 This association was first observed a thousand years ago by 
Avicenna (980–1027 CE), who noted that diabetes was frequently complicated 
by tuberculosis.564 In the pre-insulin era, Joslin noted in a series of 1000 cases 
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that diabetic coma was usually precipitated by infection.565 Even today, 
infection remains an important cause of death in diabetics.566 Much of the 
literature does not distinguish between types of diabetes and regards all 
complications as secondary to hyperglycaemia and as independent of diabetes 
aetiology. 
A small number of conditions are strongly associated with diabetes, 
including malignant otitis externa,567–569 emphysematous pyelonephritis,570–573 
emphysematous cholecystitis,574,575 Klebsiella liver abscesses,576 and 
rhinocerebral mucormycosis,577,578 so much so, that when the diagnosis is made 
in someone who is not known to have diabetes, the clinician should consider 
testing for diabetes. 
Most of the aforementioned infections are unusual. Instead, most 
infections in patients with diabetes are those that occur also in the general 
population. Two population-based studies have proved pivotal to our 
understanding of the susceptibilities of patients with diabetes:561,562 a study of 
523,749 Canadians with diabetes and an equal number of matched controls 562 
found diabetes increased the risk for cystitis (risk ratio 1·39–1·43), pneumonia 
(1·46–1·48), cellulitis (1·81–1·85) and tuberculosis (1·12–1·21). A study of 7,417 
Dutch patients with diabetes found a higher incidence of lower respiratory tract 
infection (adjusted odds ratios 1·42 for type 1 diabetes and 1·32 for type 2), 
urinary tract infection (1·96 and 1·24), and skin and mucous membrane 
infection (1·59 and 1·33).561 The association between diabetes and tuberculosis 
was re-confirmed by a recent meta-analysis of 16 studies spanning a 50-year 
period.579 
Although diabetes mellitus is implicated in susceptibility to infection, its 
influence on the subsequent clinical course and outcome is less clear. Some 
studies have shown an association with increased mortality,580–583 others found 
no effect,563,584–592 while still others found improved survival.574,575,593 The 
largest of these (12·5 million sepsis cases)574 found that patients with diabetes 
were less likely to develop acute respiratory failure and linked this to two 
previous studies that found diabetics seem protected from acute lung 
injury.594,595 The largest single study to show an adverse effect of diabetes on 
mortality in sepsis was conducted in 29,900 Danish patients with community-
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acquired pneumonia and found that patients with diabetes had a higher risk of 
mortality (OR 1·2).582 
The reasons for different outcomes between these studies are unclear, but 
may relate to differences in study population, varying outcome measures, 
differences in statistical analysis and in diabetes drug prescription habits 
between countries.329 Population-based studies are less prone to selection bias 
compared to hospital-based studies, but more detailed clinical information is 
usually available in hospital-based studies. In terms of outcome measures, 
studies with outcomes at longer time points (e.g., 6 months versus 28-day 
mortality) are more likely to find informative differences, but are much more 
difficult to conduct.596 Observational studies often make use of multivariable 
regression techniques to correct for confounders (a common, but incorrect, 
approach to model-building is to include all measured parameters and then 
remove parameters on the basis of p-value). Overadjustment or unnecessary 
adjustment for variables that are not confounders can produce biased or 
spurious results (these issues are further discussed in Chapter 2).597 Patients 
with diabetes also have multiple co-morbidities that may worsen outcomes: it is 
debatable whether these co-morbidities should be adjusted for, since many are 
caused by diabetes itself and therefore, by definition, are not confounders.598 
Nevertheless, a number of studies have adjusted their results for these 
comorbidities, regardless of the validity of these adjustments.581,582,584 
1.8.2 Diabetes and the host response 
In 1904, Lassar suggested that high levels of glucose may drive infection by 
serving as a nutrient source for bacteria,599 but in 1911 Handmann showed that 
glucose supplementation did not enhance bacterial growth,600 and proposed 
instead a defect in immune function, which Da Costa and Beardsley 
demonstrated in 1907.601 The subsequent literature on this topic is complicated 
by the fact that different techniques have been used over the years, and gaps of a 
decade or more may separate experiments, making it difficult to compare 
results. Most studies have shown defects in neutrophil function, with good 
evidence for abnormalities in adhesion, chemotaxis and intracellular killing, but 
evidence for a phagocytosis defect are contradictory. The evidence that 
neutrophil defects are solely responsible for the increased susceptibility of 
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diabetics to infection is equivocal.602 There is good evidence that humoral 
responses in diabetics are poorer, and may play a larger role than previously 
recognized. 
1.8.3 Diabetes and general markers of inflammation 
Diabetes is associated with elevations in CRP,603 TNFα,604 IL6603 and 
IL8,605 but no differences are seen in circulating cell surface markers or 
coagulation markers between patients with and without diabetes in the context 
of sepsis. 
In a cohort of 1,799 patients with community-acquired pneumonia 
(CAP),606 concentrations of pro-inflammatory cytokines (TNFα, IL6 and IL10), 
coagulation (antithrombin, Factor IX and thrombin-antithrombin complexes) 
and fibrinolysis (PAI-1 and D-dimer) biomarkers were similar in subjects with 
and without diabetes at presentation and in the first week of hospitalization.606 
In addition, monocyte expression of CD120a, CD120b, HLA-DR, TLR4 and 
TLR2 on monocytes was not different between the groups.606 These results are 
consistent with a cohort study of 830 sepsis patients, in whom plasma 
concentrations of IL6 and TNFα were elevated to the same extent in patients 
with and without diabetes, both at admission and at follow-up.563 In this second 
study, diabetes was not found to exacerbate the known procoagulant response 
seen in sepsis.563 Since sepsis and diabetes both induce a proinflammatory and 
procoagulant state and since both interfere with the host response, the lack of a 
strong influence of diabetes on the proinflammatory and coagulation pathways 
during sepsis is remarkable. Preclinical studies in healthy volunteers have 
shown that acute hyperglycæmia and insulin resistance may both directly 
influence inflammation and coagulation,607,608 but these changes may not be 
detectable on the background of the much larger abnormalities attributable to 
sepsis. There is also evidence that local responses may be impaired in diabetes: 
e.g., levels of urinary IL6 and IL8 are lower in diabetic women with 
bacteriuria.609 Endothelial activation has been implicated in the pathogenesis of 
sepsis610 and diabetes is itself known to activate endothelium. A recent study of 
207 sepsis patients (of whom 30% had diabetes) showed that markers of 
endothelial cell activation (plasma E-selectin and sFLT-1) were higher in 
diabetes.611 
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1.8.4 Diabetes and neutrophil adhesion 
Recruitment of neutrophils to a site of inflammation requires endothelial 
adhesion followed by transmigration and exit from the circulation, a process 
requiring the expression by neutrophils of integrins (e.g., CD11a/CD18 and 
CD11b/CD18),612,613 which then bind to endothelial cell adhesion molecules 
(e.g., intercellular adhesion molecule 1, or ICAM-1614–616). 
A study in which neutrophils were harvested from 26 patients with 
diabetes and an equal number of controls demonstrated that adhesion to bovine 
aortic endothelium was increased for neutrophils from diabetics, but only if the 
endothelium was also incubated with plasma from patients with diabetes.617 
Increased adhesion appears to be due to both an increase in expression of 
integrins by diabetic neutrophils and of adhesion molecules by endothelium. 
Diabetic neutrophils have increased expression of CD11b and CD11c,618 and 
glucose itself appears able to stimulate the expression of ICAM-1 by endothelial 
cells,614–616,619–621 possibly via an osmotic effect.620,621 
1.8.5 Diabetes and neutrophil chemotaxis 
Chemotaxis is the ability of neutrophils to detect and move towards a 
chemical stimulus. Studies of chemotaxis may be divided by technique: those 
using the two-chamber Boyden technique622 have produced conflicting 
results,623,624 but the subagarose technique625 (which includes a negative 
control, which Boyden’s technique lacks) have reproducibly shown a defect in 
diabetes.618,626 
1.8.6 Diabetes and neutrophil phagocytosis 
Phagocytosis is the engulfment and ingestion of foreign bodies by a cell, 
allowing neutrophils to remove and destroy pathogens. 
The evidence for a defect in phagocytosis in diabetes is contradictory, with 
some reporting a defect,627–630 but others not.618,631 These inconsistencies may 
be attributed to differences in methodology: neutrophils will not phagocytose 
unopsonised particles, so bacteria and cells need first to be incubated with 
serum containing C3b or IgG. Many studies have used autologous serum,627–630 
but those that have used a standard serum or opsonin have found no 
defect.618,631 In 1976, Bagdade found that phagocytosis of Streptococcus 
pneumoniae was reduced in neutrophils recovered from eight patients with 
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poorly-controlled diabetes, but this defect improved with diabetes treatment.629 
Notably, control neutrophils incubated with serum taken from patients with 
diabetes also demonstrated a defect in phagocytosis, implying that the defect is 
in fact due to defective opsonisation and not to a deficit in neutrophil 
phagocytosis per se: in other words, the defect is humoral. In 1984, Davidson et 
al. studied ingestion of Candida guilliermondii by neutrophils from 11 patients 
with diabetes and found that phagocytosis was reduced. However, if pre-
opsonized yeast cells were used, then phagocytosis was no different from 
controls, again suggesting that a humoral defect must exist.631 Delamaire et al. 
used a single control serum for all samples to remove the possibility of a 
difference in opsonisation,618 convincingly demonstrating that no phagocytosis 
defect exists in diabetic neutrophils. 
1.8.7 Diabetes and neutrophil-mediated killing 
Neutrophils have two distinct mechanisms for killing bacteria, 
intracellular and extracellular. Phagocytozed bacteria are killed by superoxide 
anions and other oxygen-derived species. Culture-based methods have 
demonstrated a defect in intracellular killing of Staphylococcus aureus,626,632,633 
Streptococcus pneumoniæ,628,634 and Candida albicans.635 More recent studies 
have confirmed this finding used chemiluminescence methods,636–639 a superior 
method compared to culture, because it separates the effect of phagocytosis 
from that of intracellular killing. The killing defect cannot be corrected by 
incubation with normal serum,633 suggesting that it is cellular in origin. The 
defect improves with glycaemic control.638 
Neutrophils are also able to kill bacteria extracellularly by expelling 
chromatin, which combines with granule proteins to form NETs.542 
Interestingly, β-hydroxybutyrate (a ketone body present in diabetic 
ketoacidosis) has been shown to inhibit the formation of NETs,640 but the 
relevance of this finding to patients remains to be demonstrated. 
1.8.8 Diabetes and monocyte function 
Monocytes in diabetes have been less well studied than neutrophils, but 
also appear to have defects of chemotaxis641 and phagocytosis.642,643 Adhesion to 
endothelium is also enhanced.644,645 In contrast to neutrophils, intracellular 
killing seems to be enhanced.646 Monocytes obtained from 24 diabetic patients 
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produced similar amounts of TNF-α when compared to healthy controls when 
stimulated with lipopolysaccharide (LPS), but IL-6 levels were higher in 
patients with type 1 diabetes.647 
1.8.9 Diabetes and lymphocyte function 
Few studies have looked at the effect of diabetes on lymphocyte function. 
One measure of lymphocyte function is transformation in response to a mitogen 
or bacterial antigen. Studies containing acidotic patients appear to find that 
responses are diminished648,649 and that correction of the acidosis leads to 
prompt resolution of the defect,649 but more recent studies have found deficient 
proliferative T-cell responses even in treated patients.639,650 Diabetic T-cells 
express higher levels of CD152, a down regulator of the immune response.651 
Three other studies failed to find a defect in lymphocyte function.624,652,653 
1.8.10 Humoral defects 
In 1907, Da Costa and Beardsley found that sera from diabetes patients 
were less able to opsonize S. aureus compared to sera from controls.601,654 In 
1973, Farid and Anderson surveyed 46 patients and found that IgG levels were 
lower in insulin-treated diabetics, but not in patients on oral treatments or diet 
alone. More recently, a study of 66 patients with type 1 diabetes demonstrated 
that total IgG levels were lower in patients with uncontrolled diabetes as 
measured by HbA1c.655 Also, the apparent defect in neutrophil phagocytosis 
appear to be humoral and not cellular in origin (see above). 
The best evidence for a humoral defect in diabetic patients comes from 
vaccine studies. It was described as early as 1930 that deficient agglutinin 
responses are seen in diabetic patients after subcutaneous typhoid 
vaccination.656,657 Multiple studies have shown that patients with diabetes are 
less likely to mount a protective antibody response to hepatitis B 
vaccination,658–661 leading some authorities to recommend routinely adding a 
booster dose to the standard regimen for patients with diabetes.658,662 The 
literature on influenza vaccination is more mixed (reviewed by Brydak and 
Machala663). Pozzilli et al. looked at 52 diabetic patients and found fewer 
activated lymphocytes in patients with type 2 diabetes following influenza 
vaccination, but no differences in antibody responses.664 Muszkat et al., 
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studying a more elderly population, found lower antibody responses in patients 
with type 2 diabetes.665 
Diabetes is also associated with a waning in the duration of protection 
afforded by tetanus vaccination although the initial response appears to be 
normal.666,667 Patients with diabetes appear to respond well to pneumococcal 
polysaccharide vaccine,668 although there are no studies studying duration of 
protection in diabetic patients. There are also no studies specifically linking 
humoral responses in sepsis to diabetes. 
1.8.11 Complement abnormalities 
Inherited deficiencies of component 4 (C4) have been implicated in the 
pathogenesis of type 1 diabetes,669–671 but whether this contributes to 
susceptibility to infection in type 1 diabetics is not known. By contrast, obesity 
and elevated insulin levels (as occur in type 2 diabetes) appear to be associated 
with elevations in C3.672 Karlsson et al., looking for biomarkers for maturity-
onset diabetes of the young (MODY), found that complement C5 and C8 are 
both elevated in diabetes regardless of etiology,673 a possible mechanism for 
these abnormalities being that complement activation can be driven by glycated 
immunoglobulins.674 One explanation for why diabetic sera are less able to 
opsonize bacteria may be that glucose attacks the thiolester bond of 
complement C3, thus preventing it from binding to the bacterial surface.675 
1.9 Diabetes and melioidosis 
1.9.1 B. pseudomallei and the diabetic neutrophil 
Diabetes is the most important risk factor for melioidosis, and the 
epidemiological evidence for this has been reviewed above. We also know that 
the host response to melioidosis is critically dependent on neutrophils,326 and 
diabetes is known to cause defects in neutrophil function, as reviewed above. 
The effect of diabetes on the neutrophil response to B. pseudomallei 
infection has been explored by Chanchamroen et al.539 Neutrophils were 
collected from 56 patients with diabetes who were otherwise healthy and 
compared to 36 healthy controls. Cells were then infected with B. pseudomallei 
K96243. All study subjects were from Northeast Thailand.  
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Chanchamroen demonstrated that B. pseudomallei is able to persist 
intracellularly in neutrophils. She also reported impairment of phagocytosis, 
chemotaxis and an increased rate of neutrophil apoptosis. Her results are 
difficult to interpret due to a number of limitations in the study design as 
follows:– 
Chemotaxis was studied using the two-chamber method,622 which is 
inferior to the subagarose technique625 because it has no negative control and 
cannot distinguish between specific and non-specific migration. Despite this, 
she was still able to show a chemotactic defect in diabetic neutrophils.  
Phagocytosis was measured using autologous serum, a method which we 
now know to be severely confounded by humoral effects. The study appeared to 
show increased intracellular killing by diabetic neutrophils, which is a totally 
unexpected finding. The intracellular killing assay is severely confounded by the 
fact that phagocytosis was poorer in diabetic neutrophils, which means the 
initial number of intracellular bacteria was smaller in the diabetic neutrophils. 
This was not corrected for in the analysis, which in turns means that no 
meaningful comparison between diabetic and non-diabetic neutrophils was 
possible. The same study demonstrated that B. pseudomallei appeared to delay 
apoptosis in healthy neutrophils but not in diabetic neutrophils: however, 
interpretation of this result is also problematic due to the same confounding 
factors. 
1.9.2 B. pseudomallei and the diabetic macrophage 
Williams et al. studied peritoneal macrophages and bone marrow-derived 
dendritic cells harvested from C57Bl/6 mice made hyperglycaemic by treatment 
with low-dose streptozocin (STZ).676 In this model, mice were treated with 
55 mg/kg STZ intraperitoneally for six days; control mice were treated with 
buffer only. Mice were considered diabetic if their blood glucose levels were 
≥13 mM for 9 days. Mice in the ‘acute diabetes’ group were sacrificed 19 days 
after the first STZ injection, while mice in the ‘chronic diabetes’ group were 
sacrificed 70 days after the first infection. 
Dentritic cells were harvested by culturing bone marrow for 10 days with 
GM-CSF. Peritoneal macrophages were harvested after injection of the 
inflammatory agent, Brewer’s thioglycollate. Phagocytosis was measured using 
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the ability to internalise fluorescent beads. Intracellular killing was measured by 
lysing the cells with 0·1% Triton-X, then culturing the lysate on Ashdown’s agar. 
Colony counts at 18 hours were expressed as ratios of the number of bacteria 
internalised at 4 hours, thus adjusting for differences in phagocytosis. Cytokine 
expression was measured by quantitative PCR. 
Williams found no differences in cells collected from the acute diabetes 
group when compared to the controls, but in cells collected from the chronic 
diabetes group, intracellular survival of B. pseudomallei was greater than in 
controls. She also found that expression of IL11β, IL12, IL18 and TNFα were 
depressed in the chronic diabetes group compared to the control group. 
1.9.3 Melioidosis in murine models of diabetes 
Hodgson has published a murine model of melioidosis in type 2 diabetes, 
using the BKS.Cg-Dock7m +/+ Leprdb/J mouse (also called the db/db mouse).677 
This inbred strain was originally created in 1966 from a C57Bl/KsJ 
background.678 Homozygotes for the spontaneous leptin receptor mutation, 
Leprdb, become hyperinsulinaemic at 10–14 days of age, obese at 3–4 weeks, 
hyperglycaemic at 4–8 weeks and die at around 10 months.679 Non-diabetic 
litter mates heterozygous for the Leprdb mutation were used as controls. 
Diabetic mice were more susceptible to B. pseudomallei infection than age 
and sex-matched controls: following a subcutaneous challenge of 4·6 × 106 cfu, 
all mice in the diabetic group were dead by day 4, whereas the control mice all 
survived until day 11. In this study, no differences in neutrophil oxidative burst 
were found between diabetics and controls, but no other test of neutrophil 
function was performed. This is in contrast to another study by a different group 
using S. aureus that showed impaired oxidative burst in db/db neutrophils.680 
Hodgson found no differences in bacterial loads in liver or spleen, but did 
find higher loads in subcutaneous tissue. Concentrations of TNFα and IL1β 
mRNA in the spleens of db/db mice were higher than controls. In vitro studies 
of peritoneal macrophages harvested from db/db mice showed that 
B. pseudomallei was better able to survive in db/db macrophages and that 
db/db macrophages produced lower levels of nitric oxide. Hodgson therefore 
attributed the increased susceptibility of diabetic mice to a defect in 
macrophage responses. 
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1.9.4 Melioidosis and diabetes in the clinic 
It has been recognised that once melioidosis has been acquired, patients 
with diabetes paradoxically seem to do better. In a prospective observational 
study of 755 melioidosis patients, diabetes was independently associated with 
survival (adjusted odds ratio for mortality 0·36, 95% confidence interval 0·25–
0·50).681 This is at odds with what we know about the effect of diabetes on the 
host response, which would lead us to predict that outcomes should be poorer in 
diabetes. This finding is not unique to melioidosis, and the conflicting data in 
the literature on the influence of diabetes on sepsis outcomes has been 
discussed above. 
1.10 Outline of the work 
In this dissertation, the link between diabetes and melioidosis is explored 
using classical epidemiological techniques (Chapter 2), and it is shown that this 
link is attributable to the use of glibenclamide prior to hospital admission for 
melioidosis and not to diabetes per se. The host response to melioidosis is 
explored by studying gene expression in peripheral blood leukocytes 
(Chapter 3), and glibenclamide is shown to have an anti-inflammatory effect in 
patients with melioidosis. The effect of glibenclamide is then described in a 
mouse model of melioidosis (Chapter 4), in which it is shown that glibenclamide 
reduces interleukin-1β secretion. 
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2 Glibenclamide, not diabetes, protects 
from mortality in melioidosis 
2.1 Introduction 
2.1.1 The melioidosis cohort at Sappasithiprasong Hospital 
The Wellcome Trust was founded in 1936 under the will of Sir Henry 
Wellcome, co-founder of the pharmaceutical firm, Borroughs-Wellcome, who 
established tropical medicine research laboratories in London and Khartoum 
following visits to Ecuador and The Sudan. The Wellcome Trust Unit in 
Bangkok was started in 1979 as a long term collaboration between Oxford 
University and Mahidol University by Professor Sir David Weatherall, Professor 
David Warrell, Professor Emeritus Chamlong Harinasuta and Professor 
Emeritus Khunying Tranakchit Harinasuta with support from the then director 
of the Wellcome Trust, Dr Peter Williams. 
The Unit’s involvement in melioidosis research began when the then 
director of the Wellcome Trust Unit, Professor Nicholas White, was approached 
by a physician from Ubon Ratchathani, Professor Wipada Chaowagul, who had 
noticed increasing numbers of melioidosis cases in her practice. The laboratory 
at Sappasithiprasong Hospital (Figure 11) was established by David Dance and 
Nicholas White in 1986. 
Ubon Ratchathani is a province in Northeast Thailand (Figure 12), 
629 km to the east of Bangkok. It is bordered by Laos to the east (from which it 
is separated by the Mekong River) and Cambodia to the South. Ubon 
Ratchathani was founded in 1786 as a vassal state of Siam and became a 
province of Thailand in 1882. It was the largest province in Thailand until 
Yasothon (1972) and Amnat Charoen (1993) gained status as independent 
provinces. 
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Figure 11. Sappasithiprasong Hospital, Ubon Ratchathani. 
Note.—The front façade of Sappasithiprasong Hospital, Ubon Ratchathani. 
Sappasithiprasong is a 1000-bedded tertiary referral centre for the province of Ubon 
Ratchathani. ©2008 GCKW Koh. 
 
Ubon Ratchathani province has an area of 16,112 square kilometres and a 
population of 1·8 million (2009 data). It is subdivided into 25 districts (called 
amphoe) and is further subdivided into 219 subdistricts (thambon). The largest 
city is Ubon Ratchathani city (population 85,000), followed by Warin Chamrap 
(population 31,000). The main industry is rice farming. The climate is tropical, 
with a rainy season that runs roughly from June to October, and a dry season 
that runs roughly from November to May. 
Sappasithiprasong Hospital is a 1000-bedded provincial hospital. It is the 
largest hospital in the region and a tertiary referral centre for 25 community 
hospitals. Data from all patients who were culture-positive for B. pseudomallei 
have been collected prospectively from the establishment of the Wellcome Trust 
laboratory at Sappasithiprasong until 2007. The data from this cohort has been 
an important source of information on the epidemiology of melioidosis.125,169,170 
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Figure 12. Ubon Ratchathani province. 
Note.—Ubon Ratchathai province is marked in red. The province is bordered by the 
Mekong River to the east, which separates it from Laos, and Cambodia to the south. Its 
internal boundaries are formed by the provinces of Yasothon and Amnat Charoen to the 
north and Srisaket to the west. ©2009 NordNordWest, Wikimedia Commons. 
 
 
It has previously been observed in Ubon Ratchathani, that although 
patients with diabetes are more likely to develop melioidosis, they are also less 
likely to die from it.681 This finding was made incidentally in a study of the 
prognostic value of semi-quantitative urine cultures in melioidosis and diabetes 
was not the primary exposure of interest. We sought to confirm this association 
between diabetes and survival in a separate cohort of patients from the same 
hospital using causal reasoning to identify possible confounders, and then to 
adjust for these confounders using multivariable logistic regression models. We 
hoped our methods would be rigorous enough either to confirm convincingly 
the effect of diabetes, or else to identify alternative explanations for the 
observed effect.  
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2.1.2 Logistic regression 
Logistic regression has two common uses. The first is to estimate the 
probability of a particular outcome given some set of risk factors. An example of 
this first use is the APACHE score, which combines multiple clinical and 
laboratory parameters to provide an estimate for ICU mortality. A second use is 
to adjust for confounding in an estimate of the effect of an exposure on 
outcome. It is for this second use that we employed logistic regression in the 
cohort study. 
 
Figure 13. The logistic function. 
Note.—The logistic function can take any value as its input, but its output is 
constrained to lie between 0 and 1. More formally, the domain of the logistic function is 
(–∞, +∞), and its co-domain is (0, 1). ©2008 Qef, WikiMedia Commons. 
 
The logistic equation may be defined as,  
 ! = !!!!!!,  Equation 1 
  where  ! = !! + !!!! + !!!! +⋯+ !!!!. Equation 2 
 
The main value of the logistic function is that it may take as its input, !, 
any value for ! from −∞ to +∞, but its output, !, is constrained to lie between 0 
and 1 (Figure 13). This is why the function is given the name, ‘logistic’: it is 
useful for circumstances where the outcome may take only two values, e.g., 
1/0, yes/no, true/false. The value of ! may then be interpreted as the probability 
of the outcome being ‘yes’ or ‘true’, given a particular value for !. 
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The logistic function may take any number of inputs, !, (in the equation 
above, these inputs are numbered, !!, !!, …, !!), however, there can be only one 
output, ! . The variables, !  and ! , may be called by a variety of names, 
depending on the context (Table 7). 
 
  x   y 
input output 
abscissa ordinate 
independent variable dependent variable 
co-variate outcome 
exposure disease 
risk factor  
Table 7. Alternative names for x and y in multivariable regression 
models. 
Note.—The variables ! and ! can take a great many names depending on the context. 
The terms input/output and abscissa/ordinate are used mainly be mathematicians. 
Statisticians tend to speak of independent/dependent variables, while epidemiologists talk 
of exposure/outcome or risk factor/disease. The term ‘disease’ is very inexact, because 
depending on the context, different diseases may appear as x or y variables. 
 
 
The logistic equation has been presented here in a form that emphasises 
its link to linear regression. Equation 2 is in fact the linear regression model. In 
Nelder and Wedderburn’s method of generalised linear models,682 logistic 
regression is related to linear regression via equation 1, which is the link 
function. 
The logistic function, in its simplest form, was first described by a Belgian 
mathematician, Pierre-François Verhulst, in 1838,683 as the exact solution to the 
first order differential equation,† !!"!" = !!"(1− !). 
                                                   
† Here is a simple demonstration that ! = !!!!!! is a solution for !"!" = !(1 − !). 
Note that ! may be any constant, so for the purposes of this analysis we may set it to 1 without 
affecting the validity of the results. 
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The paper of 1838 was brief, but a fuller account was given in 1845,684 in 
which, for the first time, Verhulst calls the solution, la courbe logistique or ‘the 
logistic curve’. Verhulst applied the equation to model population growth, in the 
situation where that growth is initially exponential, but then encounters 
resistance (that is, the exhaustion of resources). Berkson was the first to 
advocate its use in bioassays685 (a variation of this curve is commonly used to 
analyse ELISA results) and other catalytic processes.686 Berkson also introduced 
the term ‘logit’ (by analogy to ‘probit’).686 The logistic function is therefore also a 
good model for the market penetration of iPhones, which are also a catalytic 
process: growth is initially exponential, but then slows as the market becomes 
saturated.686 
The use of the logistic function in case-control studies arose naturally. If !! 
is defined as the odds, then !  is the log odds, and the linking function 
(Equation 1) is then mathematically identical to the risk. The application of the 
logistic function to binary data may be attributed to Cox, who published a series 
of papers in the 1960’s, culminating in an influential textbook on the subject in 
1969.687 Two events allowed the expansion of logistic regression in 
epidemiological research during the 1990’s: the first was the availability of 
computer software packages that could fit the models automatically (fitting 
curves by hand is laborious and takes weeks of tedious calculation). The second 
was the publication of a textbook by Hosmer and Lemeshow in 1989,688 which 
provided guidance on building models while omitting mathematical details that 
could be left to the computer. 
Mathematically, the minimum number of precisely specified data points 
needed to fit a logit model is one plus the number of inputs to be estimated. In 
Verhulst’s original 1838 paper, he fit curves for the populations France, England 
and Russia based on three points only each. The naturally occurring variation in 
clinical data means this is never possible in practice. Instead, the number of 
inputs that may be included in a model is limited by the amount of data 
available to fit the model.  
There is no consensus on how much data is ‘enough’. Computer 
simulations suggest that for ! variables, a minimum of 10n data points are 
                                                                                                                                                     
Starting with ! = !!!!!! = !!!!!! , multiplying out the fractions yields ! + !!! = !!. 
Differentiating, gives us , 
!"!" + !! !"!" + !!! = !!. Re-arranging,  !"!" = !!!!!! 1 − ! = !(1 − !). 
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needed for each input variable.689 Some authorities have suggested that is too 
stringent;690 but some have suggested instead much larger numbers, of the 
order of 4n.691 If the figure of 10n is right, then a model with ten variables only 
needs a study of 50 patients; using a figure of 4n, the same study needs 1024 
patients. These uncertainties mean that sample size calculations for 
multivariable models are often done simply for the univariable analysis relating 
exposure and outcome, and not for the multivariable analysis. 
2.1.3 Adjusting for confounding 
Logistic regression provides a powerful method for adjusting for 
confounding. In a cohort study, where the natural metric for risk is the risk 
ratio, odds ratios are still frequently reported, because these can be adjusted for 
confounders using logistic regression. 
The classical method of adjusting for confounding is the Mantel-Haenszel 
method. Briefly, one stratifies the data by each confounder, calculates the 
estimate for each stratum, then combines the stratified estimates into a single 
summary estimate. 
The method is best illustrated using a hypothetical example. Consider the 
effect of diabetes on mortality (Figure 14). A worked example of stratification 
using invented data is presented in Table 8. 
The Mantel-Haenszel method has two major problems: the first is that it is 
not good at handling adjustment for several confounders. The second is that the 
method will only allow categorical confounders, so continuous data first needs 
to be transformed into categorical data before it can be used, which in turns 
leads to inefficiencies (in that one has to discard information before performing 
the analysis). Using a logistic regression model to adjust for confounding 
addresses many of these concerns. The model easily accepts continuous 
variables as inputs and is more forgiving of sparse data. 
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Figure 14. The influence of diabetes on mortality is confounded by 
gender. 
Note.—The effect of diabetes on mortality is confounded by the effect of gender, because 
gender is associated with both diabetes and with mortality and does not lie on the causal 
pathway between diabetes and mortality. 
The thick arrows in the graph indicate the flow of causation and must always follow the 
direction of time, because effect always follows cause. Confounding occurs when one is 
able to follow a path from exposure to outcome that goes against the direction of 
causation at some point (i.e., against the flow of time). This is known as a backdoor path. 
In this example, the effect of interest is the effect of diabetes on mortality (black arrow); 
there is however, a backdoor path linking diabetes and mortality that runs through gender 
(blue arrows). Gender is therefore a confounder for the effect of diabetes on mortality. 
One cannot infer causation from data alone, in part, because the data contain no 
information about time sequence. Information about time ordering must be added to the 
analysis by the investigator. In epidemiological studies, the person with this information 
is the epidemiologist, not the statistician. It is therefore never the statistician’s 
responsibility to identify confounding. 
  
Gender Mortality Diabetes 
Flow of time 
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A. Fictional population 
 Male Female 
 Diabetic Not diabetic Diabetic Not diabetic 
Died 450 10 200 360 
Total 900,000 100,000 100,000 900,000 
 
B1. Matched case control study: unstratified 
 Diabetic Not diabetic 
Died 650 370 
Alive 470 550 
 
B2. Matched case-control study: stratified by gender 
 Male Female 
 Diabetic Not diabetic Diabetic Not diabetic 
Died 450 10 200 360 
Alive 414 46 56 504 
Table 8. A hypothetical study population. 
Note.—Table A presents data from a purely hypothetical population categorised by three 
parameters: gender (male/female), diabetic (yes/no) and mortality (died/survived). Table B 
shows data from a case-control study drawn from that hypothetical population. The study 
investigators in our idealised study were able to recruit every patient who died, and the 
controls are perfectly frequency matched by gender. 
A: the odds ratio for a person dying if he or she has diabetes is 5.0 
= (450×100,000)/(10×900,000) = (200×900,000)/(360×100,000). 
B: In B1, the odds ratio as estimated from the unstratified data is (650×550)/(370×470) = 
2·1. This value is clearly incorrect, because in this hypothetical example, we know that 
the true population odds ratio is 5·0, because that is what we set it to be. In this case, we 
know that the estimate is confounded by gender. In B2, the same data has been divided 
into two strata, Male or Female. This removes the effect of confounding, because every 
person in each stratum has the same gender (either Male or Female). In the Male stratum, 
the odds ratio is (450×46)/(414×10) = 5·0; In the Female stratum, the odds ratio is 
(200×504)/(56×360) = 5·0. Combining the odds ratios in this simple example yields a 
summary odds ratio of 5·0, which is the correct value. 
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Aside from demonstrating how to adjust for confounding, this example demonstrates that 
matching on a confounder in a case-control study is not sufficient to remove the 
confounding. The final estimates from a matched case-control study must still be adjusted 
for all confounders that were matched, and failure to do so will produce erroneous 
results. It is even possible to demonstrate that matching for a variable that is not a 
confounder in a case-control study is capable of introducing confounding into the results. 
Many authors have therefore argued against matching in case-control studies, and many 
case-control study designs are now unmatched. This example is adapted from Rothman 
1986.692 
 
 
To adjust for more confounders, the data must be divided into strata for 
every possible combination of variables. For example, to adjust for the effect of 
obesity as well as a the effect of gender, a minimum of four strata would be 
needed: obese/male, obese/female, non-obese/male, non-obese/female. The 
number of strata required therefore increases exponentially with the number of 
confounders. If there are too many confounders to adjust for, there will not be 
enough data to fill every stratum and some strata will be empty or partly empty. 
The calculation becomes impossible for empty strata, because the estimated 
odds ratios will be either zero or undefined (division by zero).  
The statistical package, Stata (StataCorp, College Station, Texas), fits 
logistic regression models using maximum likelihood estimation, which is 
better able to cope with sparse data. The command logistic reports odds 
ratios, while logit reports log odds ratios: the models produced by both 
commands are identical. 
Logistic regression can be extended to accommodate outputs with more 
than two levels (multinomial or multivariate logit modelling), or situations 
where the inputs are not independent (conditional random field modelling). 
These are implemented in Stata as blogit and glogit, respectively. 
2.1.4 Identification of confounders and causal reasoning 
Informally, a confounder is one that accounts for all or part of an apparent 
association between the exposure and the outcome and is not itself affected by 
the exposure. One definition of a confounder is that a confounder is any 
parameter associated with both exposure and mortality, but which does not lie 
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on the causal pathway between exposure and mortality.598 The identification of 
confounders is the business of the epidemiologist and not the statistician, 
because it requires knowledge about the data that cannot be inferred from the 
data itself.693 There is no statistical test for confounding, so any method based 
solely on p-values is incorrect.694 
The greatest challenge facing the model-builder is the correct 
identification of confounders to include in the model. There exists a popular 
misconception that adjusting for more variables is a good thing. Few data sets 
are large enough to allow adjustment for every possible confounder and 
unnecessary adjustment wastes power: in other words, a true effect can be made 
to spuriously disappear by adjusting unnecessarily for something that is not a 
confounder.597,688,695 
There is an even more serious problem with unnecessary adjustment. 
Adjusting for a parameter which is not a confounder may introduce 
confounding and hence produce biased results.597,693,696 
When logistic regression models were first introduced into clinical 
research in the 1970’s and 80’s, model fitting had to be performed by hand. 
Starting in the early 1990’s, computer software packages became available that 
would fit logistic regression models in milliseconds, which has led to an over-
dependence on computer-led methods of model building, principally, the step-
wise selection of variables. 
Generally speaking, step-up procedures add variables one by one on the 
basis of p-value (smallest p-value first), while step-down procedures throw all 
the variables into the model and then remove them one by one according to p-
value (largest p-value first).697 The attraction of these data-driven approaches is 
that they remove the necessity for careful thought and will invariably produce 
models with excellent fit. Unfortunately, it has been repeatedly shown that 
models produced in this way give overoptimistic estimates for p-values and 
seldom give reproducible results688,695 (a problem known as ‘over-fitting’). 
A more serious problem with stepwise methods is their validity. The p-
value reported (whether calculated by the Wald test or by the likelihood ratio 
test) measures the value of that risk factor in predicting the outcome. Stepwise 
methods are therefore only valid (if they are ever valid) for the purpose of 
building a predictive model. When models are built to adjust for confounding, 
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the p-values are irrelevant, because the hypothesis they test is unrelated to 
whether the variable is or is not a confounder.698 
The selection of variables for inclusion in a model is always dependent on 
external information,693,699 and is only weakly dependent on information 
contained in the data itself. An important example of this external information 
is a knowledge of the temporal relationship between variables. In fact, this is 
probably the single most important piece of information available to the 
investigator, for the single reason that effect must always follow cause. If 
variable A follows variable B in time, then variable A can never be a confounder 
for variable B, because confounders must always precede in time, or at least be 
roughly contemporaneous with the variables they confound (thus allowing for 
the possibility that variable A might precede variable B). 
The simplest tool for identifying confounders is the conceptual 
hierarchy700 (Figure 15). In the hierarchical conceptual framework that we built 
for this cohort study, time flows from the top of the chart to the bottom. In our 
cohort study, the exposure of interest was diabetes (Figure 15, level 2) and the 
outcome of interest was death (Figure 15, level 6). Any one factor can be 
confounded only by other factors in the same level or in the levels above. 
Factors in lower levels must be either in the causal pathway or be common 
effects: they cannot be confounders. 
The question then arises: What is the effect of adjusting for variables on 
the causal pathway? All diabetes drugs must lie on the causal pathway between 
diabetes and death, the reason being that they are only prescribed after the a 
diagnosis of diabetes is made and are only prescribed in the context of diabetes. 
However, the choice of drug may be manipulated by the clinician. Adjusting for 
drug therapy allows us to ask the question, “what if we did not prescribe this 
drug?” It provides an elaboration of what is going on and it permits us to look 
for possible mechanisms. It is important to note that while this operation is 
mathematically identical to adjustment for confounding, the interpretation of 
the result is completely different from adjusting for a confounder. 
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1 gender age access to healthcare 
2 diabetes mellitus chronic kidney disease corticosteroid use 
3 glibenclamide metformin insulin admission 
antimicrobials 
4  Melioidosis  
5 bacteraemia respiratory failure hypotension 
6  Death  
Figure 15. Conceptual hierarchical framework of risk factors for 
melioidosis mortality. 
Note.—Gender, age and access to healthcare occupy the highest level in the hierarchy 
because they are not dependent on any other factors. Factors in each level are dependent 
on factors in the level above and factors in lower levels cannot confound the effect of 
factors in higher levels because they occur later in time. Factors in level 5 are immediate 
proximate causes of death. Other pre-existing medical conditions were omitted from 
level 2 (e.g., malignancy, thalassaemia, etc.) because they do not confound diabetes or its 
treatment. We used occupation (rice farming) as a proxy for access to healthcare. 
 
 
Measures of disease severity must also lie on the causal pathway. Why 
then is it possible to adjust for drug therapy and not disease severity, when both 
must lie on the causal pathway? The answer is that any exposure which changes 
mortality must automatically change severity. It is implausible that any effective 
intervention might reduce mortality while having no effect on clinical severity. 
To adjust for severity in the analysis is an uninterpretable exercise, because the 
clinician cannot modify severity independent of mortality. 
2.2 Methods 
We prospectively identified all patients aged 15 years or more presenting 
to Sappasithiprasong Hospital, Ubon Ratchathani, northeast Thailand with 
culture-confirmed melioidosis between 1st January 2002 and 31st December 
2006. Patients on their first admission for culture-confirmed melioidosis were 
Fl
ow
 o
f t
im
e 
 83 
eligible, but patients under the age of 15 were excluded because paediatric cases 
have a different clinical presentation and prognosis. There were no other 
exclusion criteria. 
Patients were classified into three groups according to diabetes status at 
presentation: known diabetes, hyperglycaemia or no diabetes. Patients with a 
pre-existing diagnosis of diabetes mellitus were classified as having known 
diabetes. The hyperglycaemia group were patients not previously known to have 
diabetes, who had either a blood glucose >200 mg/dl (11·1 mmol/l) at any point 
during the admission or new diabetes diagnosed after recovery as defined by 
WHO criteria. We did not sub-classify this group further for the following 
reasons: melioidosis is a common first presentation of type 2 diabetes in this 
region175 and an associated mortality of 50% (half of which occurs in the first 48 
hours) means that a new diagnosis of diabetes cannot be made for a significant 
proportion of cases, and hyperglycaemic patients who die are more likely to be 
classed as having sepsis-induced hyperglycaemia while cases who survive are 
more likely to be classed as having a new diagnosis of diabetes. Patients who did 
not fall into the known diabetes or hyperglycaemia groups were classified as 
having no diabetes. Hb A1c values were not available for patients in this cohort. 
A full history and clinical examination were recorded from culture-
confirmed cases of melioidosis, and each patient was seen daily until discharge 
or death. Blood samples were taken on admission for a complete blood count, 
capillary glucose, blood urea nitrogen, creatinine, electrolytes and liver function 
tests. Intravenous ceftazidime, imipenem or meropenem was started as soon as 
melioidosis was suspected and continued for a minimum of 10–14 days. Clinical 
data were recorded on a password-protected computer database. 
Details of pre-admission drug treatment for diabetes (glibenclamide, 
metformin and insulin) and duration of infection-related symptoms prior to 
admission were obtained by questioning the patient or nearest relative. We 
recorded whether effective admission antimicrobial therapy (parenteral 
ceftazidime, imipenem, meropenem, co-amoxiclav, or cefoperazone-sulbactam) 
was given within 24 hours of admission. 
Sepsis was defined, using a simplified version of the 1992 joint American 
College of Chest Physicians and Society of Critical Care Medicine Consensus 
Conference Committee definition, as two or more of (1) temperature <36°C or 
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>38°C; (2) heart rate >90 beats per minute; (3) respiratory rate >20 breaths per 
minute; or (4) total white cell count >12 × 109 cells/l. Bacteraemia was defined 
as one or more blood cultures positive for B. pseudomallei. The extent of 
infection was based on the number of organs or anatomical sites involved in the 
infective process: Single organ disease meant involvement of a single site, and 
multiorgan disease meant infection of more than one site. Blood culture and 
throat swab positivity were excluded from the organ count. Pneumonia was 
defined as the presence of clinical features consistent with pneumonia, plus 
radiographic changes or sputum culture positive for B. pseudomallei. Duration 
of symptoms prior to admission was recorded in days (but entered into the 
analysis as fractions of weeks). A history was taken for chronic kidney disease, 
thalassemia, malignancy and chronic liver disease (chronic hepatitis B or C 
infection, or chronic alcoholic liver disease). Patients with nephrolithiasis were 
identified from either the history or calculi visible on a plain abdominal 
radiograph or ultrasonography. 
The primary study outcome was in-hospital mortality, but we also pre-
defined two secondary outcomes: hypotension (a systolic blood pressure of less 
than 90 mmHg at any point during admission), and respiratory failure (hypoxia 
judged clinically to require mechanical ventilation; arterial blood gases are not 
taken routinely in our setting). 
2.2.1 Statistical analysis 
Analyses were performed using Stata/SE 9 (StataCorp, College Station, 
Texas). Differences between the three patient groups were compared using the 
Fisher’s exact test for categorical variables and the Mann-Whitney U test for 
continuous variables. Time to death (to a maximum of 28 days) was analysed 
using the Kaplan-Meier method; patients discharged alive from hospital within 
28 days were assumed to have survived, but patients who self-discharged 
against medical advice were censored on the day of discharge.  
To inform the selection of parameters used in the logistic regression 
models, we created a conceptual hierarchical framework700 of risk factors to 
explore interactions between a number of variables (Figure 15). Parameters 
were chosen on the basis of whether they were possible confounders for the 
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effect of diabetes on mortality (Model A, Table 10);90 p-values reported are for 
the likelihood-ratio test, but were not used to inform parameter selection. 
In Model A (Table 10), we adjusted for age and sex as possible 
confounders. We also adjusted for corticosteroid use because corticosteroids are 
available without a prescription in northeast Thailand, are commonly abused, 
and may cause diabetes. It is possible that patients in the known diabetes group 
had increased access to healthcare, so we adjusted for this by using the 
occupation of rice farmer as a proxy since this is associated with poverty, 
increased physical distance from hospitals and clinics and poorer transport 
links. It is impossible for parameters occurring below diabetes in the framework 
to confound the effect of diabetes (e.g., treatment, pneumonia, severity, organ 
failure).700 
A second regression model was developed to explore explanations for the 
survival advantage in known diabetics (Model B, Table 10) by examining 
modifiable parameters lying on the causal pathway between diabetes and 
mortality. This included analysis of treatment for diabetes prior to admission, 
and administration of appropriate admission antimicrobial therapy within 24 
hours of admission. We adjusted for chronic kidney disease in this model 
because metformin is contra-indicated in renal failure, and renal failure is 
associated with mortality. Additional models were developed to evaluate the 
effect of diabetes on our secondary outcomes (hypotension and respiratory 
failure: Table 11, Models C & E), and to explore factors that could explain the 
difference in outcomes observed in patients with diabetes (Table 11, Models D 
& F). 
The result of the Hosmer-Lemeshow test for goodness-of-fit for Model A 
was p=0·41, B was p=0·53; C was p=0·22; D was p=0·28; E was p=0·51; and F 
was p=0·47. 
2.2.2 Glibenclamide inhibition study 
Plates of Müller-Hinton agar were inoculated with a lawn of 
B. pseudomallei (0·5 MacFarland standard). A single glibenclamide tablet was 
crushed and dissolved in 1 ml DMSO, with 100 µl of the solution (~100 µg of 
glibenclamide) dropped onto the centre of the agar plate. The same volume of 
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DMSO was used for control plates. The plates were incubated at 37°C for 
48 hours and the plates examined for a zone of inhibition. 
2.3 Results 
2.3.1 Diabetes and mortality 
We identified 1384 patients with culture-positive melioidosis, of whom 
224 were removed from the final analysis for reasons shown in Figure 16. Of the 
remaining 1160 patients, 410 (35%) had known diabetes, 250 (22%) had 
hyperglycaemia and 500 (43%) had no diabetes. Patient characteristics, clinical 
features of melioidosis and primary and secondary outcomes were compared 
between the three groups, using the no diabetes group as the comparator for the 
two other groups (Table 9). In-hospital mortality was lower in patients with 
known diabetes compared with non-diabetics (p=0·04), with no difference 
observed between non-diabetics and patients with hyperglycaemia. These 
findings were reproduced in the survival analysis (Figure 17A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Summary of patient recruitment for cohort study. 
 
1384 culture-positive 
1182 eligible 
1160 study patients 
202 excluded 
• 129 age <15 
• 73 repeat admissions 
 
22 discharge date unknown 
• 17 glucose never tested 
• 4 no diabetes 
• 1 known diabetes 
500 (43%) 
No diabetes 
410 (35%) 
Known diabetes 
250 (22%) 
Hyperglycaemia 
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 No diabetes 
(n=500) 
Known diabetes 
(n=410) 
Hyperglycaemia 
(n=250) 
Total 
(n=1160) 
 number (%) number (%) p-valuea number (%) p-valuea row total (%) 
Female 165 (33) 219 (53) – 114 (46) – 498 (43) 
Male 335 (67) 191 (47) <0.001 136 (54) 0.001 662 (57) 
Median age (yrs, IQR) 52 (39–63) 51 (42–59) 0.40b 51 (42–59) 0.22b – 
Rice farmer 367 (73) 326 (80) 0.04 212 (85) <0.001 905 (79) 
Median (IQR) days of 
infective symptoms prior to 
presentation  
7 (4–15) 10 (5–21) 0.02b 8 (5–15) 0.03b 7 (5–20) 
Diabetes treatmentc       
Glibenclamide – 208 (51)  –  208 (18) 
Metformin – 51 (12)  –  50 (4) 
Insulin  – 81 (20)  –  81 (7) 
Other sulphonylurea  – 10 (2)  –  10 (0.9) 
Unknown oral drug – 51 (12)  –  51 (4) 
No medication – 53 (13)  –  53 (5) 
Risk factors for melioidosis      
Chronic kidney disease 54 (11) 36 (9) 0.32 9 (4) 0.001 99 (9) 
Nephrolithiasis 35 (7) 15 (4) 0.03 6 (2) 0.01 56 (5) 
Corticosteroid use 21 (4) 19 (5) 0.75 9 (4) 0.84 49 (4) 
Thalassaemia 11 (2) 4 (1) 0.19 2 (0.8) 0.24 17 (1) 
Malignancy 9 (2) 1 (0.2) 0.03 1 (0.4) 0.18 11 (1) 
Chronic liver disease 6 (1) 5 (1) 1.00 1 (0.4) 0.43 12 (1) 
Organ involvement       
Pneumonia 190 (38) 154 (38) 0.95 117 (47) 0.02 461 (40) 
Skin or soft tissue 86 (17) 94 (23) 0.04 42 (17) 0.92 222 (19) 
Urinary tract 78 (16) 48 (12) 0.10 15 (6.0) <0.001 141 (12) 
Liver abscess(es) 33 (7) 48 (12) 0.01 27 (11) 0.06 108 (9) 
Spleen abscess(es) 45 (9) 45 (11) 0.37 35 (14) 0.04 125 (11) 
Septic arthritis 24 (5) 40 (10) 0.004 24 (10) 0.02 88 (8) 
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Distribution of disease       
Bacteraemia 274 (55) 238 (58) 0.35 164 (66) 0.005 676 (58) 
Single organ disease 291 (58) 240 (59) 0.95 146 (58) 1.00 677 (58) 
Multiorgan disease 110 (22) 102 (25) 0.31 58 (23) 0.71 270 (23) 
Complications       
Hypotension 187 (37) 135 (33) 0.16 99 (39) 0.58 421 (36) 
Respiratory failure 179 (36) 117 (29) 0.02 101 (40) 0.23 397 (34) 
Sepsisd 392 (78) 334 (81) 0.28 209 (84) 0.10 935 (81) 
Antibiotic treatment and in-hospital mortality     
Effective antibiotic treatment 
within 24 hours of admission 
367 (73) 359 (88) <0.001 212 (85) <0.001 938 (81) 
Died 225 (45) 157 (38) 0.04f 117 (47) 0.64f 499 (43) 
Discharged well 254 (51) 245 (60) – 128 (51) – 627(54) 
Outcome unknown 
(Self-discharged) 
21 (4) 8 (2) – 5 (2) – 34 (3) 
Table 9. Patient characteristics, clinical features of melioidosis and outcome. 
Note.—IQR = interquartile range. Anatomical sites for which there were less than 20 cases in the 5-year period are omitted from the table. 
Variables recording organ involvement at ten sites are not shown here, because there were fewer than 20 events recorded: these were parotitis, 
pleural disease, central nervous system disease, peritonitis, pericarditis, osteomyelitis, prostatitis, thyroiditis, ophthalmitis and cholecystitis. They 
were, however, taken into account when counting the number of organs involved. 
aFisher’s exact test, except where indicated. 
bMann-Whitney U test with No diabetes as the comparator group, because the data was non-normal and could not be transformed to normal. 
cNumbers do not add up to 410 (100%) because some patients were taking more than one type of medication. 
dSepsis defined as temperature >38ºC or <36ºC, heart rate >90 beats per minute, respiratory rate >20 breaths per minute, or total leucocyte count 
>12 × 109 cells/L. 
fPatients who took their own discharge were counted as alive. 
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Figure 17A 
 
Numbers at risk on day 0 day 7 day 14 day 21 day 28 
No diabetes 500 304 281 271 265 
Known diabetes 410 279 259 252 251 
Hyperglycaemia 250 154 138 130 130 
 
—— No diabetes   —— Known diabetes   —— Hyperglycaemia  
Known diabetes v. No diabetes (p = 0·03) 
Hyperglycaemia v. No diabetes (p = 0·91) 
Known diabetes v. Hyperglycaemia (p = 0·05) 
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Figure 17B 
 
Numbers at risk on day 0 day 7 day 14 day 21 day 28 
No diabetes 500 304 281 271 265 
Known diabetics on glibenclamide 209 158 153 153 149 
Known diabetics not on glibenclamide 201 121 106 103 102 
Hyperglycaemia 250 154 138 130 130 
 
—— No diabetes group      —— Known diabetes on glibenclamide 
—— Known diabetes not on glibenclamide   —— Hyperglycaemia group 
Known diabetes on glibenclamide v. No diabetes (p<0·001) 
Known diabetes on glibenclamide v. Hyperglycaemia (p<0·001) 
Known diabetes on glibenclamide v. Known diabetes not on glibenclamide 
(p<0·001) 
Known diabetes not on glibenclamide v. No diabetes (p = 0·59) 
Hyperglycaemia v. no diabetes (p = 0·91) 
Figure 17. Kaplan-Meier survival curves of 1160 patients with 
melioidosis. 
Note.—The survival curves in A show that patients with diabetes have a survival 
advantage after the development of melioidosis, but the survival curves in B 
indicate that this effect was seen only in the patient group taking glibenclamide. 
The p-values reported are for the log-rank test. Median duration of follow-up was 
6·5 days and total follow-up was 11,845 patient days. 
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A previous study conducted at the same hospital but in a different (earlier) 
patient cohort reported an inverse association between diabetes and 
mortality (unadjusted odds ratio [OR] 0·49).681 We confirmed this 
observation in our independent cohort (OR 0·76; adjusted odds ratio 
[AOR] 0·78, 95% confidence interval [CI] 0·59 to 1·0, p=0·07), and 
extended previous observations that patients in the hyperglycaemia group 
had no survival advantage (Model A, Table 10). 
2.3.2 Glibenclamide and mortality 
We hypothesised that the association between diabetes and a reduced 
risk of death was due to the treatment received for diabetes and/or 
melioidosis. This was tested in a second logistic regression model (Table 
10, Model B). We considered drugs prescribed for diabetes (glibenclamide, 
metformin, insulin) prior to admission, noting that more than half of 
known diabetics were receiving glibenclamide (Table 9). We adjusted for 
chronic renal failure, because metformin is avoided in renal failure, 
because of the risk of lactic acidosis, and because renal failure is associated 
with mortality. We included the administration of appropriate admission 
antimicrobial therapy because the association between diabetes and 
melioidosis is well-described and could lead clinicians to prescribe these at 
an earlier stage in diabetic patients.  
The adjusted odds ratio for death was lower for patients who received 
glibenclamide therapy prior to admission (AOR 0·47, 95%CI 0·28–0·74, 
p=0·005) and for those receiving effective antimicrobial chemotherapy at 
admission (AOR 0·23, 95%CI 0·17–0·34, p<0·001) (Table 10, Model B). 
Neither metformin nor insulin treatment were associated with survival in 
any analysis. The unadjusted survival curve for patients in the 
glibenclamide group is shown in Figure 17B. 
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 univariable analysis  logistic regression 
model A 
(n = 1160) 
 logistic regression 
model B 
(n = 1109)c 
 OR (95% CI)  AOR (95% CI)  AOR (95% CI) 
No diabetesa 1·0 —  1·0 —  1·0 — 
Known diabetes 0·76 (0·58–0·99)  0·78 (0·59–1·0)  1·4 (0·89–2·3) 
Hyperglycaemia 1·1 (0·79–1·5)  1·1 (0·81–1·5)  1·4 (0·98–1·9) 
Ageb 1·1 (1·0–1·2)  1·1 (1·0–1·2)  1·1 (0·99–1·2) 
Male sex 1·2 (0·94–1·5)  1·1 (0·89–1·5)  1·0 (0·78–1·3) 
Rice farming 0·97 (0·74–1·3)  1·0 (0·75–1·3)  1·2 (0·86–1·6) 
Corticosteroid use 1·5 (0·86–2·7)  1·6 (0·87–2·8)  1·0 (0·62–2·2) 
Chronic kidney disease 2·8 (1·8–4·3)     2·2 (1·6–4·0) 
Glibenclamide treatmentc 0·48 (0·35–0·67)     0·47 (0·28–0·74) 
Metformin treatmentc 0·61 (0·33–1·1)     1·1 (0·62–2·4) 
Insulin treatmentc 0·79 (0·49–1·3)     0·65 (0·37–1·2) 
Effective admission antibiotic 
treatmentc 
0·22 (0·16–0·31)     0·23 (0·17–0·34) 
Table 10. The effect of diabetes on mortality. 
Note.—OR = odds ratio (not adjusted); AOR = adjusted odds ratio; CI = confidence interval. An odds ratio below 1 indicates association with 
survival, whereas an odds ratio above 1 indicates association with mortality. The first column describes the contribution of each factor in isolation. 
The second column (model A) attempts to explain the effect of diabetes by adjusting for several possible confounders for diabetes simultaneously; 
the third column (model B) adjusts additionally for the effect of diabetes treatment and post-admission antibiotics. 
When considered in isolation, diabetes (OR 0·76), glibenclamide treatment (OR 0·48) and effective admission antibiotic treatment (OR 0.22) were 
associated with survival. The effect of diabetes persisted after correcting for confounders for diabetes (AOR 0·78, model A). When the effect of 
glibenclamide treatment and effective admission antibiotic were taken into account, diabetes was no longer associated with survival (AOR 1·4, 
model B). Sensitivity analysis. We conducted a sensitivity analysis to examine the impact of the missing data. Model A was constructed by 
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assigning the patients who self-discharged as “alive”; but if these patients were instead assigned as “dead”, then the AOR for known diabetes in 
model A became 0·71 (0·54–0·93, p = 0·01). In model B, assigning the patients who self-discharged to “dead”, caused the AOR for known diabetes 
to become 1·3 (0·79–2·1, p = 0·31), glibenclamide treatment AOR 0·48 (0·28–0·83, p = 0·008), and effective admission antibiotic treatment AOR 
0·18 (0·13–0·27, p<0·001). Putting the patients on an unknown oral diabetes medication into the glibenclamide group (n = 1160) in model B, 
meant the AOR for glibenclamide treatment rose to 0·59 (0·36–0·97, p = 0·04) and effective admission antibiotic treatment became 0·24 (0·17–
0·34, p<0·001).  When the patients on an unknown oral diabetes medication are put into the metformin group (n = 1160), the AOR for 
glibenclamide treatment becomes 0·49 (0·30–0·78, p = 0·003) and effective admission antibiotic treatment becomes 0·25 (0·18–0·34, p<0·001). 
aComparator group. 
bNumber of decades above age 15 years. 
cThe patients on unknown oral diabetes medication were omitted (n = 1109) in model B and in the unadjusted OR for treatment variables. 
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Table 11 
Hypotension 
 univariable analysis  logistic regression 
Model C 
(n = 1160) 
 logistic regression 
Model D 
(n = 1109)a 
 ORb (95% CIc)  AORd (95% CIc)  AORd (95% CIc) 
No diabetese 1·0 —  1·0 —  1·0 — 
Known diabetes 0·80 (0·62–1·0)  0·84 (0·63–1·1)  1·3 (0·79–2·0) 
Hyperglycaemia 1·2 (0·90–1·6)  1·1 (0·83–1·6)  1.3 (0·91–1·7) 
Agef 1·2 (1·1–1·3)  1·1 (1·0–1·3)  1·1 (1·0–1·2) 
Male sex 1·1 (0·87–1·4)  1·1 (0·87–1·4)  1·0 (0·77–1·3) 
Rice farming 1·0 (0·75–1·4)  1·0 (0·76–1·4)  1·1 (0·78–1·5) 
Corticosteroid use 2·9 (1·6–5·2)  3·0 (1·6–5·4)  2·4 (1·3–4·5) 
Chronic kidney disease 2·0 (1·3–3·0)     1·8 (0·92–3·5) 
Glibenclamide treatmenta 0·56 (0·40–0·78)     0·48 (0·30–0·78) 
Metformin treatmenta 1·1 (0·60–1·9)     1·8 (0·92–3·5) 
Insulin treatmenta 0·69 (0·42–1·2)     0·60 (0·33–1·1) 
Effective admission 
antimicrobial therapya 
0·46 (0·34–0·62)     0·51 (0·37–0·70) 
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Respiratory failure 
 univariable analysis  logistic regression 
Model E 
(n = 1160) 
 logistic regression 
Model F 
(n = 1109)a 
 ORb (95% CIc)  AORd (95% CIc)  AORd (95% CIc) 
No diabetese 1·0 —  1·0 —  1·0 — 
Known diabetes 0·72 (0·54–0·95)  0·73 (0·54–0·97)  1·2 (0·74–1·9) 
Hyperglycaemia 1·2 (0·89–1·7)  1·2 (0·90–1·7)  1·4 (1·0–2·0) 
Agef 1·0 (0·94–1·1)  1·0 (0·93–1·1)  0·99 (0·92–1·1) 
Male sex 1·2 (0·94–1·5)  1·2 (0·91–1·5)  1·1 (0·82–1·4) 
Rice farming 0·98 (0·73–1·3)  0·99 (0·73–1·3)  1·0 (0·76–1·4) 
Corticosteroid use 1·6 (0·90–2·8)  1·7 (0·92–3·0)  1·2 (0·62–2·2) 
Chronic kidney disease 2·2 (1·5–3·3)     2·0 (1·2–3·1) 
Glibenclamide treatmenta 0·44 (0·31–0·64)     0·50 (0·28–0·86) 
Metformin treatmenta 0·52 (0·26–1·0)     1·0 (0·48–2·1) 
Insulin treatmenta 0·80 (0·49–1·3)     0·75 (0·39–1·4) 
Effective admission 
antimicrobial therapya 
0·40 (0·29–0·54)     0·42 (0·31–0·58) 
Table 11. Effect of diabetes on hypotension and respiratory failure. 
Note.— 
aPatients on unknown oral diabetes medication were omitted (n = 1109) in Models D & F and in the unadjusted OR for treatment variables. 
bOdds ratio (unadjusted).  
cConfidence interval. 
dAdjusted odds ratio. 
eComparator group. 
fNumber of decades above age 15 years. 
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Patients in the known diabetes group were more likely to receive effective 
antimicrobial therapy on admission compared to patients without diabetes 
(88% versus 73%, p<0·001), an association that was seen in each of the 
treatment groups (glibenclamide 92%, p<0·001; metformin 98%, p<0·001; 
insulin 90%, p=0·02), but the association between glibenclamide therapy and 
survival was independent of admission antimicrobial therapy (Table 10). 
We used logistic regression to evaluate the relationship between diabetes 
and the secondary outcome measures. We found that diabetes was negatively
associated with both hypotension and respiratory failure (AOR 0·84, Model C, 
Table 11) and AOR 0·73, Model E, Table 11), but that this association did not 
persist after adjustment for treatment (antimicrobials and anti-diabetic 
treatment) (Models D & F, Table 11). However, glibenclamide was negatively 
associated with both hypotension (AOR 0·48, 95%CI 0·30–0·78, p=0·007) and 
respiratory failure (AOR 0·50, 95%CI 0·28–0·86, p=0·01), as was effective 
antimicrobial therapy within 24 hours of admission (AOR 0·51, 95%CI 0·37–
0·70, p<0·001 and AOR 0·42, 95%CI 0·31–0·58, p<0·001 respectively) (Models 
D & F, Table 11). In a sensitivity analysis, if patients taking an unknown oral 
drug were placed in the glibenclamide group, then the associations between 
glibenclamide and hypotension (AOR 0·65, 95%CI 0·39–1·1, p=0·09) and 
between glibenclamide and respiratory failure (AOR 0·60, 95%CI 0·36–1·0, 
p=0·05) were no longer significant statistically. 
2.3.3 Glibenclamide does not inhibit growth of B. pseudomallei 
We observed that glibenclamide did not inhibit the growth of 
B. pseudomallei at the concentrations used. 
2.4 Discussion 
We confirmed the finding that diabetes patients were more likely to 
survive, and that this was associated with a reduction in the number of cases of 
respiratory failure. These results are consistent with those of the three 
observational studies cited in the introduction.574,594,595 
We further noted that this difference for mortality was attributable to 
glibenclamide treatment and the fact that diabetes patients were more likely to 
receive appropriate antimicrobial chemotherapy at admission. Diabetes mellitus 
had no independent effect on mortality from melioidosis after adjustment for 
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these two factors, but none of the previously-cited studies574,594,595 looked for an 
effect of diabetes treatment. 
The effect of antimicrobial chemotherapy is unsurprising, and is consistent 
with what we know from other causes of sepsis.701 The effect of glibenclamide 
was unexpected and has not previously been described. 
2.4.1 Glibenclamide 
Glibenclamide rINN (=glyburide USAN, Figure 18) is a second-generation 
sulphonylurea widely used to treat type 2 diabetes and acts by inhibiting ATP-
sensitive699 (KATP-channels) in pancreatic β-cells,95 leading to stimulation of 
insulin secretion. 
 
 
Figure 18. Glibenclamide rINN or glyburide USAN. 
Note.— IUPAC name, N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-
methoxybenzamide.  Molecular weight 494·0 g/mol. Daonil® (formerly Hoechst, now 
Aventis); Eugluclon® (Roussel); Sigma-Aldrich catalogue no. G0639. 
 
  
 
 
Figure 19. General structure of sulphonylureas and sulphonamides. 
Note.—H = hydrogen; N = nitrogen; O = oxygen; R = general alkyl group, S = sulphur. 
The generalised structure on the left is a sulphonylurea (A); the structure on the right is a 
sulphonamide (B). The part of the structure highlighted in red is the sulphonamide 
moiety, which is clearly present in the sulphonylurea structure as well. 
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The sulphonylureas were first described in the 1942 by Janbon et al. while 
searching for novel antimicrobials. From a chemical point of view, the 
sulphonylureas are also sulphonamides (Figure 19) and we initially 
hypothesised that glibenclamide was acting via an antimicrobial action on 
B. pseudomallei. However, we were unable to show that glibenclamide inhibits 
growth of B. pseudomallei, thus excluding an antimicrobial effect of 
glibenclamide on B. pseudomallei. 
2.4.2 Glibenclamide and vascular smooth muscle 
KATP-channels are also expressed in the heart and on vascular smooth 
muscle, and excessive opening of vascular KATP-channels in sepsis (due to a fall 
in the ATP/ADP ratio, pH or oxygen tension, or a rise in intracellular lactate) 
leads to hyperpolarization of the cell membrane, a blocking of the calcium influx 
and loss of vascular tone (contributing to the ‘vascular paresis’ of septic shock). 
By blocking vascular smooth muscle KATP-channels, glibenclamide is able to 
protect from shock in animal models of sepsis,702 although this did not translate 
into a detectable effect on cardiovascular parameters in two small clinical trials 
in which glibenclamide was given at doses normally used to treat diabetes.703,704 
Neither study was designed to find an effect on mortality, and neither looked at 
end points such as respiratory failure or inflammation. 
2.4.3 Limitations of this study 
In seeking confounders for our study, we considered whether 
glibenclamide treatment was simply a marker for less advanced diabetes and 
that this was associated with a survival benefit compared with patients on 
insulin which is reserved for patients who fail to achieve adequate diabetic 
control on oral medication. However, only glibenclamide treatment and not 
metformin was associated with an improvement in mortality. We also 
considered whether thiazolidinediones and statins (which are anti-
inflammatory and may be required more commonly in diabetics) was a 
confounder, but found that although available, these are very rarely used in our 
setting. This is an observational study in which glibenclamide was given for a 
specific indication, namely, the treatment of type 2 diabetes and it is not 
possible to exclude unequivocally the possibility of confounding.705 
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3 Glibenclamide is associated with 
reduced inflammation in melioidosis 
3.1 Introduction 
Having observed an association between glibenclamide and survival, we 
initially postulated that glibenclamide was acting as an antimicrobial drug based 
on its structural homology with the sulphonamides (to which B. pseudomallei is 
susceptible). However, a solution of glibenclamide in DMSO has no inhibitory 
effect B. pseudomallei grown in LB or on tryptic soy agar. We therefore 
hypothesized that glibenclamide was having an effect on the host response to 
melioidosis. 
Glibenclamide is a broad-spectrum ABC transporter inhibitor that alters 
responses of macrophages to a range of stimuli in vitro and in vivo.706–708 We 
used peripheral leukocyte gene expression as a screening tool to identify global 
trends in gene function that might be ascribed to the action of glibenclamide. 
We compared gene expression profiles in 10 diabetic patients who were taking 
glibenclamide at the time of presentation with melioidosis against 10 diabetic 
melioidosis patients who were not taking this or another sulfonylurea, and 
repeated the comparison in healthy controls. 
3.1.1 DNA microarrays 
DNA microarrays are a multiplex assay, consisting of two-dimensional 
arrays of DNA fragments immobilized on a solid substrate. The first DNA 
microarray had 378 probes, but current commercial arrays may contain tens of 
thousands of probes and are able to interrogate across an entire eukaryotic 
genome. When investigating gene expression, messenger RNA is first purified 
from lysed white blood cells and then converted to cDNA. The cDNA is then 
amplified by transcription to RNA by an RNA polymerase, which is preferable to 
PCR amplification because the amplification proceeds in a linear fashion that 
preserves the relative proportions of each mRNA transcript. A fluorescent label 
is attached to the RNA, and the RNA is then hybridised with a DNA microarray, 
where each RNA fragment will bind to matching DNA probes on the chip. The 
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fluorescence read out gives an estimate of the amount of RNA bound to each 
probe. 
Microarrays are a refinement of the Southern blot. DNA blotting was first 
described by Edwin Southern in 1975 at the University of Edinburgh.709 
Southern described a method for identifying specific sequences by separating 
DNA fragments electrophoretically by size on an agarose gel, blotting the DNA 
onto nitrocellulose filters, then detecting the sequences of interest using 
complementary radiolabelled or fluorescent-labelled DNA probes.709 
Microarrays arose from the need for an assay that was able to 
simultaneously detect the presence or absence of multiple sequences. In 1982, 
at the Sloan-Kettering Institute in New York, Augenlicht and Kobrin realised 
that it was not necessary to separate the DNA fragments in the sample, but that 
similar results could be obtained by spatially separating and immobilising the 
probes in an array instead. Their first array consisted of 378 probes immobilised 
on nitrocellulose membranes, on which they were able to semi-quantitatively 
describe differences in gene expression in a mouse tumour.710 Five years later, 
the same team published a protocol for computerised scanning and image 
processing that allowed quantitative analysis of 4000 human sequences 
simultaneously.711 
Affymetrix was founded by Stephen Fodor in 1992 and has its 
headquarters in Santa Clara, California. Affymetrix began marketing the first 
commercially viable DNA microarrays (under the trademark, GeneChip®) in 
1994, produced using semiconductor manufacturing techniques, and this made 
microarray technology widely available to researchers. 
3.1.2 Illumina BeadChip 
Illumina was founded in 1998 to develop and manufacture integrated 
systems for the analysis of genetic variation of function. The company was 
founded to exploit the BeadArray technology developed at Tufts University and 
has its headquarters in San Diego, California. The first BeadArray application 
was to genotype single-nucleotide polymorphisms, but has expanded to include 
copy number variation analyses, DNA methylation and gene expression 
profiling. 
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In a BeadArray, each microarray consists of hundreds of thousands of 
3 µm silica beads randomly assembled in 3 µm microwells on silica glass slides, 
and each silica bead is coated with hundreds of thousands of copies of a single 
complementary DNA (cDNA) probe. The arrays are self-assembling, with each 
bead bound to its well by van der Waals forces alone. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Illumina BeadArray. 
Notes.—A Illumina BeadArrays are distinguished from other microarrays principally by 
their method of manufacture. Conventional microarrays are created by printing spots 
onto slides or membranes: BeadArrays are created from randomly self-assembling beads. 
First, 3 µm microwells are etched into glass slides, then a mixture of glass beads, each 
coated with hundreds of copies of a single probe are poured onto the slide. The 3 µm 
beads slot randomly into wells and are held there by van der Waals forces. Excess beads 
are then washed off. Each probe is represented by ~30 beads distributed randomly across 
the array. B The glass slide on the right is the Illumina HumanWG-6 v.3 BeadChip used 
for this project. Each BeadChip contains twelve strips (two strips per array, one sample 
per array). In contrast, Affymetrix GeneChips will only take a single sample per chip. 
Images taken from Illumina product literature. 
 
Each probe is replicated by ~30 beads per strip (the actual number of 
beads varies randomly from ~15 to ~60) and the final position of each bead is 
completely random. Each probe consists of a 50-mer probe sequence and a 29-
mer address sequence. The address sequence is decoded at the factory to reveal 
A B 
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the probe sequence at each position. Each chip is shipped with this information 
and this information is unique for each chip. The sequence of these address tags 
is commercial confidential. 
This method of manufacture has a number of advantages. Conventional 
arrays are printed onto slides or membranes using pins. Small defects in 
individual pins result in systematic errors that propagate across the entire array, 
because every spots printed by the same pin will carry the same defect. The 
BeadArray technology relies on random self-assembly of the array, which means 
that this kind of systematic error cannot occur. A further advantage of the 
BeadArray is the high degree of replication, which means that Illumina 
BeadArrays are robust to spatial defects. As much as three-quarters of each strip 
could be destroyed with only minimal loss of information. By contrast, 
Affymetrix GeneChips each contain only one copy of each probe at a constant 
location on every chip: GeneChips are therefore extremely susceptible to spatial 
artefacts, with no way of recovering from these defects. A final advantage is that 
BeadArrays are cheaper to manufacture than conventional spotted arrays and 
cheaper to use. At the time the project was planned. Affymetrix GeneChips 
would only take a single sample per GeneChip, whereas a BeadChip could take 6 
or 8 samples per chip. 
The microarray used in this project was the HumanWG-6 v3.0,712 which 
contains 12 strips per glass slide, or six samples (two strips per array, one array 
per sample). The array covers 48,804 probes or 25,440 manually curated genes 
from the NCBI RefSeq713 (build 36.2, release 22) and UniGene714 databases 
(build 199). The genes included cover the whole human genome and are not 
restricted to well-characterised genes, but also includes gene candidates and 
splice variants.712 The platform is single colour (Cy3, which fluoresces green), 
which avoids the problems associated with ozone degradation from which two-
colour platforms suffer,715 and the need for complicated experimental designs 
involving dye swaps. 
3.1.3 Analysis of microarray data 
The output of a microarray experiment consists of a fluorescence value per 
probe per sample. Fluorescence values are proportional to absolute expression 
values, but are measured in arbitrary units. They therefore gain meaning only in 
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comparisons between groups (treated versus untreated, wild-type versus 
knockout, etc.). This also means that it is very hard to compare raw data 
acquired by different scanners. The most commonly used statistical test is the 
Student t-test (or a modified version thereof, such as a moderated t-test or B-
statistic). 
The primary difficulty in the statistical analysis of microarray results is the 
large number of statistical tests that are carried out, often with small sample 
sizes. Should one set a p-value cut-off of 5% then one expects 5% of the tests to 
have a p-value <5% (because the distribution of p-values should be uniform). 
With 48,804 probes, this means 48,804 t-tests, with an expected 2440 ‘hits’, 
even in the case when there is actually no difference between the groups. When 
a statistical test calls a gene differentially expressed when there is in fact no 
difference in expression, then a type 1 error is said to have occurred (i.e., a false 
positive). 
There are a number of methods available to deal with this problem and 
they all involve manipulations of the p-values or its cut-off (these are 
mathematically equivalent procedures). The simplest (and most conservative) of 
these is the Bonferroni correction.716 If n tests are performed, then the p-value 
cut-off is divided by n. If 48,804 tests are performed, then the new p-value cut-
off is 0·05/48,804 = 0·00000102. In the case where there is truly no difference 
between groups, the new cut-off reduces the expected number of false positives 
to <1. 
The Bonferroni correction follows naturally from Boole’s inequality, ! !!!!!! ≥ ! !!!!!! . 
The inequality states that the sum of the individual probabilities of each of the 
events !! to !! occurring is greater than or equal to the probability that one or 
more of the events occurs. Other frequently used corrections include the Dunn-
Šidák717 and Holm-Bonferroni.718 These all work by modifying (‘correcting’) the 
p-values, or by defining a lower cut-off, but are all less conservative. 
A slightly different approach is taken by Benjamini and Hochberg,719 who 
define a quantity called the ‘false-discovery rate’, which is the proportion of 
statistically significant tests that are in fact false; or, put another way, the 
proportion of ‘hits’ that are due to type 1 error. It may be considered a less 
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conservative method than family-wise error correction methods (which are the 
Bonferroni method and its relatives), but in essence, the method also works by 
changing the p-value threshold to achieve the desired false discovery rate. 
The major criticism of these methods this is that they all simultaneously 
increase the type 2 error rate while reducing the type 1 error rate.720 A type 2 
error occurs when a true difference is missed by a statistical test (i.e., a false 
negative) and it has been argued that type 2 errors are as important as type 1 
errors.720 The assumptions underlying these methods have also been 
questioned: if each test is independent, then why should the result of each test 
be corrected for the number of tests performed? The number of tests performed 
depends on the investigator and is not a characteristic of the test, so it seem 
irrational to address the problem by modifying the test720 (in slightly more 
technical terms: these are mathematically rigorous methods for maintaining the 
family-wise error rate, but there are no strong arguments why maintaining the 
family-wise error rate should be desirable in the first place). It should also be 
noted that all p-value cut-offs are arbitrary (including the ‘conventional’ 
threshold of 0·05), because all p-values exist on a continuum from 0 to 1, and 
therefore the decision to set any threshold (whether 0·001 or 0·1) may be 
criticised.721 It is also worth mentioning that even in classical significance 
testing, the decision is not merely to accept or reject the null hypothesis. Keppel 
has pointed out that under certain circumstances, a third option may be more 
appropriate, which is to suspend judgement.722 
The strongest single argument against adjusting for multiple comparisons 
is that blind reliance on stringent statistical criteria gives results that cannot be 
reproduced.723 The MicroArray Quality Control project (MAQC) is an initiative 
of the US Food & Drug Administration, the aim of which is to assess the 
reproducibility of microarray experiments and the comparability of results 
across different platforms. In a study published in 2006, two distinct, high-
quality RNA samples were assayed at 137 different sites on seven different 
microarray platforms across the continental USA. A major finding of that study 
was that reproducibility falls as statistical stringency increases, leading the 
investigators to recommend that non-stringent p-value cutoffs be used for 
microarray experiments.723 
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A second (complementary) method of dealing with the gene lists generated 
by microarray experiments is to group them by function. The rationale behind 
this is that genes that are truly differentially regulated are likely to share the 
same function. In contrast, the false positives in the gene list are likely to come 
from any part of the genome and are less likely to form functional groupings.724–
726 This group of methods is commonly known as gene set enrichment and is a 
necessary part of the interpretation of any gene set. 
Broadly speaking, there are two main functional groupings: the first is 
pathway and the second is ontology. 
Pathways may be defined most generally as a sequence of biochemical 
interactions within a cell. Metabolic pathways are easy to define and 
circumscribe, because they follow the serial modifications of a single molecule, 
where the product of one reaction is the substrate for another. For example, in 
glycolysis (the first metabolic pathway to be described), glucose (substrate) is 
phosphorylated to glucose-6-phosphate (product) by the enzyme, hexokinase. 
Glucose-6-phosphate is the substrate for phosphoglucose isomerase, and so 
forth down the pathway, ending with pyruvate or acetyl-CoA. In signal 
transduction, there is not usually a single molecule that can be followed, but 
instead the trail follows a notional ‘signal’ that is passed from protein to protein. 
The first signalling pathway to be described was glucagon signalling by Martin 
Rodbell (who first described G-proteins, for which he won the 1994 Nobel Prize 
for Medicine).727,728 Signalling pathways follow a series of activation steps and 
secondary messengers. Unlike metabolic pathways, there is usually no single 
molecule that follows the course of the entire pathway. Although signalling 
pathways are usually defined as the events downstream of an initiating signal 
molecule (e.g., insulin or adrenalin), that molecule seldom progresses along the 
entire pathway. Pathways often interact, multiple signalling molecules may 
initiate identical events in the same pathway, and some pathways may require 
multiple signals. The ‘canonical’ or textbook description of any signalling 
pathway is therefore a subjective construct, its boundaries defined by ease of 
interpretation and not by biological function. The descriptions of many 
pathways will therefore vary from textbook to textbook and from database to 
database, with no clear reasons why some proteins are included and some 
omitted. The pathways for coagulation and inflammation have multiple 
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initiators and are even harder to describe clearly or consistently because of 
multiple overlaps and interactions, with some molecules having apparently 
contradictory roles (for example, IL10 is said to be both pro-inflammatory and 
anti-inflammatory). There are two currently two large systematic efforts to 
develop canonical databases of known pathways: Reactome729 and KEGG (the 
Kyoto Encyclopedia of Genes and Genomes).730 
Gene ontology is an even more nebulous concept and the dictionary 
definition is ‘the branch of metaphysics dealing with the nature of being’. A 
more helpful definition is that gene ontology is accurate and succinct 
description of genes. There are a number of projects that do this, the largest of 
which is the Gene Ontology project.731 The GO project is developing and 
maintains three separate ontologies (controlled, structured vocabularies) for the 
description of gene products. These are (i) cellular component (e.g., nucleus or 
membrane or organelle), (ii) biological process (e.g., inflammation or small 
molecule transport or DNA replication), and (iii) molecular function (e.g., 
protein kinase or transmembrane transporter or oxidoreductase). 
We elected to use Innate DB for our analysis because of its focus on 
manually curating pathways related to innate immunity.725 It is also linked to 
other protein interaction databases and uses standard nomenclature such as 
those developed by HUGO and GO. The database takes lists of genes and 
clusters them by pathway or by ontology, the statistical test being the 
hypergeometric test. 
The techniques for analysing microarray data (and high throughput data 
generally) are still an active area for research. There is therefore no definitive 
‘best practice’ defined, but the literature support an approach that uses a 
relatively lax statistical criteria, so that both type 1 and type 2 error rates are 
reasonably controlled, then use functional analysis to eliminate false positives 
and aid interpretation. 
The main barrier to exchanging microarray data and to reproducing 
microarray experiments is the complete lack of standardisation of fabrication, 
assay protocols or analysis methods. Many of these details of fabrication are 
commercial confidential, and assay protocols are usually specific to platform. 
However, in theory, analyses should be reproducible. The MIAME checklist 
(minimum information about a microarray experiment) defines the minimum 
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level of detail that should be reported for all microarray experiments, and has 
been adopted by many journals as a requirement for the submission of papers 
that incorporate microarray results,732 with the aim of improving the 
reproducibility of microarray experiments.733 
3.2 Methods 
3.2.1 Study subjects 
We compared peripheral white blood cell gene expression in (i) diabetics 
who were taking glibenclamide (case) or were not taking this or another 
sulfonylurea (control) at the time of admission to Sappasithiprasong Hospital 
with culture-confirmed melioidosis and sepsis, and (ii) otherwise healthy 
diabetics attending a routine out-patient clinic who were taking glibenclamide 
(case) or were not taking this or another sulfonylurea (control). Eligible cases 
for both studies were persons aged between 18 and 75 years. A total of 40 
patients (10 in each group) were recruited in the period 31 Jan 2008 to 31 Oct 
2008. Diabetes was defined as an abnormal Hb A1c at enrolment (7.8% or 
greater,734 Bio-Rad® D-10 fully-automated Hb A1c system, Bio-Rad 
Laboratories) or a previous diagnosis of diabetes. The Hb A1c concentration 
allowed us to identify patients with previously unrecognized diabetes who went 
on to die before we could make a diagnosis of diabetes by WHO criteria. 
We obtained approval from the Oxford Tropical Research Ethics 
Committee and the Ethics Committee of the Faculty of Tropical Medicine, 
Mahidol University for the gene expression study. Written informed consent 
was obtained from all subjects by a native Thai speaker. All procedures 
performed were in accordance with the Helsinki Declaration of 1975 (revised 
1983). 
3.2.2 RNA extraction and microarray analysis 
A 3 ml blood sample was collected from each subject in a PaxGeneTM Blood 
RNA tube (PreAnalytiX) and stored at –70°C prior to mRNA extraction 
according to the manufacturer’s instructions. At study completion, blood 
samples collected in PaxGeneTM Blood RNA tubes were transported in one 
shipment on dry ice to the Wellcome Trust Sanger Institute, Cambridge, where 
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RNA was extracted using the PaxGeneTM Blood RNA Purification Kit 
(PreAnalytix, GmbH) according to the manufacturer’s instructions. 
RNA purity was measured using the ratio of absorbance at 260 and 280 
nm and all samples had ratios between 1·7 and 2·1. RNA integrity was evaluated 
using the Bioanalyzer (Agilent) and all samples had RNA integrity numbers 
greater than 6. The RNA was amplified using the Illumina® TotalPrep RNA 
Amplification Kit (Applied Biosystems, Carlsbad, California) and assayed using 
the Illumina® HumanWG-6 v3.0 Expression BeadChip (Illumina, Cambridge, 
UK), which probes 48,804 transcripts from across the human genome. We 
examined all genes with ≥1·5-fold difference in expression with the false-
discovery rate set to 10% (Student’s t-test with Benjamini-Hochberg 
correction;719 GeneSpring GX version 10.0, Agilent Technologies, California). 
3.2.3 Quantitative reverse-transcriptase polymerase chain reaction 
Results were confirmed by quantitative reverse-transcriptase polymerase 
chain reaction (qPCR): 500 ng of sample RNA was reverse transcribed using the 
QuantiTect Reverse Transcription kit (Qiagen 205313) according to the 
manufacturer’s instructions. Primers were ordered from Qiagen gene globe, as 
follows: IL18R1 catalogue number QT00082922; IL8, QT00000322; TNF, 
QT01079561; IFNG, QT00000525; ACTB1, QT00095431. Real time PCR was 
performed in triplicate using the QuantiTect SYBR Green PCR kit (Qiagen 
204145) according to the manufacturer’s instructions on a StepOne Plus 
(Applied Biosystems) for 40 cycles. Melting curve analyses were performed for 
all PCR products. The β-actin housekeeping gene was selected as loading 
control because of the stability of its expression in the microarray analysis. Fold 
change was calculated using the comparative Ct method. 
Gene ontology over-representation analysis was performed using 
InnateDB725 (http://www.innatedb.ca/) and the p-values reported are for the 
hypergeometric test. Gene lists were supplemented by manual literature 
searches for genes not curated by InnateDB. Microarray data have been 
deposited at ArrayExpress, EMBL-EBI (accession number E-TABM-852-n). 
3.2.4 Neutrophil stimulation study 
Neutrophils from three healthy male caucasian volunteers were isolated 
using Polymorphprep™ (Axis-Shield, Oslo, Norway) according to the 
 109 
manufacturer’s instructions, then resuspended (final concentration 1·0 × 106 
cells/ml) in RPMI 1640 (Gibco, Invitrogen, Paisley, UK) + L-glutamine + 15% 
heat-inactivated fetal bovine serum (Lonza BioWhittaker, Verviers, Belgium). 
Purity was >99% by flow cytometry (Becton Dickinson FACSCalibur; monocytes 
and neutrophils identified by their characteristic scatter profile and CD14 
staining). Cells were incubated with medium or 1.0 mM glibenclamide 
(comparable to the peak human plasma concentration achieved following a 
20 mg oral dose) for 60 minutes in a 96-well plate, then stimulated with 
medium or heat-killed B. pseudomallei 1026b (5 × 107 cfu/ml) for 4 hours at 
37°C in 5% carbon dioxide. The cells were centrifuged (300 × g, 5 minutes) and 
the supernatant removed. The pellet was resuspended (5% bovine serum 
albumin w/v, 350 µM EDTA, 0·01% sodium azide w/v in phosphate-buffered 
saline) and stained for CD14 and CD11b (BD Pharmingen, Erembodegem-Aalst, 
Belgium). IL1β (Invitrogen™, Camarillo, California), IL8 (Arcus Biologicals, 
Modena, Italy) and TNFα (Arcus) were measured by enzyme-linked 
immunosorbent assay according to the manufacturers’ instructions. Paired 
t-tests were performed using Prism 5.0c for Mac (GraphPad Software, San 
Diego, California). 
3.3 Results 
There were no significant differences in any of the clinical parameters 
recorded for the two patient groups (Table 12). The expression of 205 probes 
(representing 186 distinct genes), were significantly different in patients taking 
glibenclamide compared to those who were not (Figure 21). Sixty-three 
immune-related genes were differentially expressed in melioidosis patients on 
glibenclamide (p=0·001), the net effect of which would be postulated to be anti-
inflammatory (Appendix A). Prominent among the immune-related genes 
include those implicated in neutrophil activation, endothelial adhesion and 
transmigration. There was no statistical difference in neutrophil, lymphocyte or 
monocytes counts between the two groups (Table 12), indicating that this was 
not merely an effect of differences in cellular blood constituents. In the 
microarray analysis, tumor necrosis factor (TNF)-α, interleukin (IL)-18R1 and 
IL-8 expression were all down-regulated in glibenclamide-treated patients; 
interferon (IFN)-γ showed a modest trend to down-regulation. Quantitative 
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reverse-transcriptase PCR corroborated the TNFα and IL18R1 results; IFNγ was 
down-regulated by this methodology, but the IL8 results were not confirmed 
(Table 13). 
We sought further evidence for an effect of glibenclamide on gene 
expression profiles in otherwise healthy diabetics who were taking 
glibenclamide (n=10) or who were not taking a sulfonylurea drug (n=10). There 
were no significant differences in baseline parameters between the two groups 
(Table 12). We found that 31 probes (29 distinct genes) were significantly 
different in patients taking glibenclamide compared to those not, 13 of which 
were immune related (Appendix A), again suggesting an anti-inflammatory 
effect. Of note, genes associated with neutrophil function were down-regulated 
in the glibenclamide group (p<0.001). 
We then looked for a direct effect of glibenclamide on neutrophil function. 
Neutrophils harvested from healthy human volunteers were pre-treated with 
glibenclamide, then stimulated with LPS or heat-killed B. pseudomallei. CD11b 
expression and IL8 secretion were used to measure neutrophil stimulation. 
Concentrations of IL1β and TNFα were below the limit of detection. We were 
unable to find any direct anti-inflammatory effect of glibenclamide on 
neutrophils in vitro (Figure 22). 
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Diabetes patients with melioidosis 
Parameter Taking glibenclamide Not taking 
glibenclamide 
p-value 
Male gender 6 of 10 5 of 10 1·00a 
Age (years) 60±7 51±9 0·02b 
Glucose (mg dL–1) 218±64 256±111 0·37b 
Hb A1c (%) 10·8±3.2 11·1±3.3 0·83
c 
Neutrophils (×109 L–1) 10·8±8·5 8·8±4.6 0·52b 
Lymphocytes (×109 L–1) 1·6±0.9 1·5±1.4 0·93b 
Monocytes (×109 L–1) 0·8±0·3 0·5±0·4 0·05b 
Eosinophils (×109 L–1) 0·1±0·1 0·1±0·1 0·82c 
Mortality 2 of 10 5 of 10§ 0·41a 
Diabetes patients who were otherwise healthy 
Parameter Taking glibenclamide Not taking 
glibenclamide 
p-value 
Male gender 3 of 10 5 of 10 0·65a 
Age (years) 54±11 56±11 0·66b 
Glucose (mg dL–1) 126±31 124±48 0·93b 
Hb A1c (%) 9·0±2·1 9·0±2·2 0·98
c 
Neutrophils (×109 L–1) 4·7±1·3 5·1±2·1 0·63c 
Lymphocytes (×109 L–1) 4·4±1·4 5·1±2·1 0·40b 
Monocytes (×109 L–1) 0·4±0·2 0·6±0·3 0·19b 
Eosinophils (×109 L–1) 0·7±0·4 0·8±1·3 0·22c 
Table 12. Comparison of gene expression study patient 
characteristics. 
Note.—Values are reported as means, except where stated. Errors reported are standard 
deviations. 
aFisher exact test. 
bWelch t-test. 
cStudent t-test. 
dOne patient in this group was lost to follow-up following discharge from hospital, and 
was counted as having survived to discharge. 
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Figure 21. Differential expression of inflammation-associated genes 
in diabetic patients with acute melioidosis with or without 
glibenclamide. 
Note.—Gb = glibenclamide. Genes that are up-regulated are shown in red, down-
regulated in green; genes in black are not differentially expressed. The gene symbols used 
are those assigned by the HUGO gene nomenclature committee. 
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Gene Fold change attributable to 
glibenclamide therapy in melioidosis 
patients 
IFNγ –2·32 
IL8 +4·23 
IL18R1 –1·39 
TNFα –15·2 
Table 13. Results of quantitative reverse-transcriptase polymerase 
chain reaction. 
Note.— IFNγ= gamma interferon; IL8 = interleukin 8; IL18R1 = interleukin 18 receptor 1; 
TNFα = tumour necrosis factor alpha. 
 
Figure 22. Effect of glibenclamide pre-treatment on neutrophil 
stimulation 
Note.—Bps = heat-killed Burkholderia pseudomallei; Gb = glibenclamide, 
IL = interleukin. The interrupted line marks the limit of detection. Black dots represent 
control samples; open circles are samples pre-treated with glibenclamide. Isolated human 
neutrophils (1·0 × 106 cells/ml, >99% purity) were treated for 60 minutes with 1·0 mM 
glibenclamide then stimulated with heat-killed B. pseudomallei (5 × 107 cfu/ml). The cells 
were incubated at 37°C for four hours in 5% carbon dioxide, then CD11b expression was 
measured by flow cytometry. IL8 concentrations were measured in supernatant by 
enzyme-linked immunosorbent assay. IL1β and TNFα concentrations were below the 
limit of detection. The p-values reported are for paired t-tests.  
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3.4 Discussion 
Glibenclamide is known to have a wide-range of anti-inflammatory effects, 
one of which is an inhibitory effect on inflammasome assembly.735 The 
inflammasome is an intracellular protein complex present in macrophages that 
activates caspase 1 and converts pre-formed IL1β and IL18 to their active forms 
when presented with an appropriate inflammatory stimulus.459 IL1β and IL18 
levels are high in bronchoalveolar lavage fluid from patients with acute lung 
injury/acute respiratory distress syndrome (ALI/ARDS) and correlate with 
mortality,736,737 which leads us to hypothesize that inhibition of inflammasome 
assembly may be a mechanism for our finding that glibenclamide therapy and 
respiratory failure are inversely associated. It is also unsurprising that fewer 
genes were found to be differentially expressed in the otherwise healthy diabetic 
controls than in the patients with melioidosis, as the inflammasome is only 
assembled as part of the acute inflammatory response and so we expect to see 
little effect of glibenclamide when there is no active inflammation. 
Neutrophil recruitment to an area of tissue inflammation or infection can 
also be linked to the inflammasome through the action of IL1β. While IL1β is 
not itself a chemoattractant for neutrophils,738 IL1β up-regulates the expression 
of endothelial intercellular adhesion molecules essential for the recruit of 
neutrophils to an area of inflammation.515,516 Neutrophils are a critical 
component of the host response to B. pseudomallei in vivo,326 but may also 
drive tissue injury and organ damage.739–741 The bronchoalveolar fluid of 
patients with ALI/ARDS is neutrophil-rich and some animal models of ARDS 
are neutrophil-dependent.739 Glibenclamide has been shown to prevent 
neutrophil extravasation and accumulation in animal models,740,741 and this may 
represent indirect evidence that glibenclamide was responsible for reducing the 
incidence of respiratory failure in study patients taking this drug. We speculate 
that conflicting evidence from previous observational studies of the impact of 
diabetes on outcomes from bacterial sepsis may be explained in part by 
differences in the management of type 2 diabetes between Europe (metformin 
has been available in Britain since 1958 and has traditionally been used first-
line) and the US (where sulfonylureas have often been used first-line742 and 
metformin has only been available since 1995). 
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Glibenclamide has been said to inhibit the inflammasome by blocking 
KATP-channels,743 but this seems unlikely, since the KATP-channel blockers 
glipizide and tolbutamide do not have this effect.744 The two KATP-channels 
known to be targeted by the sulphonylureas, ABCC8 (formerly SUR1) and 
ABCC9 (formerly SUR2). Neither of these proteins are expressed by 
macrophages.744 The actual target therefore remains to be elucidated.735,745 
The P2X7 receptor has been suggested as a possible target,746,747 but the 
target appears to be downstream of P2X7735 and there is no sequence or 
structural homology between P2X7 and any of the known targets for 
glibenclamide. The development of inflammasome-inhibitors that do not have 
the hypoglycaemic effects of glibenclamide may depend on unravelling this 
pathway. However, enthusiasm for this approach should be tempered by the 
finding of one multi-centre trial that direct IL1β blockade does not improve 
survival in all-cause sepsis.363 Our study is also unable to provide guidance on 
whether any benefit would be seen were glibenclamide started following the 
onset of infection in non-diabetic patients. 
Inflammasome function is not restricted to IL1β activation and 
inflammasome inhibition is not the only action of glibenclamide. Glibenclamide 
is a broad-spectrum inhibitor of ABC-transporters706–708 and many members of 
this family have been implicated in regulating immune function. Glibenclamide 
also has a direct effect on neutrophils chemotaxis when administered at a dose 
100-times the concentration achievable in humans,748 although we found no 
direct effect of glibenclamide on neutrophils in vitro. 
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4 Glibenclamide reduces interleukin 1β 
secretion in a mouse model of 
melioidosis 
4.1 Introduction 
Having found an anti-inflammatory effect of glibenclamide in patients 
with melioidosis, we sought to replicate this finding in an experimental model. 
The effect we found in the clinic was a general effect on inflammation, but 
without one pathway predominating. We therefore hoped than an experimental 
model might provide insight into mechanisms underlying the effect of 
glibenclamide. 
4.1.1 Animal models of melioidosis 
The model organism most commonly used to study melioidosis is the 
mouse (Mus musculus). The first report of experimental B. pseudomallei 
infection in mice was by de Moor et al. in 1932, using a strain described only as 
weiss or ‘white’.242 An important advantage of using a mouse model is the wide 
range of tools and reagents available commercially (monoclonal antibodies, 
cytokine assays, bioinformatics, and so forth). Indeed, the largest library of gene 
knockouts available is in mice,749,750 and a decision not to use mice means to 
forego access to these tools. European legislation requires that the model used 
be the least sentient model possible, and there exist established models of both 
melioidosis and diabetes in the mouse: this was therefore a consideration in the 
selection of a suitable model for this part of the project. 
A number of mouse models of melioidosis have been described, but 
current published work uses only one of two inbred strains: BALB/c and 
C57Bl/6.751,752 Other strains that have been used include the C3H mouse,752 the 
DBA/2 mouse752 and the Taylor outbred mouse.373 Older mouse studies refer to 
no specific mouse strain and refer only to colour (white, black or agouti), if at 
all. 
BALB/c and C57Bl/6 inbred mouse strains form contrasting models of 
melioidosis. In 1999, Hoppe et al. surveyed four mouse species (C57Bl/6N, 
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BALB/c, C3H/HeN and DBA/2).752 He found that BALB/c mice were relatively 
susceptible to B. pseudomallei infection, while C57Bl/6N mice were relatively 
resistant. Susceptibility of the C3H/HeN and DBA/2 strains were intermediate. 
The contrasting susceptibilities of BALB/c and C57Bl/6 has been independently 
replicated by other groups.751,182 The BALB/c mouse is more susceptible to 
B. pseudomallei infection, with an LD50 of ~5 cfu. By comparison, the LD50 for 
C57Bl/6 mice is consistently two to four orders of magnitude higher, depending 
on route of infection.751,752,182 In C57Bl/6 mice, smaller inocula (e.g., 100 cfu of 
B. pseudomallei 576) produce a chronic version of melioidosis.753 
Hoppe found that in BALB/c mice, bacterial loads increased faster in the 
first 24 hours than in C57Bl/6 mice. Hoppe also found a higher IgG2a:IgG1 ratio 
in C57Bl/6 mice compared to BALB/c mice, which is suggestive of a Th1-type 
immune response,752 because IFNγ promotes IgG2a isotype switching. 
This dichotomy between BALB/c and C57Bl/6 has been found in other 
infections, e.g., Leishmania major,754 Mycobacterium tuberculosis,755 and 
Yersinia enterocolitica,756 where in each instance, BALB/c mice are relatively 
susceptible, but C57Bl/6 mice are resistant.* The susceptibility of BALB/c mice 
to Leishmania major526,527 and Y. enterocolitica756 correlates with a deficiency 
in the IFNγ response (traditionally considered a Th1 cytokine). Indeed, it was 
initially thought that the contrasting BALB/c and C57Bl/6 models of melioidosis 
paralleled the Th1/Th2 paradigm developed for Leishmania.751 
Ullett et al. found that contrary to there being an inadequate IFNγ-
response in BALB/c mice compared to C57Bl/6 mice, IFNγ mRNA levels in liver 
and spleen were higher in BALB/c mice than in C57Bl/6 mice.759 This finding 
was confirmed by Koo and Gan using direct measurements of IFNγ as well as 
measurements of IFNγ mRNA.410 Koo and Gan found that splenocytes from 
BALB/c mice produced higher concentrations of IL18 and TNFα compared to 
splenocytes from C57Bl/6 mice (IL12 concentrations were not different), which 
in turn resulted in high concentrations of IFNγ. They hypothesised that the 
elevated cytokine response in BALB/c mice is explained by a reduced 
responsiveness of phagocytes to IFNγ. This hyporesponsiveness manifested as a 
                                                   
* There exist infections where the converse is true. The C57Bl/6 mouse is more 
susceptible to Helicobacter felis757 and Pseudomonas aeruginosa758 compared to the 
BALB/c mouse. 
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failure of BALB/c phagocytes to kill intracellular bacteria despite adequate IFNγ 
stimulation. They felt that the continued presence of intracellular bacteria in 
macrophages was responsible for the continued secretion of IL18 and TNFα by 
macrophages, which in turn was driving IFNγ secretion. That there is no defect 
in the cytokine response was confirmed by Barnes et al., who found that 
cytokines downstream of IFNγ, such as CXCL9 (formerly called Mig) and 
CXCL10 (formerly called IP-10), were expressed earlier and at higher levels in 
BALB/c mice compared to C57Bl/6 mice.760 Recruitment of neutrophils to sites 
of infection in the liver and spleen also occur earlier and in greater numbers in 
BALB/c mice compared to C57Bl/6 mice, again consistent with an inability of 
BALB/c mice to kill the bacteria, despite apparently adequate cytokine and 
cellular responses. 
The mechanism underlying the reduced ability of BALB/c mice to kill 
intracellular B. pseudomallei is as yet unknown. Miyagi et al. showed that RNS, 
and to a lesser extent, ROS were important for intracellular killing in the J774.1 
macrophage-like cell line521 (which is BALB/c derived761). However, subsequent 
studies have found that differences in intracellular killing between BALB/c and 
C57Bl/6 strains are not explained by differences in RNS and ROS 
generation.519,523 
Watanabe et al. have reported that BALB/c macrophages expressed lower 
levels of the lysosomal enzyme, β-glucuronidase, in response to macrophage-
activating lipopeptide-2 (a synthetic TLR2 ligand) and to E. coli LPS when 
compared to C57Bl/6 macrophages.762 This is an attractive explanation for the 
susceptibility of BALB/c mouse, but the role of lysozymal enzymes has not been 
explored in the context of the host response to melioidosis. In humans, 
 β-glucuronidase deficiency manifests as Sly syndrome, or 
mucopolysaccharidosis type VII. The potential association of the BALB/c mouse 
with an inherited human disease might prompt caution in the interpretation of 
experiments conducted using this strain. 
One final comment on the Th1/Th2 balance in melioidosis may be made. 
In the context of melioidosis, IFNγ is produced predominantly by NK cells and 
CD8+ T lymphocytes, not by CD4+ T helper cells.360,411 In fact, T helper cells 
seem to play little or no role in the initial host response to melioidosis, although 
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they do have a role at later stages in the infection.411 This picture does not fit 
neatly into the conventional Th1/Th2 paradigm,763 in which T helper cells (Th) 
are the primary orchestrators of the cytokine response, even though the 
cytokine profile in melioidosis is consistent with the classical Th1 response. 
A variety of B. pseudomallei strains are used in animal models, which 
hinders the comparison of results from different groups, since different strains 
likely have different virulence. Ivo Steinmetz’s group in Greifswald uses the E8 
environmental strain of B. pseudomallei collected from Northeast Thailand in 
1996 by Andrew Simpson.32,83,519,752 Despite being an environmental strain, E8 
is more virulent than NCTC 7431, which is a clinical isolate.752 Work published 
by Greg Bancroft’s group in London uses the 708a strain,360,373 which is a 
clinical isolate from Thailand. Rick Titball’s group at the Defence Science and 
Technology Laboratory (now at Exeter University) uses the 576764 and 
K96243107 strains. We are not aware of any published studies directly 
comparing the virulence of these strains. 
The work described here uses the C57Bl/6 model of melioidosis first 
described by Wiersinga et al. in 2007.152,412,765 In this model, 10–14 week-old 
animals are inoculated with 500 cfu of B. pseudomallei intranasally. Animals 
develop a severe pneumonia, bacteraemia and microabscesses in the liver and 
spleen, and median survival is four days.152 The strain used was B. pseudomallei 
1026b, which was originally collected by David Dance in 1993 from a 29-year-
old Thai female rice farmer with bacteraemia, soft tissue, cutaneous lesions, 
septic arthritis and splenic abscesses.93 The strain was donated to Don Woods’ 
group in Calgary, Canada, in 199693 and subsequently transferred from Canada 
to Tom van der Poll’s group in Amsterdam, The Netherlands, in 2006, where it 
has since been maintained by serial passage in mice.  
A variety of other animals have been used to model human melioidosis. In 
Whitmore’s 1912 description of the disease, Koch’s postulates were established 
using guinea pigs,8 while Stanton & Fletcher and de Moor et al. both described 
rat models of melioidosis. Rats are relatively resistant when inoculated 
intraperitoneally (LD50 >108 cfu), unless made susceptible by inducing diabetes 
with streptozocin (LD50 103–104 cfu).151 Like mice, susceptibility is also 
increased by administering the inoculum directly into the respiratory tract (<102 
to 4·0×104 cfu).766 Hamsters (Mesocricetus auratus) are extremely susceptible 
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to B. pseudomallei infection,35,155 which has led to their use in the study of 
bacterial virulence factors86,88,91 and for the purification of mixed cultures.140,156 
However, some bacterial mutants that are attenuated in mice are not attenuated 
in hamsters,86,88,93,94,767 and it is unclear which model better identifies virulence 
factors important to clinical melioidosis. 
The first primate model of melioidosis was reported by Miller in 1948 
using macaques.155 More recently, a marmoset model of melioidosis has become 
available at the UK Defence Science and Technology Laboratory.768 An NIH 
grant has also been awarded to Don Estes at the University of Texas, Galveston, 
to develop a marmoset model of melioidosis (grant no. 5U01AI082103-02 dated 
29 Jul 2010). Other models reported in the literature include baboons (Simia 
hamadryas)769 ferrets (Mustela putorius furo),155 goats (Capra aegagrus 
hircus),770 guinea pigs (Cavia porcellus),769 pigs (Sus scrofa domestica 
Landrace),771 and roundworms (Caenorhabditis elegans).772,773 
The development of large animal models of melioidosis is critical, because 
in the evaluation of a new drug, both the US Food and Drug Administration and 
the European Medicines Agency require data from at least two animal models 
(small and large) as a pre-condition for the commencement of phase I clinical 
trials. 
4.1.2 Mouse models of diabetes 
Animals have had a prominent role in diabetes research for over a hundred 
years. In 1889, Oskar Minkowski removed the pancreas from a dog and found 
that it became diabetic,774 leading the way to Banting and Best’s discovery of 
insulin in 1922.775 
We hypothesized that the effect of glibenclamide was independent of its 
effect on glucose control. Although the majority of cases of diabetes in Thailand 
have type 2 diabetes, we elected to use a model of diabetes in which glucose 
concentrations were not responsive to glibenclamide, because alterations to 
plasma glucose and insulin concentrations are themselves associated with 
changes to the immune response (as reviewed in Chapter 1 of this dissertation). 
This review is therefore confined to mouse models of type 1 diabetes. 
The best-characterised and most widely-used mouse model of 
spontaneous type 1 diabetes is the inbred non-obese diabetic (NOD) mouse, 
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developed in 1974 by Makino at Shionogi Research Laboratories,  Japan, from 
outbred Swiss mice.776,777 Most mice of this strain develop some degree of 
insulitis (inflammation and destruction of β-islet cells), but progression to 
diabetes takes up to 24 weeks and depends on sex and environmental factors. 
Under specific pathogen-free (SPF) conditions,778 80–90% of females are 
diabetic by 24 weeks of age; by contrast, only 40% of males are diabetes by 30 
weeks of age. The development of diabetes in this strain may be synchronised by 
a single dose of intraperitoneal cyclophosphamide 200 mg/kg,779 which makes 
the mice easier to use. 
The selection of an appropriate control for the NOD mouse is difficult 
because the NOD mouse was developed from an outbred strain, not an inbred 
strain, and because the defect is polygenic in origin and poorly defined.780,781 
Both C57Bl/6 mice and BALB/c mice have been used as control strains despite 
the fact that neither strain is Swiss-derived. Multiple Swiss-derived control 
strains have been developed for the NOD mouse, including the non-obese non-
diabetic (NON) mouse (also developed by Makino), SJL/J, outcrosses of NOD 
with diabetes-resistant strains and various NOD congenic strains. The NON 
mouse is a particularly troublesome control, because despite its name, it is 
prone to obesity and develops impaired glucose tolerance. 
Two other mouse models are worth mentioning briefly: the C57Bl/6NJCL-
Insulin2Akita and the C57BLKS/J-Cpefat mice. 
C57Bl/6NJCL-Insulin2Akita heterozygous males develop diabetes at 
weaning (four weeks of age) and the mouse was described in 1997 as a model for 
maturity onset diabetes of the young.782 Histological examination showed that 
the mice had atrophic pancreatic islets deficient in β-cells and the mouse is 
therefore a model of type 1 diabetes. The defect is a missense mutation in the 
insulin 2 gene (Ins2) on chromosome 7, that renders it non-functional. Note 
that Mus musculus possesses two equally-expressed insulin genes: Ins1 is 
located on chromosome 19.783 These mice are insulin-responsive, and non-
diabetic littermates may be used as controls. This mouse model has been 
proposed as a replacement for the STZ model.784 
The C57BLKS/J-Cpefat mouse homozygous males are severely obese by 8 
weeks of age, and this is associated with very high circulating insulin levels and 
hyperglycaemia, but not severe diabetes.785 The model was therefore initially 
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described as a model for type 2 diabetes. The defect is a point mutation in 
carboxypeptidase E (Cpe) on chromosome 8, which results in abnormal 
proinsulin processing. The mouse is therefore insulin-responsive and not 
insulin-resistant. The C57BLKS/J background has problems with dental 
malocclusion and polycystic kidney lesions which the Jackson Laboratories 
solved in 2005 by moving the Cpefat mutation to a C57Bl/6 background. 
 
 
 
 
 
 
 
 
Figure 23. A. D-Glucose. B. Streptozocin. 
Note.—H = hydrogen; N = nitrogen; O = oxygen. The glucose and streptozocin (STZ) 
molecules are oriented to emphasise their structural similarity. 
 
 
Streptozocin (STZ) was first identified in the late 1950’s by scientists at 
Upjohn (U.S. patent 3,027,300 granted 1961) and is a true antibiotic produced 
by Streptomyces achromogenes (an actinomycete isolated from soil collected in 
Blue Rapids, Kansas).786  
STZ is a glucosamine-nitrosourea compound and, like other nitrosoureas, 
it exerts its cytotoxic effects by alkylating DNA.787 The glucose transporter, 
SLC2A2 (previously called GLUT2), is highly expressed by β-cells. The 
structural homology between glucose and the glucosamine moiety of STZ 
(Figure 23) allows STZ to be preferentially taken up by the β-cell,788 which then 
induces a cytotoxic inflammatory response that destroys the cell.789 This 
explains the specificity of STZ for pancreatic β-cells and STZ therefore has a 
clinical application as treatment for β-islet-cell tumours.790 
STZ-treated animals were first described in 1963 by Rakieten et al.791 as a 
model for diabetes and the model is similar to the older alloxan model of 
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diabetes (first described 1943).792 Both STZ and alloxan are taken up by 
SLC2A2, but alloxan kills the cell by producing reactive oxygen species instead 
of by DNA alkylation. The main advantage of STZ over alloxan is its (relative) 
chemical stability, which makes it easier to use.788 The main disadvantage of 
both chemical models of diabetes is that SLC2A2 is also expressed in the renal 
tubule, which means both STZ and alloxan are potentially nephrotoxic. This 
nephrotoxicity may be avoided by using multiple smaller doses of STZ (e.g., 
60 mg/kg over five days) instead of fewer large doses (e.g., two doses of 
150 mg/kg).793 In the STZ model of diabetes, glucose levels start to rise a week 
after initiating STZ treatment and plateau roughly two weeks after the last dose 
of STZ. Only male mice are susceptible to the effect of STZ, which may seem 
unusual, but in fact, all mouse models of diabetes exhibit some sexual 
dichotomy. The reason for this is not known. 
 
Figure 24. Development of hyperglycaemia in mice treated with STZ. 
Sixty mice were injected with STZ 60 mg/kg daily for five days (marked by arrows on 
horizontal axis) and compared to 60 controls (treated with citrate buffer pH 4). STZ-
treated mice are shown in red, control mice are shown in black. The horizontal 
interrupted line is the 16·7 mM cutoff we used to define diabetes in mice. This number of 
mice was chosen to allow for losses due to mice not becoming diabetic or mice dying 
from hyperglycaemia prior to inoculation. 
 
An STZ model of melioidosis has previously been described by Woods et 
al., who used an infant rat model of melioidosis.151 In Woods’ report, STZ-
treated infant rats were more susceptible to B. pseudomallei infection than 
untreated animals (LD50 ~103–104 cfu compared to >108 cfu).  
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STZ is stable in solution at pH 4 and rapidly degrades at higher or lower 
pH.791 STZ solutions are therefore made up with cold sodium citrate buffer 50–
100 mM.793,794 Higher concentrations of sodium citrate are more irritant.  
Solutions are not stable for longer than 12 h and must be made up freshly each 
day. Woods’ model uses intraperitoneal streptozotocin 80 mg/kg on two 
consecutive days,151 with controls given phosphate buffered saline. It might be 
argued that Woods should have used citrate buffer for controls instead of 
phosphate-buffered saline in his experiments. Another idiosyncracy of Woods’ 
report is that the STZ dose he used is not attested elsewhere in the literature: he 
references the STZ rat model of Tancrède et al., but Tancrède does not describe 
a 80 mg/kg dose.795 
Since starting this project, we have become aware of two other groups 
working on STZ-models of melioidosis. The first group is based in Townsville, 
Australia, and used a BKS.Cg-Dock7m+/+Leprdb/J mouse model of diabetes.677 
This model has a spontaneously arising autosomal recessive mutation in the 
leptin receptor (Leprdb) that arose in the C57BLKS/J (BKS) colony at The 
Jackson Laboratories in 1966 and is considered a model of type 2 diabetes.796 
This model is characterized by obesity, hyperglycaemia and insulin insensitivity. 
Using this model, Hodgson et al. found that diabetic mice had decreased 
survival following subcutaneous B. pseudomallei infection, with 100% 
succumbing to the disease in the first four days post-infection, compared to 
non-diabetic mice, all of which survived ≥10 days. The group found no defect of 
neutrophil or dendritic cell function. The second group is in Kuala Lumpur and 
is run by Sheila Nathan at the Universiti Kebangsaan Malaysia; their data is 
awaiting publication and was not available at time of writing. 
Of the available models for type 1 diabetes, we elected to use the STZ 
model of diabetes for practical reasons. The model is easy to use: the phenotype 
may be induced on any background, at any time, to produce a cohort of mice 
that become diabetic synchronously. At the time the experiments were 
designed, we considered the possibility that we might need to use knockout 
mice to elucidate mechanisms and the knockouts available to us were all on a 
C57Bl/6 background. Furthermore, the murine melioidosis model in 
Amsterdam was already established in C57Bl/6 mice. 
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The C57Bl/6 inbred strain separated from the parent C57Bl outbred strain 
in 1937 and the colony was moved to the Jackson Laboratories in 1948. The 
C57Bl/6J substrain male mouse (Jackson Laboratories) is a model for diet-
induced type 2 diabetes. This is due to a spontaneous 17·8 kb deletion in the 
nicotinamide nucleotide transhydrogenase gene, Nnt, that appeared in the 
Jackson Laboratories colony some time between 1951 and 1970.797,798 The 
C57Bl/6N substrain (National Institutes of Health, Bethesda, Maryland) 
separated from the Jackson Laboratories colony in 1951 and was distributed to 
Charles River (Wilmington, Massachusetts) in 1974 (designated C57Bl/6NCrl). 
The C57Bl/6N substrain has an intact Nnt gene799 and is the substrain used for 
all mouse experiments described here. The C57Bl/6N substrain is also the 
background used by the Knockout Mouse Project.749,750 This is important, 
because there are published studies that have inadvertently used wild-type 
C57Bl/6J mice as non-diabetic controls, not realising that this substrain is a 
model for diabetes. 
4.2 Methods 
4.2.1 Mouse experiments 
Specified pathogen-free 10-week-old C57Bl/6NCrl mice (Charles River) 
were given STZ 60 mg/kg daily for five days.793 We chose to use a low-dose 
regimen because at this dose, STZ does not have a direct toxic effect on the 
kidneys,793 which might otherwise confound our results. STZ 6 mg/ml (Sigma-
Aldrich, Zwijndrecht, The Netherlands) was prepared fresh every day in citrate 
buffer (pH 4), then passed through a 0·2 µm polyethersulphone filter (VWR 
514-0073) and administered intraperitoneally within 60 minutes of 
preparation. Losses were around 20% with this regimen, either from 
complications of the hyperglycaemia or because the animals failed to become 
diabetic and had to be sacrificed. 
Animals were allowed ad libitum access to food (801733 CRM, Tecnilab-
BMI) and water, and were group-housed in polycarbonate cages with 12-hour 
light/dark cycles, temperature 18–22°C, humidity 40–65%. Plasma glucose was 
checked weekly by cheek puncture800 (Bayer Contour meter). For 10-week-old 
mice not treated with STZ, glucose was 8·75±1·52 mM (mean±standard 
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deviation) and for 16-week-old mice, 9·30±1·64 mM. We defined diabetes as a 
plasma glucose ≥16·7 mM.793 
Mice were infected with ~6×102 Burkholderia pseudomallei intranasally 
4–5 weeks after STZ treatment. In order to mimic the clinical situation seen in 
our cohort study, we treated all animals with full-dose antibiotics. Ceftazidime 
600 mg/kg (GlaxoSmithKline, Brentford, England) was administered 
intraperitoneally starting 24h after inoculation and continued twice daily until 
sacrifice.296  
For glibenclamide experiments, glibenclamide 50 mg/kg (Sigma-Aldrich) 
in 20% dimethylsulphoxide (DMSO) was administered intraperitoneally 
starting 7 days before inoculation and continued until sacrifice; control mice 
were given 20% DMSO. This dose of glibenclamide was chosen because it is 
equivalent to the highest human dose (20 mg daily to a 50 kg Thai male) after 
taking into account differences in pharmacokinetics (human t½ ≈ 8 hours, 
mouse t½ ≈ 1 hour). 
Eight animals from each group were sacrificed 48, 72 and 96 hours after 
inoculation. Mice were sedated with ketamine/medetomidine intraperitoneally 
(12·5 mg/20 µg per 100 g weight), then exsanguinated by cardiac puncture. 
Death was confirmed by cutting the diaphragm. Glucose measurements were 
obtained prior to sedation as medetomidine itself elevates glucose 
concentrations. 
The lungs were lavaged with three 300 µl aliquots of sterile 0·9% saline 
then collected for culture. Lung, liver and spleen were homogenized in four 
volumes of sterile saline. Organ homogenates, blood and bronchoalveolar lavage 
fluid (BALF) were plated onto blood agar in serial dilutions to quantify bacterial 
burdens. The remaining lung homogenate was incubated for 30 minutes with 
Greenberger lysis buffer then centrifuged at 650 × g for 10 minutes. The 
supernatant was passed through a 0·2 µm filter to remove viable bacteria, then 
stored at –20°C for cytokine measurements. Heparinized blood was centrifuged 
at 700 × g for 10 minutes; the plasma was filtered and stored at –20°C pending 
analysis. 
In lung homogenates and BALF, interleukin(IL) 1β, IL6, IL10, CXCL5 
(LIX) and tumor necrosis factor-α (TNFα) were measured by sandwich ELISA 
(R&D Systems, Oxford, England). Cytokine levels in plasma were measured by 
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particle immunoassay (mouse inflammation cytometric bead array, BD 
Biosciences, San Jose, California) because of limited sample quantity. Protein 
concentrations were measured using the DC™ protein assay (Bio-Rad, 
Hercules, California). 
Statistical analyses were performed on Stata 11 (StataCorp, College Station, 
Texas). Bacterial loads and cytokine concentrations were log-normal. Linear 
regression was used in preference to ANOVA because it reports not just a p-
value for each group, but also estimates size of difference and permits 
interaction testing. Models were fit by the method of variance-weighted least-
squares, because the method does not assume homoscedasticity and because all 
explanatory variables could be treated as categorical. Responses were not 
assumed to vary linearly with time. Separate p-values were reported for each 
time point only when justified by a test for interaction. 
Mouse experiments were performed at the Academic Medical Center, 
University of Amsterdam and were approved by the animal experimentation 
committee there (DIX101725). 
4.3 Results 
4.3.1 Glibenclamide does not reduce glucose concentrations in the STZ model 
of diabetes 
The host response is altered by changes in glucose concentration. The 
primary action of glibenclamide in diabetes is to reduce blood glucose 
concentrations by stimulating insulin secretion by the β-islet cells of the 
pancreas. STZ treatment destroys the β-cells of the pancreas, making the 
animals hyperglycaemic and unresponsive to the action of glibenclamide. This 
allows us to dissect out the separate effects of glibenclamide on glucose and on 
the inflammatory response. Blood glucose measurements taken at sacrifice 
confirmed that in the STZ model of diabetes, blood glucose concentrations are 
not altered by glibenclamide treatment (Figure 25). 
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Figure 25. Glucose concentrations do not fall with glibenclamide 
treatment in strepztozocin-treated mice. 
The graph shows plasma glucose at sacrifice in mice with STZ-induced diabetes and 
compares mice treated with glibenclamide against control mice treated with vehicle 
alone. Glibenclamide 50 mg/kg once daily was started 7 days prior to inoculation and 
continued until sacrifice; controls were given vehicle alone. All mice were infected with 
B. pseudomallei 48, 72 or 96 hours prior to sacrifice. 
 
 
4.3.2 Glibenclamide does not alter bacterial loads in the lungs 
Glibenclamide is structurally related to the sulphonamides, which are 
active against B. pseudomallei. If glibenclamide inhibits the growth of 
B. pseudomallei, then any differences in the inflammatory response might be 
explained by a direct effect on the bacterium and not by an effect on the host 
response. 
In this model of melioidosis pneumonia, the primary site of infection is the 
lungs. We found no effect of glibenclamide on bacterial loads in either lung 
tissue or in bronchoalveolar lavage fluid at any of the three time points 
measured. 
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Figure 26. Bacterial loads in the lungs and BALF are unaffected by 
glibenclamide therapy. 
Note.— BALF = bronchoalveolar lavage fluid. 
Mice were treated with glibenclamide or vehicle for 7 days prior to inoculation with 
650 cfu B. pseudomallei. All mice were treated with ceftazidime 600 mg/kg twice daily 
started 24 h after inoculation and continued until sacrifice at 48, 72 or 96 h (n = 8 per 
group per time point). Results for glibenclamide-treated animals are indicated in blue, 
while results from control animals are indicated in black. Error bars indicate standard 
deviations. Bacterial loads were determined by serial dilution on horse blood agar. The 
horizontal interrupted line marks the limit of detection for the assay. 
 
4.3.3 Glibenclamide is associated with lower IL1β concentrations 
Glibenclamide has previously been reported to inhibit inflammasome 
assembly735 and one of the roles of the NLRP3 inflammasome is the activation 
and secretion of interleukin(IL)-1β. We found that in glibenclamide-treated 
animals, concentrations of IL1β were 73·3% lower in lung tissue 48 hours after 
inoculation compared to controls (p < 0·001, Figure 27). 
In lung tissue, IL1β is present in both its mature and immature forms. 
Only mature IL1β is secreted into the alveolar space, and IL1β in 
bronchoalveolar lavage fluid (BALF) should therefore be a better measure of 
inflammasome activation than lung tissue. We found that IL1β concentrations 
in BALF were 81·7% lower than controls (p < 0·001) at 48 hours.  
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Figure 27. Cytokine levels in glibenclamide-treated mice 
(inflammasome related). 
Note.— BALF = bronchoalveolar lavage fluid; IL = interleukin; IFNγ = interferon γ. 
Mice were treated with glibenclamide or vehicle for 7 days prior to inoculation with 
650 cfu B. pseudomallei. All mice were treated with ceftazidime 600 mg/kg twice daily 
started 24 h after inoculation and continued until sacrifice at 48, 72 or 96 h (n = 8 per 
group per time point). Results for glibenclamide-treated animals are indicated in blue, 
while results from control animals are indicated in black. Error bars indicate standard 
deviations. A single p-value is reported for each cytokine unless there is evidence from a 
test of interaction that effects at each time point are different. The horizontal interrupted 
line marks the limit of detection for the assay. 
 
 
4.3.4 Glibenclamide is associated with a reduced cellular influx into the lungs 
Melioidosis pneumonia is characterised by a florid influx of cells into the 
lungs, and these cells are predominantly neutrophils.765 Although neutrophils 
form a critical part of the innate host response to melioidosis,326 neutrophils 
may also contribute to mortality by causing damage to the respiratory tract and 
have been implicated in the pathogenesis of the acute respiratory distress 
syndrome.739 IL1β has been implicated in the recruitment of neutrophils to the 
inflamed lung, and we hypothesised that glibenclamide might function by 
limiting this influx of cells.515,738 
In this study, we found that glibenclamide did not influence the wet weight 
of the inflamed lungs or the amount of protein in BALF (both are markers for 
capillary leakage) (Figure 28). We did however find that the total number of 
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cells was reduced in glibenclamide-treated animals compared to controls. The 
majority of cells in this inflammatory infiltrate were neutrophils, but 
macrophages were also present in significant numbers. This difference in cell 
counts was most apparent at the 48 h time point (Figure 28). 
 
Figure 28. Lung infiltration in glibenclamide-treated mice. 
Note.—BALF = bronchoalveolar lavage fluid. Mice were treated with glibenclamide or 
vehicle for 7 days prior to inoculation with 650 cfu B. pseudomallei. All mice were 
treated with ceftazidime 600 mg/kg twice daily started 24 h after inoculation and 
continued until sacrifice at 48, 72 or 96 h (n = 8 per group per time point). Results for 
glibenclamide-treated animals are indicated in blue, while results from control animals 
are indicated in black. Error bars indicate standard deviations. A single p-value is 
reported for each cytokine unless there is evidence from a test of interaction that effects at 
each time point are different. 
 
 
4.3.5 Glibenclamide is associated with reduced dissemination of 
B. pseudomallei from the lungs 
Melioidosis is characterised by haematogenous spread from the primary 
site of infection to distant organs such as a liver and spleen.765 B. pseudomallei 
is a facultative intracellular organism with an ability to parasitise leukocytes. 
We hypothesised that a reduction in leukocyte recruitment to the site of primary 
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infection might therefore hinder the spread of infection to distant organs. We 
therefore measured bacterial loads in liver and spleen and found that bacterial 
loads were lower at all three time points measured (Figure 29). Consistent with 
this, bacterial burdens were also lower in blood, but this is less easy to interpret 
statistically, as a large proportion of points were below the limit of detection.  
 
Figure 29. Bacterial loads in blood, liver and spleen are lower in 
glibenclamide-treated mice. 
Note.—Mice were treated with glibenclamide or vehicle for 7 days prior to inoculation 
with 650 cfu B. pseudomallei. All mice were treated with ceftazidime 600 mg/kg twice 
daily started 24 h after inoculation and continued until sacrifice at 48, 72 or 96 h (n = 8 
per group per time point). Results for glibenclamide-treated animals are indicated in blue, 
while results from control animals are indicated in black. P-values reported are for 
variance-weight least squares regression. Error bars indicate standard deviations. Bacterial 
loads were determined by serial dilution on horse blood agar. The horizontal interrupted 
line marks the limit of detection for the assay, which is 3 cfu/50 µl of sample (corrected 
for dilution), which is the smallest concentration of bacteria that may be distinguished 
from zero with 95% confidence. It was not possible to report a p-value for blood as 
>50% of data points were below the limit of detection. 
 
4.3.6 Glibenclamide is not associated with differences in other cytokines 
Another role of the NLRP3 inflammasome is the activation and secretion 
of IL18. IL18 then stimulates natural killer and CD8+ cells to secrete interferon γ 
(IFNγ). Inflammasome inhibition would be expected to inhibit the secretion of 
mature IL18, and in turn reduce IFNγ secretion. 
Immature IL18 is constitutively expressed at high concentrations in 
unstimulated cells.503 We therefore did not measure IL18 in lung tissue. Instead, 
IL18 was measured in BALF, which should represent the mature secreted form 
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of the cytokine only. At the 48-hour timepoint, we found that IL18 
concentrations were lower in glibenclamide-treated mice when compared to 
controls, however, this difference was not statistically significant (Figure 30). 
We found no difference in IFNγ concentrations in lung. IFNγ 
concentrations in blood were lower at 48 hours, but this difference was also not 
statistically significant (Figure 30). IFNγ was not measured in BALF because 
previous experiments have shown it to be at or below the limit of detection in 
this model. 
 
Figure 30. IL18 and IFNγ  levels in glibenclamide-treated mice. 
Note.—BALF = bronchoalveolar lavage fluid; IL = interleukin; IFN = interferon. 
Mice were treated with glibenclamide or vehicle for 7 days prior to inoculation with 
650 cfu B. pseudomallei. All mice were treated with ceftazidime 600 mg/kg twice daily 
started 24 h after inoculation and continued until sacrifice at 48, 72 or 96 h (n = 8 per 
group per time point). Results for glibenclamide-treated animals are indicated in blue, 
while results from control animals are indicated in black. Error bars indicate standard 
deviations. The horizontal interrupted line marks the limit of detection for the assay. 
 
 
4.3.7 Glibenclamide has no effect on cytokines unrelated to the 
inflammasome 
In order to determine if the effect of glibenclamide was isolated to IL1β, or 
whether it was a general anti-inflammatory effect, we assayed the pro-
inflammatory cytokines, IL6, TNFα and CXCL5. The secretion of these three 
cytokines is unrelated to the inflammasome. We also considered the possibility 
that glibenclamide might be acting to promote secretion of the anti-
inflammatory cytokine, IL10. 
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Although there were differences in IL6 and TNFα at the 48 h time point, 
these differences were small and did not reach statistical significance. Overall, 
we found no evidence of an effect of glibenclamide on the secretion of CXCL5, 
IL6, IL10 or TNFα (Figure 31). 
 
 
Figure 31. Levels of cytokine unrelated to the inflammasome in 
glibenclamide-treated mice. 
Note.—IL = interleukin; TNF = tumour necrosis factor; CXCL5 = chemokine (CXC-motif) 
ligand 5. Mice were treated with glibenclamide or vehicle for 7 days prior to inoculation 
with 650 cfu B. pseudomallei. All mice were treated with ceftazidime 600 mg/kg twice 
daily started 24 h after inoculation and continued until sacrifice at 48, 72 or 96 h (n = 8 
per group per time point). Results for glibenclamide-treated animals are indicated in blue, 
while results from control animals are indicated in black. Error bars indicate standard 
deviations. A single p-value is reported for each cytokine unless there is evidence from a 
test of interaction that effects at each time point are different. The horizontal interrupted 
line marks the limit of detection for the assay. In blood, concentrations of IL1β, IL10 and 
IL12p70 were all below the limit of detection (data not shown). 
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4.4 Discussion 
We have presented evidence for an anti-inflammatory effect of 
glibenclamide in a diabetic mouse model of melioidosis and this anti-
inflammatory effect appears specific to IL1β. This is consistent with the results 
of previous in vitro and in vivo reports.735,801,802 To the best of our knowledge, 
this is the first time an inhibitory effect of glibenclamide on IL1β secretion has 
been described in any sepsis model. 
A limitation of clinical studies of infection has always been that the 
interplay between the burden of infection and the inflammatory response has 
been difficult to tease out. Cytokine levels may be higher because bacterial 
burdens are higher, or bacterial burdens may be higher because of an ineffective 
innate host response.376 Animal studies allow us to control the size of the initial 
inoculum and therefore the initial burden of infection. In this study, we found 
that bacterial loads in the lungs (the primary site of infection in our model) were 
not different between glibenclamide-treated and untreated mice. This excludes 
the possibility that the differences in IL1β levels in the lungs are due to an effect 
of glibenclamide on the burden of infection in the lungs. 
We found that glibenclamide limits the cellular influx into the lungs, with 
effects on both neutrophil and monocyte numbers. Neutrophils are a crucial 
part of the host response to melioidosis,326 but neutrophils have also been 
implicated in the pathogenesis of the acute respiratory distress syndrome.739 
Glibenclamide was not associated with a complete ablation of the neutrophil 
response (neutrophils are not a normal constituent of BALF taken from the 
healthy lung). Glibenclamide was only associated with a reduction in the 
magnitude of the neutrophil response and not its complete ablation. This 
balance between ‘enough’ and ‘too much’ is a common theme in the 
pathogenesis of sepsis and its complications.803 A reduction in neutrophil influx 
into the lungs is consistent with our finding that glibenclamide is associated 
with a lower incidence of respiratory failure in patients with melioidosis 
(Chapter 2). 
It is also worth noting that B. pseudomallei is a facultative intracellular 
pathogen and that it is capable of parasitizing macrophages.79–81 Bacterial 
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burdens in blood, liver and spleen were lower in our model, suggesting that 
glibenclamide reduces bacterial dissemination. The role of neutrophils and 
macrophages in the dissemination of B. pseudomallei is not known, but it is 
possible to speculate that the reduced influx of leukocytes into the lungs reduces 
the number of cells parasitized by the bacterium and therefore impairs the 
ability of B. pseudomallei to disseminate. 
We found no effect on cytokines unrelated to the inflammasome. 
Specifically, there was no effect on CXCL5, IL6, IL10 or TNFα secretion, which 
is again consistent with previous reports in the literature735,804 and rules out a 
more general anti-inflammatory effect. In this model, all animals were treated 
with full-dose ceftazidime in order to simulate the clinical study that motivated 
this experiment.329 Under this regimen, all animals showed signs of recovery by 
96 hours and the fact that no differences were seen in cytokine responses at 
later time points is therefore not surprising. 
The mechanism by which glibenclamide is able to inhibit IL1β secretion is 
not known. Lamkanfi et al. demonstrated that glibenclamide is able to inhibit 
assembly of the NLRP3 inflammasome in response to stimulation with 
lipopolysaccharide (LPS) and adenoside triphosphate (ATP). However, when 
S. Typhimurium was used as a stimulus, glibenclamide was not able to prevent 
inflammasome assembly, as measured by caspase 1 cleavage (caspase 1 being a 
critical component of the NLRP3 inflammasome). This suggests that there are 
alternative pathways which permit the assembly of the NLRP3 inflammasome, 
and the specific pathway that glibenclamide blocks is bypassed when 
macrophages are confronted by a complex stimulus such as a whole bacterium. 
In our model, glibenclamide-treatment reduced IL1β secretion in BALF, 
but did not block it completely. This means that there must have been some 
inflammasome assembly despite glibenclamide treatment, because only mature 
IL1β is secreted into BALF. Immature IL18 is also cleaved by the 
inflammasome, so our finding that inflammasome assembly is not completely 
blocked by glibenclamide in melioidosis is supported by the fact that we 
observed only a modest reduction in IL18 that was not statistically significant. 
Our study does not exclude other mechanisms for the action of 
glibenclamide. Aside from an effect on the inflammasome, Hamon et al. have 
presented evidence that glibenclamide may block the secretion of mature 
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IL1β.804 Glibenclamide has also been shown to have other anti-inflammatory 
effects, including the prevention of ischaemic reperfusion injury,740,741 and an 
enhancement of intracellular killing of Leishmania parasites.805 
In conclusion, we have replicated our clinical finding that glibenclamide is 
associated with reduced inflammation in melioidosis. Specifically, we found 
reductions in IL1β secretion, cellular infiltration into the lungs and 
dissemination to distant organs. Glibenclamide has previously been shown to 
prevent IL1β maturation and secretion by inhibiting inflammasome assembly, 
but the presence of detectable IL1β in BALF coupled with smaller-than-expected 
effects on IL18 and IFNγ means inflammasome inhibition is incomplete, or that 
this may not be the mechanism by which glibenclamide acts to reduce IL1β in 
the context of melioidosis. 
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5 Final discussion and conclusion 
We have shown that patients with a pre-existing diagnosis of diabetes have 
a lower mortality than patients without diabetes and patients with 
hyperglycaemia or undiagnosed diabetes. There is no protective effect of 
diabetes per se: instead, the mortality benefit seen is associated specifically with 
glibenclamide therapy. There was no evidence for an effect of diabetes on 
mortality after adjusting for the effect of glibenclamide. We also found that 
glibenclamide appears to protect from respiratory failure. 
In a gene expression study of total peripheral blood leukocytes in 
melioidosis patients, glibenclamide was associated with a broad decrease in 
inflammation, with no one pathway predominating. We therefore used a mouse 
model to dissect out the effect of glibenclamide on the host response and found 
that glibenclamide reduces IL1β secretion in melioidosis with no effects on other 
cytokines. The reduction in IL1β secretion is also associated with a reduced 
cellular influx into the lungs, which may help explain the clinical association 
with a reduced incidence of respiratory failure, because neutrophils have been 
implicated in the pathogenesis of the acute respiratory distress syndrome. There 
was also an association with decreased bacterial dissemination to distant sites, 
which we speculate is related to the reduced cellular influx. 
The mechanism by which glibenclamide reduces IL1β production by 
monocytes is not known. In the context of LPS stimulation, glibenclamide has 
been shown to block inflammasome assembly in isolated macrophages, 
however, we have only equivocal evidence for an effect of glibenclamide on the 
inflammasome in the context of melioidosis. 
It may be argued that a knowledge of mechanism is not required for a drug 
to enter therapeutic use. The primary indication for glibenclamide is the 
treatment of diabetes and glibenclamide stimulates insulin production 
regardless of plasma glucose concentrations. The administration of 
glibenclamide to the critically ill but euglycaemic patient may therefore induce 
potentially fatal hypoglycaemia. While hypoglycaemia is managed with relative 
ease in the setting of the Western intensive care unit, the use of glibenclamide is 
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dangerous in a resource poor setting where close monitoring is not so readily 
available. 
5.1 Cardiac effects of glibenclamide 
A further problem with the use of glibenclamide is its effect on the heart. 
In 1970, the University Group Diabetes Program (UGDP) reported that 
cardiovascular mortality was 2½-times higher in patients treated with the 
sulphonylureas (principally, tolbutamide) compared to patients treated with 
placebo and that limb of the trial was terminated early.2 These findings created 
controversy for a number of reasons: first, because they were unexpected and, 
second, because the excess mortality was seen at only three centres. These 
findings were not unchallenged806,807 and the criticism surrounding their report 
was heated. The subsequent debate was governed in part by emotion,808 but also 
by commercial interests centred around tolbutamide (Orinase®, then 
manufactured by Upjohn). Subsequent studies have reported mixed 
conclusions, with some supporting the effect of sulphonylureas on 
cardiovascular mortality and some not. The interested reader is referred to the 
fully referenced record of that debate which has been published elsewhere.808 
The response to the UGDP results was mixed. Phenformin (the only 
biguanide then available in the US, and also the only oral alternative at that 
time) was withdrawn in the mid-1970’s, on the back of evidence that it caused 
fatal lactic acidosis (also from the UGDP). The lack of oral alternatives and 
mixed evidence from subsequent trials meant a partial return of confidence in 
the use of sulphonylureas.809 Doubts have lingered and the FDA mandated 
package insert for all sulphonylureas sold in the US still contains a bold-print 
warning about cardiovascular risks.742 
Follow up studies looking at the effect of sulphonylureas of cardiovascular 
mortality have found that it is not a class effect, and that in addition to 
tolbutamide, glibenclamide is a prime offender.810–812 Other members of the 
class, such as gliclazide do not appear to have this problem. 
Glibenclamide is thought to increase the risk of cardiovascular disease by 
blocking ischaemic pre-conditioning.813 Ischaemic pre-conditioning is a 
phenomenon in heart muscle where brief episodes of ischaemia render the heart 
more resistant to subsequent ischaemia. Diabetics often have diffuse coronary 
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disease which means diabetic patients who have a heart attack are likely to have 
had smaller ischaemic insults that presage the heart attack and later partially 
protect it from the effect of the larger, more serious event through ischaemic 
pre-conditioning. Ablation of the ischaemic pre-conditioning response removes 
this acquired resistance to ischaemia. There is indeed evidence from the warm-
up phenomenon (patients with coronary artery disease are given two 
consecutive exercise tests, the relevant outcomes being symptomatic angina and 
electrocardiographic changes on the second test)814,815 and from human 
angioplasty studies that glibenclamide is able to block ischaemic pre-
conditioning.816–818 The experimental evidence therefore supports the 
observational evidence that glibenclamide predisposes to cardiovascular 
mortality. 
The effect on ischaemic preconditioning is not seen across the whole 
family of sulphonylureas. The second-generation sulphonylurea, glipizide, did 
not block ischaemic preconditioning in rabbits,819 and the meglitinide analogues 
(“glinides”) were originally marketed on the basis that they have a lower affinity 
for cardiac receptors (however, the post-marketing evidence for that is mixed: 
glimepiride appears not to block ischaemic pre-conditioning,817,818,820 but 
repaglinide does821). 
There is a second mechanism by which sulphonylureas might increase 
cardiovacular mortality, which is through their effects on smooth muscle. The 
second-generation sulphonylureas, glibenclamide and gliclazide, and (to a lesser 
extent) the glinide, glimepiride, all reduce coronary artery blood-flow, increase 
coronary resistance, depress the mechanical activity of the heart and increase 
myocardial oxygen extraction.822 It may be noted that this vasopressor effect is 
precisely that which made glibenclamide an attractive candidate for the 
adjunctive treatment of sepsis in the 1990’s. 
These data should give us pause when considering the possibility of using 
glibenclamide to prevent infection-related mortality in patients with diabetes, 
because any gain from preventing infection-related mortality might be wiped 
out by an increase in cardiovascular mortality. 
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5.2 Separating the anti-inflammatory effects of glibenclamide 
from its effects on insulin secretion 
Purely chemical considerations mean that separating the anti-
inflammatory effect of glibenclamide from its hypoglycaemic effect may not be 
possible. To explain why this is so requires elaborating on the chemical 
structure of glibenclamide, its metabolites, and the pharmacological properties 
of the related compound, meglitinide. 
The two major metabolites of glibenclamide are 4-trans-hydrocyclohexyl 
glibenclamide (M1) and 3-cis-hydrocyclohexyl glibenclamide (M2 or M2b)823 
and account for 36% and 15% of the total, respectively (Figure 32). Experiments 
in rabbits suggested that these two compounds are biologically inactive (they 
are 1/400th and 1/40th as active, respectively, and data from rats show that 4-
trans-hydrocyclohexyl glibenclamide is only 1/6·5 as potent as 
glibenclamide).824 However, Rydberg et al. reported that in healthy human 
volunteers, glibenclamide, M1 or M2, all have equivalent biological activity.823 
Indeed, glibenclamide is much more likely to cause hypoglycaemia than its half-
life would suggest (particularly in patients aged 70 years and older),825 
presumably because of its active metabolites. 
Glibenclamide metabolites are excreted 50% in urine and 50% in bile. This 
is qualitatively different from that of other sulphonylureas, which are excreted 
primarily in the urine. Other metabolites that have been described are 4-cis- 
(M2a), 3-trans- (M3), 2-trans-hydrocyclohexylglibenclamide (M4), and ethyl-
hydroxyglibenclamide (M5) (Figure 32).826 Although the procedure for 
synthesising these metabolites has been described,827 these compounds are not 
available commercially and their pharmacological and pharmacokinetic 
properties have not been studied clinically. 
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General 
structure: 
 
 
 
      
Glibenclamide: R1 = 
 
R2 = –H 
M1: R1 = 
 
R2 = –H 
M2a: R1 = 
 
R2 = –H 
M2b: R1 = 
 
R2 = –H 
M3: R1 = 
 
R2 = –H 
M4: R1 = 
 
R2 = –H 
M5: R1 = 
 
R2 = –OH 
Figure 32. Structure of glibenclamide and its metabolites. 
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Figure 33. Structure of meglitinide. 
The molecule is oriented to emphasise its homology with glibenclamide (above). IUPAC 
name: 4-[2-[(5-chloro-2-methoxy–benzoyl)amino]ethyl]benzoic acid (molecular weight, 
333·8 g/mol). At present, meglitinide is not available commercially or clinically, but the 
compound was previously available as a gift from Hoechst (now part of Sanofi-Aventis). 
The patent on meglitinide is still in force, so it is not possible to study this compound 
without the cooperation of Sanofi-Aventis. 
 
 
Nevertheless, certain properties may be deduced from the chemical 
structure of these compounds. Lamkanfi et al. have found that inflammasome 
inhibition by glibenclamide is not dependent on the cyclohexyl ring of 
glibenclamide.735 Metabolites M1, M2a, M2b, M3 and M4 (M1–4) only differ 
from glibenclamide in that the cyclohexyl ring has been hydroxylated. If 
Lamkani is right, then the five compounds, M1–4, would all be predicted to 
inhibit inflammasome assembly. M5 differs from glibenclamide in that one of 
the carbons between the two aromatic rings patients has been hydroxylated and 
the effect of this modification is unknown. 
Meglitinide is an insulin secretagogue that is not a sulphonylurea, but like 
the sulphonylureas, meglitinide will stimulate pancreatic β-islet cells to secrete 
insulin (Figure 33).828 Comparison of the meglitinide with M1–4 reveals that the 
half of the glibenclamide molecule containing the two aromatic rings is almost 
identical to meglitinide. This means that metabolites M1–4 should all possess 
insulin secretagogue properties also, because the meglitinide moiety is 
unaltered. Evidence that this is true in humans is provided by Rydberg’s clinical 
study, cited above.823 This means that the anti-inflammatory part of the 
glibenclamide molecule is probably also responsible for at least part of its 
hypoglycaemic effect. 
 144 
5.3 Suggestions for future research 
The unwanted effects of glibenclamide (hypoglycaemia and adverse 
cardiovascular effects) mean that glibenclamide is an unattractive candidate 
drug for the prevention of melioidosis-related mortality. Further advances will 
only occur when the precise mechanism underlying the action of glibenclamide 
has been elucidated, because only then may rational therapies be designed. 
IL1β is a product of the macrophage inflammasome and the 
inflammasome has already been studied in bone marrow-derived macrophage 
models of B. pseudomallei infection.473,474 Future studies using these systems 
may help either to confirm or refute the role of the inflammasome in the effect 
of glibenclamide on the host response to melioidosis. 
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A Appendix. Microarray results 
Appendix Table 1. List of genes differentially expressed in patients with melioidosis on glibenclamide at the time of 
admission 
ProbeID Symbol Gene RefSeq ID Absolute 
fold change 
Corrected 
p-value 
Comment 
Immune-related 
5860377 ABCG1 ATP-binding cassette protein G1 NM_016818.2 +1·55 0·03 Regulation of Toll-like receptor expression 
5420440 ABP1 Amiloride-sensitive amine oxidase NM_001091.2 –2·80 0·07 Postulated to be involved in endocytosis 
6220195 BATF Basic leucine zipper transcription factor, 
ATF-like 
NM_006399.2 –1·54 0·05 Transcription factor elevated in B-cells following EBV 
infection 
3140487 BMX BMX non-receptor tyrosine kinase NM_001721.4 –1·60 0·07 Regulates TLR-4-mediated IL-6 production. 
6270681 BST1 Bone marrow stromal cell antigen 1; CD157 NM_004334.1 –1·56 0·05 ?Regulation of B-cell maturation  
1070367 C19orf59 or 
MCEMP1 
Mast cell expressed membrane protein 1; 
chromosome 19 open reading frame 59 
NM_174918.2 –2·95 0·04 Hypothesized to be involved in mast cell function or 
differentiation 
840068 C3AR1 C3a anaphylatoxin chemotactic receptor NM_004054.2 –2·30 0·03 Inflammatory response and cell motility 
2000128 C4BPA Complement component 4 binding protein, 
α subunit 
NM_000715.3 –2·42 0·03 Classical pathway of complement cascade 
6590682 CCL3 or 
MIP1A 
Chemokine (C-C motif) ligand 3; or 
macrophage inflammatory protein 1A 
NM_002983.1 –1·67 0·03 Neutrophil recruitment and activation 
1300465 CD177 Neutrophil-specific antigen 1 NM_020406.2 –2·42 0·07 Neutrophil development and differentiation 
1240450 CD27 CD27 NM_001242.4 +1·62 0·04 Generation and long-term T-cell immunity. Regulates 
B-cell activation and immunoglobulin synthesis 
4610110 CD300LB CD300 molecule-like family member B, 
TREM5 
NM_174892.2 +1·57 0·04 Activating receptor expressed on myeloid cells 
4290097 CD99 CD99 protein NM_002414.3 +1·61 0·03 Cell surface glycoprotein: leukocyte migration, T-cell 
adhesion & apoptosis 
5700753 CEACAM1 Carcinoembryonic antigen-related cell 
adhesion molecule 1 (=biliary glycoprotein) 
NM_00102491
2.1 
–2·03 0·05 Myeloid cell adhesion to endothelium and 
angiogenesis 
1260228 CLEC5A C-type lectin domain family 5, member A NM_013252.2 –1·85 0·06 Myeloid cell activation 
4260484 COMMD6 COMM domain containing 6 NM_203497.2 –1·58 0·04 Inhibits NFκB 
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1050025 CR1 Complement receptor 1 NM_000573.3 –1·67 0·04 C3b and C4b binding 
6450543 CST3 Cystatin C NM_000099.2 +1·84 0·03 Inhibits lysosomal cysteine proteases 
4150189 CTSL1 Cathepsin L1 NM_001912.3 –1·73 0·04 Controls neutrophil elastase activity 
6270553 CXCL10 Chemokine (C-X-C motif) ligand 10 NM_001565.2 –2·08 0·08 Monocyte, T-cell and NK cell activation 
2340220 CD55 Complement decay accelerating factor NM_000574.2 –1·52 0·07 Complement regulation 
3360279 CFH Complement factor H NM_00101497
5.1 
–1·55 0·07 Complement cascade regulation 
2810767 EBI3 Epstein-Barr virus induced 3 NM_005755.2 –2·33 0·05 Positive regulation of IFN-γ response 
5560471 FCAR Receptor for Fc fragment of IgA NM_133280.1 –1·58 0·04 IgA receptor 
6620209 FCGR1B or 
CD64 
Receptor for Fc fragment of IgG, high affinity 
Ib 
NM_00100434
0.1 
–1·81 0·08 IgG receptor 
2350066 HLA-A Human leukocyte antigen-A NM_002116.5 +1·61 0·03 MHC class I molecule 
4250364 HPGD 15-hydroxy prostaglandin dehydrogenase NM_000860.3 –1·53 0·06 Prostaglandin metabolism 
6040647 HSH2D Hematopoietic SH2 domain containing NM_032855.2 +1·61 0·03 Target of T-cell receptor and CD28 activation. 
Function unknown. 
2000148 IFIT1 Interferon-induced protein with 
tetratricopeptide repeats 1 
NM_001548.3 +2·48 0·08 Interferon-mediated innate immune response 
4730747 IGLL1 Immunoglobulin lambda-like polypeptide 1 NM_020070.2 +1·74 0·04 Pre-B cell receptor, controls B-cell proliferation and 
differentiation 
3370326 IL18R1 Interleukin-18 receptor 1 NM_003855.2 –2·17 0·08 IFN-γ mediated immune responses 
1340743 IL8 Interleukin-8 NM_000584.2 –2·10 0·03 Neutrophil chemotaxis 
2360719 IRAK3 Interleukin-1 receptor-associated kinase 3 NM_007199.1 –2·13 0·04 Monocyte tolerance to endotoxin 
2490411 ITGB5 Integrin β5 NM_002213.3 +1·52 0·04 Cell adhesion 
4150184 LAIR1 or 
CD305 
Leukocyte-associated immunoglobulin-like 
receptor 1 
NM_021706.2 –1·78 0·04 Inhibits NK cells, T-cells and B-cells 
6110037 LILRA3 Leukocyte immunoglobulin-like receptor, 
subfamily A (without TM domain), member 3 
NM_006865.2 –1·65 0·04 ?Inhibits monocyte and B-cell function 
5890095 LILRA5 Leukocyte immunoglobulin-like receptor, 
subfamily A (with TM domain), member 5 
NM_021250.2 –1·59 0·06 Monocyte activation 
6420450 LIME1 Lck-interacting transmembrane adaptor 1 NM_017806.1 +1·55 0·09 Expressed on T-cell membranes, and down-
modulated on activation 
6840408 LY86 Lymphocyte antigen 86 NM_004271.3 +1·55 0·07 Humoral immune response 
70167 LY96 Lymphocyte antigen 96 NM_015364.2 –1·92 0·03 Associated with TLR4 
5130767 MAPK14 Mitogen-activated protein kinase 14 NM_001315.1 –1·52 0·08 Activated by pro-inflammatory cytokines 
7550066 MERTK c-mer proto-oncogene tyrosine kinase NM_006343.2 –1·58 0·08 Mediates macrophage phagocytosis of apoptotic cells 
5670674 MME Membrane metallo-endopeptidase NM_000902.3 +3·33 0·03 Lymphocyte activation; Inactivates peptide hormones 
 147 
1240228 PAG1 Phosphoprotein associated with 
glycosphingolipid microdomains 1 
NM_018440.3 –1·53 0·03 ?regulation of T-cell activation 
2230563 PPBP Platelet basic protein NM_002704.2 +1·68 0·05 CXC chemokine. Neutrophil chemoattractant and 
activator. 
7040470 PSMA6 Proteasome (prosome, macropain) subunit, 
α type, 6 
NM_002791.1 –1·52 0·04 Processing of MHA class I peptides 
4890707 PVRL2 or 
CD112 
Poliovirus receptor-related 2 (herpesvirus 
entry mediator B) 
NM_002856.2 –1·56 0·04 Enhances NK cell-mediated lysis 
130681 RNASE6 Ribonuclease, RNase A family, k6 NM_005615.4 +1·56 0·05 Expressed in neutrophils and monocytes 
6220438 RPS6KA5 Ribosomal protein S6 kinase, 90kDa, 
polypeptide 5 
NM_004755.2 +1·65 0·04 MAP kinase signaling pathway 
2490195 S100A10 S100 calcium binding protein A10 NM_002966.1 +1·66 0·03 Cell cycle progression and differentiation 
1410221 S100A12 S100 calcium binding protein A12 NM_005621.1 –2·62 0·05 Myeloid-related protein 
1510424 S100P S100 calcium binding protein P NM_005980.2 –2·27 0·09 RAGE ligand 
1410181 SAMSN1 SAM domain, SH3 domain and nuclear 
localization signals 1 
NM_022136.3 –1·97 0·07 B-cell activation 
6040577 SLAMF8 SLAM family member 8 NM_020125.2 –1·50 0·07 Lymphocyte activation 
3120543 SLC39A8 Solute carrier family 39 (zinc transporter), 
member 8 
NM_022154.5 –1·69 0·06 Cellular zinc import at onset of inflammation 
1990300 SOCS1 Suppressor of cytokine signaling 1 NM_003745.1 –1·67 0·07 Regulation of IFNγ response 
160019 SORT1 Sortilin 1 NM_002959.4 –1·62 0·07 Trans-Golgi network transmembrane protein, anti-
apoptotic and B-cell survival 
3390612 TLR8 Toll-like receptor 8 NM_016610.2 –1·60 0·03 Pathogen recognition 
2640301 TNF Tumor necrosis factor (TNF superfamily, 
member 2) 
NM_000594.2 –1·53 0·03 Proinflammatory cytokine 
6350632 TSC22D3 TSC22 domain family, member 3 NM_198057.2 +1·53 0·03 Stimulated by glucocorticoids and IL-10. Anti-
inflammatory 
5910113 VCAN Versican core protein NM_004385.2 +1·62 0·03 Leukocyte aggregation and pro-coagulant 
5310754 VNN1 Vanin 1 NM_004666.1 –2·19 0·07 Hematopoeitic cell trafficking 
7100161 VNN2 Vanin 2 NM_004665.2 –1·54 0·04 Transendothelial migration, monocyte activation 
Coagulation 
2230241 F13A1 Coagulation factor XIII, subunit A NM_000129.3 +1·89 0·04 Clotting cascade 
2340220 CD55 Complement decay accelerating factor NM_000574.2 –1·52 0·07 Complement regulation 
3360279 CFH Complement factor H NM_00101497
5.1 
–1·55 0·07 Complement cascade regulation 
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Carbohydrate metabolism 
4810438 MAN2B2 Mannosidase α, class 2B, member 2 NM_015274.1 +1·54 0·006 Carbohydrate metabolism 
290348 POFUT1 GDP-fucose protein O-fucosyltransferase 1 NM_015352.1 +1·55 0·03 Carbohydrate metabolism 
3390129 C9orf103 Chromosome 9 open reading frame 103 NM_00100155
1.1 
–1·67 0·05 Probable glucokinase 
940274 GK Glycerol kinase NM_000167.3 –1·62 0·05 Glycerol phosphorylation 
670528 GYG1 Glycogenin 1 NM_004130.2 –1·62 0·08 Regulates glycogen synthesis 
3060612 HK3 Hexokinase 3 (white cell) NM_002115.1 –1·93 0·04 Glucose phosphorylation 
6620689 MTHFD2 Methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 
NM_00104040
9.1 
–1·52 0·04 Mitochondrial bifunctional enzyme 
7040181 PFKFB2 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 2 
NM_00101805
3.1 
–2·30 0·05 Glycolysis/gluconeogenesis 
1470601 PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3 
NM_004566.2 –1·76 0·04 Glycolysis/gluconeogenesis 
4830504 PGM2 Phosphoglucomutase 2 NM_018290.2 –1·52 0·04 Glucose and glycogen metabolism 
6180465 SLC2A6 Solute carrier family 2 (facilitated glucose 
transporter), member 6 
NM_017585.2 –1·77 0·03 Hexose transport across cell membrane 
3420332 SLC37A3 Solute carrier family 37 (glycerol-3-
phosphate transporter), member 3 
NM_032295.2 –1·50 0·05 Transmembrane sugar transport 
Oxidative stress and DNA damage 
130181 ANKRD22 Ankyrin repeat domain 22 NM_144590.2 –2·93 0·06 Mediates protein-protein interactions 
4880673 GADD45A Growth arrest and DNA-damage-inducible, 
alpha 
NM_001924.2 –2·02 0·05 Stress response 
2600382 GPX4 Glutathione peroxidase 4 NM_00103984
7.1 
+1·57 0·02 Reduces peroxide 
6400392 GSTM1 Glutathione S-transferase µ1 NM_000561.2 +2·35 0·03 Deals with oxidative stress 
6130168 GSTM2 Glutathione S-transferase µ2 NM_000848.2 +2·38 0·03 Deals with oxidative stress 
150400 LBA1 Lupus brain antigen 1 NM_014831.1 +1·52 0·04 DNA repair 
5050537 OPLAH 5-oxoprolinase (ATP-hydrolyzing) NM_017570.2 –1·75 0·04 Glutathione metabolism 
2510551 STK3 Serine/threonine kinase 3 (STE20 homolog, 
yeast) 
NM_006281.2 –1·60 0·03 Stress response 
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DNA replication, cell cycle regulation, cell differentiation and proliferation 
940288 BAZ1A Bromodomain adjacent to zinc finger 
domain, 1A 
NM_182648.1 –1·60 0·03 DNA replication 
7400279 CCNA1 Cyclin-A1 NM_003914.2 –1·84 0·05 Cell cycle regulation 
6220674 CCPG1 Cell cycle progression 1 NM_020739.2 –1·54 0·03 Cell cycle regulation 
1780564 CDC42 Cell division cycle 42 NM_00103980
2.1 
–1·59 0·03 Regulation of cell cycle progression 
6200064 CECR1 Cat eye syndrome chromosome region, 
candidate 1 
NM_177405.1 +1·79 0·06 Adenosine deaminase; putative growth factor 
4490528 CKAP4 Cytoskeleton-associated protein 4 NM_006825.2 –1·79 0·05 Cell cycle regulation 
6510554 DACH1 Dachshund homolog 1 (Drosophila) NM_080760.3 –1·76 0·03 Cell fate in eye development 
7560288 DCUN1D3 DCN1, defective in cullin neddylation 1, 
domain containing 3 (S. cerevisiae) 
NM_173475.1 –1·51 0·03 Cell cycle regulation 
4220605 ETS2 v-ets erythroblastosis virus E26 oncogene 
homolog 2 (avian) 
NM_005239.4 –1·68 0·07 Stem cell development 
610164 FYN FYN oncogene NM_153047.1 +1·50 0·05 Tyrosine kinase oncogene 
6180427 G0S2 G0/G1switch 2 NM_015714.2 –1·53 0·06 Cell cycle regulation 
6130136 GPR177 G-protein coupled receptor 177 NM_00100229
2.1 
+1·57 0·04 Required for WNT3A expression (cell fate regulation) 
5490768 GPR56 G protein-coupled receptor 56 NM_201525.1 +1·61 0·10 Cell fate regulation and neurogenesis 
4120750 OBFC1 Oligonucleotide/oligosaccharide-binding 
fold containing 1 
NM_024928.3 –1·56 0·04 Increases DNA-polymerase-template affinity 
4260253 OBFC2A Oligonucleotide/oligosaccharide-binding 
fold containing 2A 
NM_00103171
6.1 
–1·51 0·03 ?DNA metabolism 
2470520 RBMS1 RNA binding motif, single stranded 
interacting protein 1 
NM_002897.3 –1·83 0·03 DNA/RNA processing 
6960022 SEPT5 Septin 5 NM_002688.4 +1·58 0·08 Cell cycle regulation 
3830735 UPB1 Ureidopropionase β NM_016327.2 –1·59 0·07 Pyrimidine degradation 
7570673 UPP1 Uridine phosphorylase 1 NM_003364.2 –1·61 0·08 Uridine phosphorylation 
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Appendix Table 2. List of genes differentially expressed in glibenclamide-treated diabetic patients who are 
otherwise healthy 
ProbeID Symbol Gene RefSeq ID Absolute 
fold 
change 
Corrected 
p-value 
Comment 
Inflammation-related 
2030142 CLC Charco-Leyden crystal protein NM_001828.4 +2·01 0·05 Lysophospholipase expressed by eosinophils and 
basophils 
2260731 ERAP2 Endoplasmic reticulum aminopeptidase 2 NM_022350.2 +1·58 0·05 Trimming peptides for MHC class I presentation 
940519 GPR44 G protein-coupled receptor 44 NM_004778.2 +1·57 0·05 Chemoattractant receptor expressed on Th2 cells 
510079 HLA-DRB4 HLA-DRB1 MHC class II antigen NM_021983.4 –1·58 0·05 Antigen presentation 
620544 HLA-DRB6 HLA-DRB6 MHC class II antigen NR_001298.1 –2·50 0·05 Antigen presentation 
4210458 KIR2DL1 Natural killer cell immunoglobulin-like 
receptor, 2 domains, long cytoplasmic chain, 1 
NM_014218.2 –1·54 0·06 NK cell modulation 
Neutrophil function 
1500735 CTSG Cathepsin G NM_001911.2 –1·84 0·05 Neutrophil azurophil granule protease 
4540239 DEFA1 Neutrophil defensin 1 NM_004084.2 –2·49 0·05 Neutrophil microbicidal peptide 
2970747 DEFA3 Neutrophil defensin 3 NM_005217.2 –2·49 0·06 Neutrophil microbicidal peptide 
6550164 DEFA4 Neutrophil defensin 4 NM_001925.1 –2·20 0·05 Neutrophil microbicidal peptide 
7650497 ELA2 Neutrophil elastase 2 NM_001972.2 –1·93 0·05 Neutrophil azurophil granule protease 
7150170 LOC728358 Neutrophil defensin 1 precursor NM_001042500.1 –2·58 0·05 Neutrophil microbicidal peptide 
2470364 PRSS33 Serine protease 33 NM_152891.2 +1·85 0·05 Serine protease expressed in neutrophils and 
macrophages 
Note.—All genes in this table have a fold change in expression greater than 1·5 and a corrected p-value less than 0·10 (Benjamini-Hochberg); 
when more than one probe for the same gene was positive, only the probe with the most significant corrected p-value is displayed. Only ontologies 
with a significance level <0·05 (hypergeometric test, InnateDB) are listed here; ontologies have been supplemented with genes not curated by 
InnateDB but which were identified on literature searches. Microarray data have been deposited at ArrayExpress, EMBL-EBI (accession number 
E-TABM-852-n) and are available publicly. 
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royalties for any use of the Work which results in commercial 
advantage or private monetary compensation. 
 
3. Warranties and Disclaimer 
Except as required by law, the Work is licensed by the Licensor on an “as 
is” and “as available” basis and without any warranty of any kind, either 
express or implied. 
 
4. Limit of Liability 
Subject to any liability which may not be excluded or limited by law the 
Licensor shall not be liable and hereby expressly excludes all liability for 
loss or damage howsoever and whenever caused to You. 
 
5. Termination 
The rights granted to You under this Licence shall terminate automatically 
upon any breach by You of the terms of this Licence. Individuals or entities 
who have received Collective Works from You under this Licence, however, 
will not have their Licences terminated provided such individuals or 
entities remain in full compliance with those Licences. 
 
6. General 
6.1. The validity or enforceability of the remaining terms of this 
agreement is not affected by the holding of any provision of it to be 
invalid or unenforceable. 
6.2. This Licence constitutes the entire Licence Agreement between the 
parties with respect to the Work licensed here. There are no 
understandings, agreements or representations with respect to the 
Work not specified here. The Licensor shall not be bound by any 
additional provisions that may appear in any communication in any 
form. 
6.3. A person who is not a party to this Licence shall have no rights under 
the Contracts (Rights of Third Parties) Act 1999 to enforce any of its 
terms. 
 226 
6.4. This Licence shall be governed by the law of England and Wales and 
the parties irrevocably submit to the exclusive jurisdiction of the 
Courts of England and Wales. 
 
7. On the role of Creative Commons 
7.1. Neither the Licensor nor the User may use the Creative Commons 
logo except to indicate that the Work is licensed under a Creative 
Commons Licence. Any permitted use has to be in compliance with 
the Creative Commons trade mark usage guidelines at the time of use 
of the Creative Commons trade mark. These guidelines may be found 
on the Creative Commons website or be otherwise available upon 
request from time to time. 
7.2. Creative Commons Corporation does not profit financially from its 
role in providing this Licence and will not investigate the claims of 
any Licensor or user of the Licence. 
7.3. One of the conditions that Creative Commons Corporation requires 
of the Licensor and You is an acknowledgement of its limited role and 
agreement by all who use the Licence that the Corporation is not 
responsible to anyone for the statements and actions of You or the 
Licensor or anyone else attempting to use or using this Licence. 
7.4. Creative Commons Corporation is not a party to this Licence, and 
makes no warranty whatsoever in connection to the Work or in 
connection to the Licence, and in all events is not liable for any loss 
or damage resulting from the Licensor’s or Your reliance on this 
Licence or on its enforceability. 
7.5. USE OF THIS LICENCE MEANS THAT YOU AND THE LICENSOR 
EACH ACCEPTS THESE CONDITIONS IN SECTION 7.1, 7.2, 7.3, 7.4 
AND EACH ACKNOWLEDGES CREATIVE COMMONS 
CORPORATION’S VERY LIMITED ROLE AS A FACILITATOR OF 
THE LICENCE FROM THE LICENSOR TO YOU. 
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